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Cyclin E is the regulatory subunit of the cyclin E/CDK2 complex that
mediates the G1-S phase transition. N-terminal cleavage of cyclin E by elastase in
breast cancer generates two low molecular weight (LMW) isoforms that exhibit both
enhanced kinase activity and resistance to p21 and p27 inhibition compared to fulllength cyclin E. Clinically, approximately 27% of breast cancer patients overexpress
LMW-E and associate with poor survival. Therefore, we hypothesize that LMW-E
disrupts normal mammary acinar morphogenesis and serves as the initial route into
breast tumor development. We first demonstrate that LMW-E overexpression in
non-tumorigenic hMECs is sufficient to induce tumor formation in athymic mice
significantly more than overexpression of full-length cyclin E and requires CDK2associated kinase activity. Further in vivo passaging of these tumors augments
LMW-E expression and tumorigenic potential. When subjected to acinar
morphogenesis in vitro, LMW-E mediates significant morphological disruption by
generating hyperproliferative and multi-acinar complexes. Proteomic analysis of
patient tissues and tumor cells with high LMW-E expression reveals that the
activation of the b-Raf-ERK1/2-mTOR pathway in concert with high LMW-E
expression predicts poor patient survival. Combination treatment using roscovitine
(CDK inhibitor) plus either rapamycin (mTOR inhibitor) or sorafenib (b-raf inhibitor)
effectively prevented aberrant acinar formation in LMW-E-expressing cells by
inducing the G1/S cell cycle arrest. In addition, the LMW-E-expressing tumor cells
exhibit phenotypes characteristic of the EMT and enhanced cellular invasiveness.
v

These tumor cells also enrich for cells with CSC phenotypes such as increased
CD44hi/CD24lo population, enhanced mammosphere formation, and upregulation of
ALDH expression and enzymatic activity. Furthermore, the CD44hi/CD24lo
population also shows positive correlation with LMW-E expression in both the tumor
cell line model and breast cancer patient samples (p<0.0001 & p=0.0435,
respectively). Combination treatment using doxorubicin and salinomycin
demonstrates synergistic cytotoxic effects in cells with LMW-E expression but not in
those with full-length cyclin E expression. Finally, ProtoArray microarray identifies
Hbo1 as a novel substrate of the cyclin E/CDK2 complex and its overexpression
results in enrichment for CSCs. Collectively, these data emphasize the strong
oncogenic potential of LMW-E in mammary tumorigenesis and suggest possible
therapeutic strategies to treat breast cancer patients with high LMW-E expression.
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CHAPTER 1: INTRODUCTION TO THE ROLE OF CELL CYCLE IN BREAST
CANCER
1.1. THE MAMMARY GLAND AND BREAST CANCER DEVELOPMENT
1.1a. Breast cancer statistics
The mammary gland is highly susceptible to tumor-initiating mutations and
oncogenic modulations since the gland itself develops after birth and undergoes
repeated cycles of remodeling and regression involving proliferation, differentiation,
and apoptosis (1). Consequently, breast cancer is currently the second most
common type of cancer in the United States with approximately 200,000 new cases
and over 40,000 expected deaths in 2010. Although breast cancer incidence has
been rising steadily mainly due to increased awareness, innovative treatment and
disease management has dramatically improved patient outcome. Estimates from
the National Cancer Institute suggested that approximately 2.5 million women who
had a history of breast cancer were still survivors in 2006. However, despite
development of better therapeutic practices that greatly improved patient survival,
breast cancer still remains the leading cause of cancer death in women worldwide.
This is due to our incomplete understanding of the biology and evolution of breast
cancer, which results in the high rate of tumor relapse and metastatic dissemination.
To improve breast cancer treatment, we must clearly elucidate the mechanism of
mammary oncogenesis in order to develop targeted therapy that can specifically
and completely eradicate tumor growth.
1.1b. The physiology of the mammary gland
The mammary gland is an exocrine gland that produces and secretes milk
during lactation. Alveoli are the most basic components of the mammary gland; they
are hollow cavities that contain luminal cells, which produce and secrete milk into
the lumen (Figure 1). These luminal cells are highly differentiated and the cells
organize to form polarized acinar structure. Myoepithelial cells surround the luminal
cells and provide basement support as well as to contract in response to oxytocin
stimulation to excrete milk. Multiple alveoli combine to form mammary lobules,

1

lumen

aveolus
(acinus)
adipocytes
inflammatory cells

Figure 1: The structure of the mammary gland. The mammary gland is composed
of multiple lobules that are connected by ducts to form a hollow network for milk
production and secretion through the nipple during lactation. The lobule consists of
multiple aveoli (acini) which are the basic unit of the mammary gland. Each aveolus
is made up of luminal cells, which produce and secrete milk into to the lumen. The
myoepithelial cells surround the luminal cells and the aveolus is enclosed by a
basement membrane. Image obtained and modified from Tutorvista.com.
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which are connected by lactiferous duct to allow milk to flow to the nipple. The
mammary extracellular matrix, which is composed of myoepithelial basement
membrane and connective tissues, along with fibroblasts, adipocytes, and
inflammatory cells, functions to maintain the morphology of the mammary gland and
to provide signaling between mammary epithelial cells as well as signaling from
other organs and tissues. The structure of the mammary gland is organized
intricately to achieve efficient function. Therefore, tissue organization or
morphogenesis in the mammary gland is critical to maintain the integrity of the
tissue and prevent pathogenesis. Breast cancer most commonly arises from luminal
cells, which are the cells that produce milk, and a smaller percentage of breast
cancer arise from the lactiferous duct (Figure 1).
1.1c. Treatment options for breast cancer
After a patient is diagnosed with breast cancer, treatment options include
surgery, chemotherapy, radiation therapy, and systemic therapy. Most patients will
undergo surgery (lumpectomy or mastectomy) to remove the cancer from the breast
tissue, and this tumor mass is also used to assess the stage of the disease. Surgery
is typically combined with other treatment options to enhance the chance of
complete remission. In cases when the tumors are in excess of 1 cm, radiation or
neoadjuvant therapy are performed to reduce the tumor size prior to surgery. Once
all detectable tumor tissue has been removed by surgery, additional adjuvant
therapy is given to women with breast tumors larger than 1 cm or have node
positive disease. Adjuvant therapy administered systemically, is defined as the use
of anti-cancer agents administered orally or intravenously and includes
immunotherapy, endocrine therapy and chemotherapy.
Immunotherapy involves the manipulation of the patient’s immune system to
fight cancer cells and thus renders less toxic side effects compared to traditional
chemotherapy. The most commonly recognized agents used in immunotherapy are
trastuzumab (Herceptin), lapatinib (Tykerb), and bevacizumab (Avastin).
Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2
(HER2), has gained tremendous recognition due to the results of clinical trials
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demonstrating that trastuzumab synergizes with standard chemotherapy to
effectively lower the risk of recurrence and death (2). As a result, trastuzumab has
been approved by the Food and Drug Administration to treat breast cancer patients
with HER2 overexpression (3).
On the other hand, breast tumors with positive expression for estrogen
receptor (ER) and/or progesterone receptor (PR) receive endocrine therapy. There
are 3 major types of endocrine therapy: ovarian ablation, selective estrogen
receptor modules (SERMs), and aromatase inhibitors. The ovaries are the main
source of estrogen production in pre-menopausal women, and estrogen is
mitogenic because it promotes growth of breast cancer cells that express ER. As a
result, women with hormone receptor positive disease are given luteinizing
hormone-releasing hormone (LHRH) to shut down estrogen production or subjected
to ovarian removal by surgery. There are a total of 3 SERMs available in the clinic:
tamoxifen, raloxifene, and toremifene, and they function by competitively inhibit the
binding of estrogen to ER. While tamoxifen is the standard treatment for both preand postmenopausal patients positive for ER expression, aromatase inhibitors
prove to be more effective in postmenopausal women (4, 5). Aromatase is an
enzyme that is responsible for the aromatization of androgen to estrogen in the final
step of estrogen synthesis. Irreversible steroidal aromatase inhibitor such as
exemestane permanently binds to and inhibits aromatase activity while nonsteroidal
inhibitors such as anastrozole and letrozole reversibly compete with the enzyme (68). The major side effects of endocrine therapy include menopausal symptoms and
increased risk of endometrial cancer.
Given that cancerous cells possess uncontrolled proliferation,
chemotherapeutic agents are designed to target rapidly dividing cells. By doing so,
chemotherapy tend to render toxic side effects because the cells in the bone
marrow, digestive tracts and hair follicles are normal cells that also undergo rapid
cell division. The mechanism of most chemotherapeutic agents is to inhibit cell cycle
progression, particularly by inducing DNA damage. These drugs include alkylating
agents, anthracyclines, topoisomerase inhibitors, antimetabolites, and plant
alkaloids. Many studies have shown that the effectiveness of chemotherapy

4

improves greatly when the agents are administered in combination regimen as
opposed to single drug treatment (9).
1.2. THE FIVE MOLECULAR SUBTYPES OF BREAST CANCER
Cancer is a heterogenous disease giving rise to dissimilar biology in different
patients. Therefore, to achieve improved patient outcome, a better understanding of
the molecular patterns of the tumors is necessary to identify clinical markers and
design effective therapeutic agents. Using DNA microarray, Perou and colleagues
first examined the gene expression signature of breast cancer tissues and applied
hierarchical clustering analysis to divide the tumors into 5 groups based on the
expression pattern of 8,102 human genes (Table 1) (10). The 5 molecular subtypes
are: basal, luminal A, luminal B, ErbB2, and normal-like, and they all differ in clinical
outcome but surprisingly not in lymph-node metastasis status (11). Significantly, the
results from this and subsequent studies changed the way we study and treat
breast cancer.
Based on its name, basal-like tumors are classified by high expression of
cytokeratins, which are basal epithelial markers, and growth factor receptors, such
as epidermal growth factor receptor (EGFR) and c-kit (12, 13). Indeed, cell culture
studies demonstrate that the basal-like breast cancer cell lines are sensitive to
EGFR inhibitors (14). The majority of basal-like tumor lacks ER, PR, and HER2
expression and therefore is frequently associated with triple negative tumors.
Consequently, patients diagnosed with basal-like tumors face with limited choices in
molecular treatment and thereby explain their association with short overall- and
disease-free survival. The genes represented in the luminal A subtype are mainly
associated with steroid hormone-mediated signaling pathways and fatty acid
metabolism. As a result, most luminal A tumors express high levels of ER and PR,
display low Ki67 index, are histologically low-grade, and associate with favorable
clinical outcome. Consequently, treatment for luminal A patients relies on endocrine
therapy such as SERMs and aromatase inhibitors. Despite being positive for ER
and PR expression, luminal B tumors are not sensitive to endocrine therapy and as
a result, patients with luminal B tumors have high genomic grade and their
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prognosis is poor.
Additionally, luminal B tumors display high Ki67 index, which is a marker for
proliferation. Since gene expression of luminal B tumors is less strictly defined, the
best treatment strategy for luminal B tumors appear to rely on chemotherapy to
target the cell cycle. Tumors with HER2 amplification are categorized in the HER2+
subtype, and patients with this subtype present poor prognosis. Given the high
HER2 protein levels, these patients are generally given trastuzumab or lapatinib.
Interestingly, most of these tumors are negative for ER and PR making them poor
candidates for endocrine therapy. Finally, normal-like tumors resemble normal
breast tissues, contain less genomic alterations, and associate with good outcome.
Seven years after the five molecular subtypes were first described, Perou and
colleagues identified an additional subtype of breast cancer termed claudin-low from
analysis of 13 breast cancer samples (Table 1) (15). These tumors exhibit low
expression for tight junction proteins such as E-cadherin, occludin, claudin 3, 4, and
7 and this subtype was also observed mouse breast tumor samples. Furthermore,
this gene expression profile is found in breast cancer stem cells (CSCs) that are
enriched for the CD44hi/CD24lo cell surface marker as well as high aldehyde
dehydrogenase (ALDH) expression, and these cells are insensitive to
chemotherapy and hormone therapy (15-17). Compared to the other subtypes,
claudin-low tumors express low levels of HER2, ER, and PR and are characterized
by relatively slow proliferation as shown by low Ki67 transcription (15). Similar to the
basal-like subtype, the prognosis of patients with claudin-low tumors is poor with a
hazard ratio of 17.98 for overall survival (15). Although claudin-low tumors
demonstrate response to chemotherapy, they are predicted to experience high
probability of relapse due to the fact that the tumor is composed of CSCs that can
reinitiate tumor growth once therapy is withdrawn and thus explain the poor clinical
outcome (17). In conclusion, the vast difference in the genomic and transcriptional
aberrations between the 6 subtypes of breast cancer suggests that perhaps each
tumor subtype originated from different neoplastic cell type (18, 19). Undoubtedly,
better understanding on the origin of tumor initiation will allow researchers to
develop targeted therapeutic strategies to prevent and treat breast cancer.
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1.3. THE CELL CYCLE AND CANCER
1.3a. Overview of the cell cycle
The cell cycle chronicles the events during which the cell undergoes DNA
duplication followed by segregation of the copies of chromosomes to create two
identical daughter cells (Figure 2). The cell cycle consists of two major stages: 1)
interphase is the period of time to allow the cells to grow in size and duplicate DNA
and 2) mitosis represents the division of the nuclei. Interphase includes G1, S and
G2 phases. Cellular growth and preparation for DNA replication occurs during G1
phase, which is followed by S phase when DNA synthesis occurs, and the cell again
prepares for mitosis during G2 phase. The two gap phases are essential to provide
the cell more time to grow in size and sufficiently prepare for the commitment to
DNA synthesis during S phase and mitosis in M phase. Cells in G1 phase can enter
G0, a quiescent state, if external conditions are not ideal for cell division such as
lack of nutrients, contact inhibition, and loss of adhesion (20). However, once the
cell has passed the G1 checkpoint, DNA replication is committed.
The engine of the cell cycle clock machinery is driven by different cyclins and
cyclin dependent kinases (CDKs) (Table 2). There are 16 cyclins (A, B1, B2, C, D1,
D2, D3, E1, E2, F, G1, G2, H, I, K, L) and 9 CDKs (CDK1-9) identified thus far;
however, not all cyclins and CDKs carry out cell cycle-related functions (21-24). All
cyclin proteins contain a “cyclin box,” a sequence of homology that binds to a
conserved region, PSTAIRE, on CDKs to activate their kinase activity (25). As
indicated by their name, the protein levels of most cyclins fluctuate at different
phases of the cell cycle to ensure the correct spatial and temporal scheduling of cell
proliferation. In contrast, CDKs belong to a family of serine/threonine protein
kinases and their protein levels remain constant throughout the cell cycle. To
achieve specific control of cell cycle progression, cyclins interact with their specific
CDK partner and thus the cyclin protein level dictates the cell cycle activity of
different cyclin/CDK complexes. To achieve full activation of the cyclin/CDK
complexes, CDK-activating kinase (CAK) composed of cyclin H and CDK7
phosphorylates CDKs at the T160 site that is adjacent to their active site (26). There
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INK4
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Figure 2: Regulation of the cell cycle by cyclin/CDK complexes. The cell cycle
is defined by 5 major phases, which are G0, G1, S, G2, and M, and is designed to
achieve faithful cellular duplication to create 2 daughter cells. The progression of a
cell through the cell cycle is guided by the kinase activity of different cyclin/CDK
complexes, which function to prepare the cell for progression into the next stage of
the cell cycle.
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are 3 types of cyclin D proteins (D1, D2, and D3), and they associate with either
CDK4 or CDK6 to promote G1 entry and progression (27). D-type cyclins carry out
redundant functions as knockout of each individual cyclin D gene does not cause
embryonic lethality while mice with loss of cyclin D2 and D3 and mice with all 3 Dtype cyclins knockout are not viable at birth (Table 2) (28-36). (Cyclin D1 will be
discussed primarily in this thesis and referred to as cyclin D.) Cyclin D expression is
predominately controlled by the presence of growth factor stimulation (37).
Unphosphorylated retinoblastoma (pRb) tumor suppressor protein forms a complex
with E2F and DP. When present in this complex, E2F and DP, which are
transcription factors for genes necessary for S phase progression (including cyclin
A, cyclin E and CDK1), cannot activate gene transcription (38-40). The cyclin
D/CDK4/6 complex phosphorylates pRb, which contains multiple phosphorylation
sites. Increasing phosphorylation of pRb displaces E2F and DP interaction, thereby
resulting in increased transcription of cyclin E. There are 2 cyclin E genes (cyclin E1
and cyclin E2) and they share approximately 47% sequence homology and
functional activity (41-43). Similar to D-type cyclins, cyclin E1 and E2 also exhibit
redundant functions since mice with loss of each cyclin E gene are viable but
double knockout mice die before birth (Table 2) (44, 45). (Cyclin E1 will be
discussed primarily in this thesis and referred to as cyclin E.) At the G1-S phase
boundary when cyclin E protein level is highest, cyclin E associates with CDK2 and
further phosphorylates pRb to completion thus creating a positive feedback loop on
its own transcription. In cells lacking pRb, cyclin E/CDK2, but not cyclin D/CDK4/6,
kinase activity is necessary for cell cycle progression suggesting that cyclin E/CDK2
activity is critical to phosphorylate other key substrates in the cell cycle (46).
During S phase, cyclin A protein accumulates and replaces cyclin E as the
partner of CDK2 to promote S phase progression (47, 48). Mice with cyclin A1
knockout are viable while those with loss of cyclin A2 show embryonic lethality
possibly due to the fact that cyclin A2 is expressed in most somatic cells and cyclin
A1 is only expressed in zygotes and testis (Table 2) (49, 50). At the G2-M transition,
cyclin A now interacts with CDK1 to prepare for entry into mitosis. Cyclin A
negatively regulates E2F transcriptional activity by phosphorylating DP and
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preventing E2F to bind to DNA and therefore shutting down S phase-related gene
transcription. At this stage, CDK1 switches partner by associating with cyclin B to
regulate mitosis by phosphorylating cytoskeleton proteins such as histone H1,
lamins, and components of the mitotic spindle (24, 51). In fact, cyclin B1 colocalizes
with microtubules and loss of this gene causes embryonic lethality in mice (Table 2)
(52). In contrast, cyclin B2 is associated with the Golgi and mice lacking this gene
are viable with no apparent abnormalities (52). Cyclin B/CDK1 kinase activity is
negatively regulated via phosphorylation by the Wee1 and Myt1 protein kinases (5356). This inhibitory phosphorylation serves to prevent premature exposure of
nuclear contents to the mitotic kinase in case the cell is not ready to enter mitosis.
These phosphorylation sites are removed by the protein phosphatase cdc25C to
activate the cyclin B/CDK1 complex when the cell is ready to divide (57, 58). During
mitosis, which consists of prophase, metaphase, anaphase, and telophase, the
duplicated chromosomes are segregated into opposing nuclei and cytokinesis
follows to generate two identical daughter cells. The cell cycle now begins again at
the entrance of G1 phase when the cell must make the decision to undergo another
round of cell division or enter quiescence in G0 phase.
In addition to regulation by the cyclic trancription of cyclin proteins, the
cyclin/CDK kinase activities are also controlled by 2 families of CDK inhibitors
(CKIs), the INK4 (inhibitors of CDK4) and Cip/Kip families (59). The INK4 family
includes p16INKa, p15INKb, p18INKc, and p19INKd whose function is to bind to CDK4
and CDK6 to prevent cyclin D association and thereby suppress their kinase activity
(60). The 4 members of the INK4 family share approximately 40% homology
through the tandem ankyrin motifs. On the other hand, the Cip/Kip family includes
p21Cip1, p27Kip1, and p57Kip2 and they are able to bind to and inhibit cyclin E/CDK2,
cyclin A/CDK1, and cyclin B/CDK1 complexes (61). In addition to its inhibitory
function on the cyclin/CDK complexes, p21Cip1 also binds to and inhibits proliferating
cell nuclear antigen (PCNA) to halt DNA synthesis (62). The p21Cip1 gene is a
transcriptional target of the tumor suppressor protein p53 (63). Upon detection of
DNA damage, p53 protein is stabilized and upregulates p21Cip1 transcription
causing cell cycle arrest to repair the damaged DNA. Paradoxically, p21Cip1 and
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p27Kip1 have been reported to stabilize and thereby stimulating the activity of the
cyclin D/CDK4/6 complex (64). In response to TGFß treatment, upregulated p15INKb
proteins bind to CDK4/6 and as a result displace p27Kip1 from the cyclin D/CDK4/6
complex (65, 66). The protein level of p27Kip1 accumulates leading to increased
binding and inhibition of cyclin E/CDK2 kinase activity (67). Thus, arrest of cell cycle
progression mediated by cyclin E/CDK2 is downstream of the growth inhibitory
effect of TGFß.
To ensure that cell division results in a faithful duplication of the cell’s genetic
information, there are a few checkpoints throughout the cell cycle in which cell cycle
progression can be halted if the previous stages have not been completed. First, the
restriction point (R) at the G1-S phase boundary is known as “the point of no return”
because it marks the commitment of the progress through the cell cycle by initiating
DNA synthesis. Prior to R, serum starvation causes the cell to enter G0 phase;
however, once the cell has passed R, the cell cycle continues to mitosis even in the
absence of serum (68). The G2 checkpoint occurs at the G2-M phase boundary
when the cell checks for completion of DNA replication before entry into mitosis.
During mitosis, detection of impaired chromosome alignment activates the spindle
checkpoint and arrests the cells in metaphase. Additionally, DNA damage
checkpoints are activated if the cell senses chromosome damage by radiation or
chemicals, and this represents the major mechanism of action of most
chemotherapeutic agents, which will be discussed in greater details in the last
section of this chapter. The cell cycle resumes once these damages are
successfully repaired.
1.3b. Deregulation of the cell cycle in cancer
By definition, cancer results from uncontrolled proliferation of transformed
cells. Therefore, in all aspects, deregulation of the cell cycle is the gateway to
oncogenesis. Nearly all regulators of the cell cycle such as cyclins, CDKs, and CKIs
have been demonstrated to participate in cancer development by altering their
expression, function, and/or localization (Table 3). Tight regulation of cyclin
expression leaves the cell cycle prone to oncogenic aberrations. Cyclin D
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transcription is mainly controlled by mitogenic stimuli and its overexpression is
reported in numerous types of human cancers, such as parathyroid adenoma,
lymphoma, breast, lung and bladder cancer to name a few (Table 3) (69-71). The
role of cyclin E in human cancer has been well documented and will be discussed in
greater details in section 1.4. Meanwhile, cyclin A has been shown to be aberrantly
high in lung carcinoma and correlate with poor survival (Table 3) (72). Since the
expression of CDKs is unchanged and thus not tightly regulated throughout the cell
cycle, deregulation of CDKs is not commonly observed in cancer. However, CDK4
overexpression has been observed in glioma, melanoma, and sarcoma (73), while
overexpression of CDK1 and 2 was reported in colon cancer (Table 3) (74, 75).
Additionally, loss of CKI binding mutations in CDK4 and CDK6 have also been
identified in neuroblastoma cell lines (76).
CKIs provide the braking mechanism in the progression of the cell cycle by
inhibiting the kinase activity of cyclin/CDK complexes. Consequently, CKI
deregulation is commonly documented in tumor development. As described
previously, p16INKa, p15INKb, p18INKc, and p19INKd are CKIs that inhibit the cyclin
D/CDK4/6 and their genes are encoded by the ARF-INK4 locus. This locus is
deleted frequently resulting in downregulation of the transcription of these CKIs
(Table 3) (77, 78). Particularly, inactivation or loss of p16INKa due to deletion,
mutation, and hypermethylation occurs in most tumors (71). In the Cip/Kip family,
p27Kip1 has been shown to be downregulated in lung, breast, and bladder due to
elevated proteolysis by the proteasome, and low p27Kip1 is associated with
increased tumor aggressiveness and poor outcome (79, 80). In addition, p21Cip1 is a
gene target of p53 and given that p53 is the most frequently mutated gene in human
cancer, p21Cip1 expression is downregulated in a number of human cancers (81).
Deregulated pRb function by gene deletion, inactivating mutations, viral
inactivation, or overexpression of cyclin D and cyclin E is frequently observed in
human cancer (Table 3). The pRb gene is mutated in retinoblastoma and lung
cancer (82). Tumor virus proteins such as the human papillomavirus (HPV) E7, the
adenovirus E1A, and the simian virus 40 (SV40) large T (tumor) antigen bind to and
sequester pRb from its inhibitory, tumor suppressive, function in the cell cycle (83-
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85). In the absence of pRb, E2F is relieved from inhibition and is now able to
activate transcription of S phase genes resulting in uncontrolled cellular proliferation
(86). The pRb pathway is an important mechanism of the cell to suppress tumor
growth since it is estimated that approximately 90% of human cancers possess
abnormalities in the components of this pathway (71). Although the involvement of
E2F gene alteration in human oncogenesis has not been observed, E2F
overexpression has been reported to induce transformation and skin tumor
development in cell culture and transgenic mouse models, respectively (Table 3)
(87-89).
1.4. THE ROLE OF CYCLIN E IN ONCOGENESIS
1.4a. Cyclin E functions
Results from knockout animal studies further advanced our knowledge on the
role of cyclin E and CDK2 in the cell cycle. Single cyclin E1 and cyclin E2 knockout
mice are viable and develop normally with normal rates of proliferation in fibroblasts
(Table 2) (44, 45). However, cyclin E1/E2 double knockout mice died during
midgestation due to endoreduplication impairment. The giant trophoblast cells and
megakaryocytes display defective endoreduplication in the cyclin E-null mice, which
could be due to defects in MCM loading (90, 91). Cyclin E-null cells fail to enter S
phase following serum stimulation and are resistant to oncogenic transformation by
Ras (45, 92, 93). Given that cyclin E and CDK2 depend heavily on their interaction
to exert their functions, one would expect CDK2-null mice to exhibit similar
phenotypes to the cyclin E-null mice. Contrary to expectation, CDK2-null mice
actually do not develop the phenotypes observed in cyclin E-null mice. That is, the
CDK2-null mice carry out normal endoreduplication, are able to enter S phase upon
serum stimulation and are susceptible to oncogenic transformation (94, 95). These
findings suggest two possible scenarios to explain for the fact that lack of CDK2
does not compromise the cell cycle functions of cyclin E. First, cyclin E is able to
form active complex with another CDK that can compensate for CDK2 absence
since cyclin E has been shown to interact with CDK1, 2, and 3 (96). The second,
more intriguing theory is that perhaps cyclin E does not require association with
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another kinase to exert its function. Indeed, evidences supporting this possibility
include the fact that CDK2-kinase dead cyclin E mutants exhibit transforming
capability in vitro and are still capable of entering S phase as long as the
centrosomal localization signal is intact (97, 98). All in all, these results suggest that
cyclin E does not require CDK2 to perform normal cell cycle activity as well as to
mediate cellular transformation.
Cyclin E protein level and, consequently, its CDK2-associated kinase activity
peak at the G1-S phase boundary making this complex the rate-limiting regulator of
this checkpoint. Indeed, constitutive overexpression of cyclin E shortens G1 phase
(46, 99, 100) and inhibition of the cyclin E/CDK2 activity prevents S phase entry
(101, 102). Geng and colleagues demonstrated that cyclin E/CDK2 activity is
sufficient to support S phase entry in the absence of cyclin D (103). That is,
replacement of the cyclin D coding sequence with cyclin E cDNA in mice rescues
the phenotypes associated with cyclin D knockout (103). Cyclin E is inactive
unbound and requires interaction with its regulatory subunit, CDK2, to exert its
kinase function. The cyclin E protein contains 2 motifs that regulate substrate
binding. In the N-terminus, MRAIL at residues 130 to 134 mediates binding of
substrates containing RXL motifs (104-106) while VDCLE at residues 274 to 278 in
the C-terminus regulates binding of pocket proteins such as pRb, p107, and p130
(107).
One critical function of cyclin E/CDK2 complex is to further phosphorylate
and inactivate pRb to allow E2F-mediated transcription of S phase genes (Table 4)
(91, 93). As mentioned previously, p27Kip1 is a CDK inhibitor that binds and inhibits
the cyclin E/CDK2 complex. However, during S phase, cyclin E/CDK2
phosphorylates p27Kip1 to mark it for ubiquitin-mediated proteasomal degradation by
the Skp2 ubiquitin ligase (Table 4) (108, 109). At the G1-S phase checkpoint, cyclin
E/CDK2 also phosphorylates p220NPAT (nuclear protein mapped to the ATM locus)
to stimulate synthesis of 3 histone genes (H2B, H4, and H3) (Table 4) (110, 111).
Particularly, the cyclin E/CDK2 complex colocalizes with p220NPAT at Cajal bodies,
which are subcellular structures associated with histone gene clusters. CBP/p300, a
histone acetyltransferase, is also a substrate of the cyclin E/CDK2 complex and
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acts as a cofactor for multiple transcription factors (Table 4) (112). Additionally,
histone H1 is a substrate for the cyclin E/CDK2 complex and phosphorylation of
histone H1 is important for chromatin rearrangement, which is required for DNA
synthesis (Table 4) (113).
Additionally, the role of cyclin E in facilitating the assembly of the prereplicative complex is important for proper DNA synthesis. At the origins of
replication, origin replication complex (ORC) recruits Cdc6 and minichromosome
maintenance complex (MCM) to the chromatin to prepare for DNA synthesis (114).
DNA replication begins once cdc6 is removed from the origin of replication.
Interestingly, cyclin E/CDK2 has been shown to bind to the chromatin via its
interaction with cdc6 through and RXL motif, and these events are necessary for
DNA replication to begin (Table 4) (115, 116). Cyclin E/CDK2 continues to bind to
the chromatin as DNA replication progresses, and this interaction is critical to
prevent re-replication of the DNA. In vitro studies demonstrated that once the cell is
in mitosis and DNA synthesis is completed, cyclin E is phosphorylated by mitogen
activated protein kinase (MAPK) and cyclin B/CDK1 causing its dissociation from
the chromatin (115).
Another function of cyclin E is in its interaction with the components of the
centrosome machinery. The centrosome is copied once per cell cycle and interacts
with chromosomes to create the mitotic spindle. During mitosis, the centrosomes
migrate to opposite poles of the cell and as a result segregate the duplicated
chromosomes. The process of centrosomal duplication must be tightly controlled
since aberrations of this event result in polyploidy and aneuploidy, which are known
to cause genomic instability. Cyclin E plays a critical role during centrosomal
duplication by phosphorylating nucleophosmin B23 (NPM/B23), CP110, and Mps1plike kinase (Table 4) (117-119). Specifically, phosphorylation of NPM/B23 by cyclin
E/CDK2 causes NPM/B23 to dissociate from the centrosome to allow centriole
orientation and splitting (118). Furthermore, Matsumoto and colleagues discovered
a centrosomal localization signal in the cyclin E gene that facilitates cyclin E’s
function during centrosomal duplication to support S phase entry (98). Tumor cells
with p53 loss and cyclin E overexpression were observed to have elevated
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frequency of centrosomal hyperamplification (120). Thus, hyperactive cyclin
E/CDK2 complexes play a major role in inducing genomic instability that ultimately
contribute to oncogenesis.
The kinase activity of the cyclin E/CDK2 complex is also important in
regulating the function of the basic-helix-loop-helix (bHLH) transcription factors. The
Id (Inhibitor of DNA binding) proteins, whose family consists of 4 members (Id1-4),
are HLH proteins that form heterodimers with the bHLH transcription factors and
prevent their binding to DNA to promote gene transcription (121). These bHLH
factors regulate the gene transcription important for G1 progression, such as
p21Cip1, as well as the differentiation pathway (122-124). The protein sequence of
the Id2, 3, and 4 members contains a consensus CDK2 phosphorylation motif and
is shown to be phosphorylated by cyclin E/CDK2 (Table 4) (125). This
phosphorylation event alters the interaction of the heterodimer between Ids and the
bHLH transcription factors thus releasing the inhibitory effect on bHLH-mediated
gene transcription. Cells expressing mutant Id2 and Id3 that lack the CDK2
phosphorylation site arrest in S phase possibly due to the repressed transcription of
p21Cip1 (126). Thus, the function of cyclin E is involved in the intricate network of
gene transcription regulation to promote a smooth G1 to S phase transition.
Cyclin E/CDK2 activity is also important in signal transduction pathways
involving TGFß. The TGFß signaling is known to induce paradoxical cellular effects
and the participation of cyclin E in this pathway may explain this phenomenon.
Under physiological condition, TGFß promotes anti-proliferative signaling by
inducing G1 arrest and promoting differentiation and apoptosis. In contrast, TGFß
promotes cancer progression and metastasis in malignant condition (127). At the
cell surface, TGFß binds to its transmembrane receptor and activates the
intracellular Smad signaling cascade (128). Upon phosphorylation by the receptor,
Smad proteins translocate to the nucleus to activate p15INKb and p21Cip1 expression
while repressing c-myc, Id1, Id2 and Id3 gene transcription (65, 129-131). In the
nucleus, Smad2 and Smad3 are phosphorylated by cyclin D/CDK4, cyclin E/CDK2,
and cyclin A/CDK2 complexes (Table 4) (132). This phosphorylation of the Smad
proteins inactivates their transcriptional activity as mutations to the CDK
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phosphorylation sites of Smads result in elevated p15INKb and p21Cip1 expression
and c-myc repression leading to enhanced G1-S progression (132, 133). These
findings are similarly observed with knockdown of CDK2 by siRNA or treatment of
the cells with CDK2 inhibitor II (compound 3) (133). Therefore, the tumor-promoting
role of TGFß is activated in cells with high CDK2 and CDK4 kinase activity, which
can suppress the growth inhibitory signal mediated by Smad proteins while
simultaneously upregulating the protein level of the oncoprotein c-myc.
1.4b. Controlling the fluctuation of cyclin E protein levels
The G1-S phase checkpoint is vital for maintaining cellular differentiation and
tissue integrity since it occurs prior to DNA synthesis. Cyclin E is a critical regulator
of cell proliferation because it positively controls the transition of cells into S phase
to signal the initiation of DNA replication. Cyclin E expression varies at different
phases of the cell cycle and is highest at the G1-S phase boundary (134). The
periodicity of cyclin E protein levels depends on transcriptional and posttranslational controls. Upregulation of cyclin E transcription during late G1 phase is
due to hyper-phosphorylation of the pRb/E2F/DP complex by cyclin D/CDK4/6
complex while removal of cyclin E proteins during S phase is achieved by ubiquitinmediated proteasomal degradation by Fbw7.
During G1 phase, cyclin D/CDK4/6 complex progressively phosphorylates
pRb to release free E2F and DP to activate S phase genes, including cyclin E (3840). Since CDK2 expression is constant throughout the cell cycle, upregulation of
cyclin E transcription results in elevated levels of active cyclin E/CDK2 complexes.
Cyclin E/CDK2 complex continues to phosphorylate and completely inactivate pRb,
thereby creating a positive feedback loop for cyclin E transcription. Cyclin E level
gradually diminishes during S phase due to reduced gene transcription and
increased proteasomal degradation.
The half-life of cyclin E in a normally cycling cell is less than 30 minutes, and
inhibition of the proteasome can extend this to more than 2 hours. Unbound cyclin E
proteins are susceptible to ubiquitin-mediated proteasomal degradation by Cul-3
during early embryogenesis (135, 136). When cyclin E is bound to CDK2, auto-
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phosphorylation of cyclin E at the T380 site is recognized by the F-box protein Skp2
to mark it for ubiquitin-mediated degradation (137). Complete knockout of Skp2
leads to the accumulation of cyclin E and p27Kip1, which is also a substrate of Skp2
(137-139). Inhibition of the cyclin E/CDK2 kinase activity by p27Kip1 prevents autophosphorylation at T380 and thus allowing cyclin E to avoid degradation. In
addition, the Fbw7 ubiquitin ligase also targets cyclin E bound to CDK2, and this
degradation is dependent of the phosphorylation status of several sites on the cyclin
E protein (140-142). In particular, T380 and T62 are the two auto-phosphorylation
sites on cyclin E critical for Fbw7 binding to cyclin E to mediate ubiquitination. Cyclin
E/CDK2 complexes that are bound to either p21Cip1 or p27Kip1 are inactive and thus
cannot be degraded by Fbw7 because they lack the required phosphorylation (135,
143). Taken together, the periodic rise and fall of cyclin E protein levels are finetuned by tight regulation of the pRb pathway and redundant degradation
mechanisms by the proteasome to ensure timely removal of this G1 cyclin.
1.4c. Deregulation of cyclin E in human cancers
The function of cyclin E is to ensure proper progression of the cell into S
phase; therefore, it is not surprising that deregulation of cyclin E contributes to
oncogenesis. Indeed, cyclin E proves to be an important oncogene since its
overexpression via gene amplification, upregulation of protein expression, or posttranslational deregulation occurs in multiple cancers, including breast, lung,
colorectal, lymphoma, leukemia, gastric, and osteosarcoma to name a few (144153). Since repression of pRb from cyclin D/CDK4/6 phosphorylation positively
controls cyclin E transcription through E2F activity, inactivation of pRb by the
oncogene HPV16-E7 causes cyclin E overexpression in human foreskin fibroblasts
(154). Additionally, multiple lines of evidence indicate Fbw7 is an important tumor
suppressor and its loss of function mutations is thought to result in high cyclin E
protein levels (141, 155, 156). Particularly, analysis of breast cancer cell lines
reveals that the cyclin E gene is amplified and gene transcription is upregulated to
as high as 64 folds resulting in elevated cyclin E activity throughout the cell cycle
(144, 157, 158). In breast cancer patients, cyclin E gene amplification is rarely
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observed in which only 14 of 1082 breast tumors were detected to show
amplification (159). In contrast, the level of cyclin E protein expression is more
frequently upregulated and our clinical study previously found that 127 of 268 breast
tumor tissues demonstrated high cyclin E protein level (160). In fact, cyclin E
overexpression was shown to be a stronger marker for predicting patient outcome
than other traditionally used markers such as lymph node, ER and PR status or
levels of HER2 (160). More specifically, high cyclin E expression was estimated with
a hazard ratio of 13.3 for death from breast cancer, which is almost 8 folds higher
than other established predictive factors such as positive nodes, late stage, and ER
negative status. In the laboratory, approximately 10% of transgenic mice with
human cyclin E overexpression in the mammary gland develop mammary gland
hyperplasia and carcinomas at 8-13 months of age (161).
One mechanism of cyclin E-mediated oncogenesis is through inducing
genomic instability (162-164). Initiation of DNA synthesis and centrosome
duplication occurs almost concomitantly and cyclin E is intimately involved in these
events. Indeed, constitutive overexpression of cyclin E, but not cyclin D or cyclin A,
in rat embryo fibroblasts and human mammary epithelial cells (hMECs) leads to
chromosome instability (163). Given the critical role of cyclin E during DNA prereplication complex formation, high cyclin E activity may cause defects in MCM
loading resulting in breakage of DNA at the replication forks, impaired chromosomal
duplication, or incomplete chromosomal replication due to premature entrance into
mitosis. Ensuring proper centrosome duplication is another cell cycle event that
requires cyclin E function. Consequently, persistent cyclin E/CDK2 activity has been
observed to lead to centrosome amplification, which predisposes the cell to
genomic instability (120). More specifically, Skp2null mouse embryonic fibroblasts
(MEFs) accumulate cyclin E and p27Kip1 proteins and exhibit chromosomal defects
such as polyploidy and centrosome amplification (137). As a result, elevated cyclin
E expression and activity leave the cell vulnerable to neoplastic transformation
brought about by genetic aberrations.
1.5. LMW-E IN BREAST CANCER
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1.5a. The isoforms of cyclin E and their subcellular localization
The transcriptional regulation of cyclin E is complex and results in multiple
cyclin E isoforms due to mainly post-translational modification as well as some
splicing and alternative start site changes. In normal cells, the predominant cyclin E
isoform is 50kD and is termed EL1, and the start codon is 15 amino acids upstream
from the originally discovered cyclin E cDNA (46, 165). Although rare, an alternative
translation site at methionine 46 gives rise to EL4. In addition to genomic and
transcriptional amplification of the cyclin E gene in breast cancer cell lines, another
mechanism of oncogenic transformation of cyclin E is post-translational modification
of the protein. Full-length cyclin E is subjected to elastase-mediated cleavage (but
not due to genomic rearrangements of the cyclin E gene) to generate 2 low
molecular weight (LMW) isoforms in breast cancer (144, 165). This alteration of
cyclin E occurs at 2 cleavage sites on the N-terminus of the full-length cyclin E (EL)
giving rise to trunk 1 (T1) and trunk 2 (T2) isoforms. T1 and its phosphorylated
isoform are named EL3 and EL2, respectively, while T2 and its phosphorylated
isoform are called EL6 and EL5, respectively (166).
Similar to most nuclear proteins, cyclin E is translated in the cytoplasm where
it forms a complex with CDK2, and then transported to the nucleus via the importindependent pathway (167). The nuclear localization signal sequence is found at the
N-terminus of the cyclin E gene, which is cleaved off in the LMW-E isoforms (168).
In fact, fractionation and protein complementation assays demonstrate that the
LMW-E/CDK2 complexes preferentially accumulate in the cytoplasm (169). Since
the Fbw7 ubiquitin ligase is located in the nucleus, the altered subcellular
localization of LMW-E renders it less susceptible to proteasomal degradation. This
finding implicates many possibilities that can explain the particular oncogenic
characteristics of LMW-E that is distinct from full-length cyclin E, and that these
effects could be independent from cell cycle regulation.
1.5b. LMW-E causes genomic instability
Since the function of cyclin E is critical during centrosome duplication and DNA
replication, the presence of hyperactive LMW-E in the cell cycle undoubtedly results
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in abnormal genetic content. Accordingly, LMW-E expression induces genomic
instability by increasing the percentage of cells with polyploid and tetraploid DNA,
subtelomeric chromatid breaks and multiple chromosomal fragments (170). Since
cyclin E participates in MCM loading during DNA pre-replication complex assembly,
elevated cyclin E activity exerted by LMW-E results in deregulation of DNA
replication. In addition to deregulation of LMW-E during S-phase, LMW-E has been
recently implicated in deregulating mitosis (171). As described previously, cdc25C is
the phosphatase that removes the inhibitory phosphorylation sites on cyclin B to
activate the cyclin B/CDK1 complex when the cell is ready for mitosis. In cells
expressing LMW-E however, LMW-E phosphorylates and prematurely activates
cdc25C causing faster mitotic exit and consequently cytokinesis failure and
chromosomal instability (171). Furthermore, LMW-E expression in breast cancer
patient samples also correlates with centrosome amplification, a process that leads
to chromosome missegration and genetic instability (171). Examination of 331
breast cancer patients revealed a significant correlation between high LMW-E
expression and polyploidy (p = 0.0003) and these patients demonstrate significantly
lower disease specific survival (p = 0.02).
1.5c. LMW-E is oncogenic by adopting the 6 hallmarks of cancer
In 2000, Hanahan and Weinberg proposed that malignant growth requires 6
specific alterations in cellular physiology collectively known as the 6 hallmarks of
cancer: 1) self-sufficiency in growth signals, 2) insensitivity to anti-growth signals, 3)
limitless replicative potential, 4) evading apoptosis, 5) sustained angiogenesis and
6) tissue invasion and metastasis (172). That is, in order for a normal cell to
successfully undergo neoplastic transformation, it must acquire most if not all of
these capabilities. These hallmarks were argued to be present in all types of human
cancer and thus explaining the relatively rare occurrence of cancer as well as the
complexity and difficulty of developing effective anti-tumor therapy. Here we present
research evidence accumulated from the last decade demonstrating that LMW-E
does indeed drive malignant transformation by adopting these 6 hallmarks of cancer
(Table 5).
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The decision to enter G1 phase is controlled by cyclin D, which requires the
presence of growth factors. One mechanism acquired by cancer cells is to amplify
growth factor signaling by upregulating the expression of growth factor receptors
such as EGFR. Indeed, the oncogenic role of LMW-E is implicated in breast tumors
with high HER2 expression. Retrospective study found that approximately 25% of
395 breast cancer patient tissues examined had high LMW-E expression, which is
associated with poor survival (p < 0.001) (160). Moreover, patients with
overexpression of both HER2 and cyclin E, particularly LMW-E, were found to
experience reduced 5-year disease-specific survival compared to patients with low
cyclin E expression (173). Interestingly, knockdown of HER2 by siRNA reduces
LMW-E expression and associated kinase activity and induces G1 arrest and
apoptosis. Similarly, trastuzumab-treated xenografts created by MCF7-HER18 cells
injection into nude mice showed reduced HER2 phosphorylation and LMW-E
expression (173). Furthermore, cyclin E overexpression and amplification has been
shown to play a direct role in mediating trastuzumab resistance in breast cancer,
and treatment of these resistant cells with CDK2 inhibitor (CYC065), which is a
2,6,9-trisubstituted purine derivative of roscovitine, induces apoptosis and inhibits
xenograft tumor growth (174). Perhaps in tumors with high HER2 and LMW-E
expression, constitutive growth signaling mediated by HER2 collaborates with the
oncogenic functions of LMW-E to increase tumor aggressiveness and thus leads to
poor patient outcome.
As described previously, cyclin/CDK complexes are the accelerators of the cell
cycle while CKIs represent the brakes. Cyclin E/CDK2 kinase activity is critical for S
phase entry and is subsequently inhibited by p21Cip1 and p27Kip1. In vitro studies
revealed that compared to EL, the LMW-E isoforms exhibit increased resistance to
inhibition by p21Cip1 and p27Kip1 even though these CKIs demonstrated equal
binding stoichiometry (175). These results suggest that the LMW-E isoforms are
sequestering the CKIs from the full-length isoform and thereby causing an aberrant
and prolonged cyclin E/CDK2 kinase activity beyond the G1-S phase boundary.
Moreover, proteolytic processing of cyclin E into LMW-E renders tighter association
with CDK2 resulting in elevated CDK2-associated kinase activity (175, 176).
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Exogenous LMW-E expression in immortalized human mammary epithelial cells
(hMECs) enhances S and G2/M phase entry thus increasing the rate of cellular
proliferation (176).
In addition to insensitivity to CKI inhibition, LMW-E also mediates acquired
resistance to pharmacological agents such as antiestrogen and aromatase inhibitor.
MCF7 cells expressing exogenous LMW-E are less sensitive to growth inhibitory
activity induced by fulvestrant treatment compared to EL-expressing cells, and this
reduced sensitivity was demonstrated to be due to increased resistance of LMW-E
to inhibition by p21Cip1 and p27Kip1 (170). These results were further confirmed using
breast cancer patient data. More specifically, patients whose tumors are ER positive
and express high cyclin E demonstrate no significant improvement in disease
specific survival compared to patients not receiving antiestrogen (p = 0.083).
Indeed, Pan and colleagues previously reported that cyclin E expression in breast
cancer is a strong predictor of endocrine therapy failure (177). Additionally,
aromatase inhibitors represent another form of endocrine therapy and have been
reported to be more effective in the treatment of postmenopausal breast cancer
patients compared to tamoxifen. Similar to fulvestrant, LMW-E expression also
renders MCF7 cells resistant to inhibition by letrozole, an aromatase inhibitor, and
breast cancer patients with LMW-E expression are predicted to be insensitive to
aromatase inhibitor treatment (178). Interestingly, roscovitine, a CDK inhibitor, can
reverse the letrozole-induced resistance mediated by LMW-E in breast cancer cells
suggesting a potential therapeutic value of using roscovitine to treat
postmenopausal breast cancer patients with high LMW-E levels.
Programmed cell death or apoptosis is a cellular event critical for the
maintenance of tissue homeostasis and prevention of accumulation of damaged
cells. Examination of xenografts generated from orthotopic injection of primary
melanoma cells revealed that the LMW-E-expressing tumors showed reduced
apoptotic cells visualized by TUNNEL staining compared to tumors with EL
expression (179). More importantly, the LMW-E-induced melanoma tumors
demonstrate higher microvessel density than tumors with EL expression indicating
enhanced angiogenic potential, which is one of the hallmarks of cancer. Further

30

analysis of these melanoma cells using an experimental lung metastasis assay
revealed that LMW-E expression induced greater metastasis potential than EL.
Increased tumor and metastasis incidence due to LMW-E has been previously
reported in breast cancer. Transgenic mice expressing LMW-E isoforms are
themselves malignant since approximately 27% of LMW-E transgenic mice develop
mammary adenocarcinomas compared to 10% of transgenic mice with EL
expression (180). The frequency of tumor development in transgenic mice with fulllength cyclin E expression reported by Akli et al is similar to results reported
previously by Bortner et al (161, 180). Furthermore, approximately 25% of the
LMW-E tumors develop metastasis compared to 8% in the EL tumors (180). Taken
together, the LMW-E isoforms are strong oncogenes that can successfully initiate
and sustain tumor development through promotion of the 6 hallmarks of cancer.
1.6. TARGETING THE CELL CYCLE
1.6a. DNA damage-inducing agents
Given the idea that tumors arise from uncontrolled proliferation by altering the
cell cycle, traditional chemotherapeutic agents were designed to target tumor cells
by inducing DNA damage to arrest the cell cycle mainly in S or G2/M phases and
subsequently induce apoptosis. Depending on the chemotherapeutic agent, tumor
cells can be targeted in one of three ways: 1) chemically alter the DNA structure, 2)
inhibit DNA synthesis, or 3) inhibit the mitotic process. For instance, cisplatin and
nitrogen mustard function by cross-linking DNA resulting in chromosome breakage
and causing the cell cycle to halt (181). As described previously, DNA damage
induces p53 stabilization, p21Cip1 transcription, cell cycle arrest and/or apoptosis
(182, 183). Topoisomerase is an enzyme that unwinds the DNA strands to aid
during DNA replication, and inhibitors to this enzyme have been shown to be
effective anti-tumor agents. More specifically, both camptothecin and etoposide are
chemicals derived from natural compounds found in plants that inhibit
topoisomerase activity by forming a ternary complex with the enzyme and DNA. As
a result, the induced DNA damage causes the cell to arrest in G1 phase, upregulate
p16INKa level and thereby inhibit the cyclin D/CDK4/6 kinase activity (184).
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Doxorubicin is another potent topoisomerase inhibitor that has been used in the
clinic, albeit dangerous heart toxicity at high dose. Doxorubicin is an anthracycline
antibiotic that functions by intercalation into DNA helices and preventing
topoisomerase from re-annealing the cut DNA during DNA replication (185).
Microtubule inhibitors, on the other hand, disrupt mitotic spindle formation and
arrest cells at the mitotic spindle assembly checkpoint, which is a radiosensitive
period in the cell cycle (186). Similar to other agents mentioned, radiation therapy
uses ionizing radiation to also inflict DNA damage, and is often combined with other
chemotherapeutic agents to enhance tumor toxicity. Consequently, taxol and vinca
alkyloids are two prominent microtubule inhibitors proven to be effective
radiosensitizers in the clinic (187, 188).
1.6b. CDK inhibitors
In the cell cycle, countless proteins are known to be involved in oncogenesis
such as cyclin D, cyclin E, pRb, and p16INKa to name a few. Particularly, CDKs are
the regulatory subunits of the cyclin/CDK complexes that exert kinase activity to
control cell cycle progression. Consequently, CDKs proved to be ideal targets to
halt cell cycle progression of tumor cells. To date, more than 50 CDK inhibitors have
been reported, and most inhibitors are small molecule inhibitors that act by
competitively binding to the ATP binding pockets of CDKs. For instance,
olomoucine and its analog roscovitine are purine analogues that were shown to
inhibit the kinase activity of CDK1 and CDK2 causing G1 and G2 cell cycle arrest
and apoptosis (189, 190). Roscovitine demonstrates stronger anti-tumor effects
compared to olomoucine and is currently under testing in clinical trials (191, 192).
Further discussion on the use of roscovitine in cancer research will be discussed in
more details below. Staurosporine and its analogue UCN-01 (7hydroxystaurosporine) are microbial alkaloids and were found to be non-specific
inhibitors of CDK1 and PKC (193, 194). When combined with camptothecin and
cisplatin, treatment of p53-deficient cells with UCN-01 induce DNA damage and
apoptosis (195). Since most of these inhibitors rely on functional pRb and p53 to
mediate cell cycle arrest and apoptosis, the status of these genes must be identified
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prior to therapy to avoid unresponsiveness or resistance of the tumor to the
therapeutic agents.
1.6c. Targeting LMW-E/CDK2 kinase activity
Cyclin E is the regulatory subunit whose function requires interaction with
CDK2 to phosphorylate target genes to allow transition from G1 to S phase of the
cell cycle. In tumor cells, high cyclin E/CDK2 kinase activity persists throughout the
cell cycle (157). Retrospective clinical evaluation of high-grade ovarian tumors
identified cyclin E/CDK2 kinase activity as a significant predictive marker for
response to platinum-based therapy (196). Moreover, CDK2 was recently reported
to be required for LMW-E-mediated mammary oncogenesis in transgenic mice
(197). Consequently, CDK2, which is a serine/threonine kinase, is and ideal antitumor target to disrupt the cyclin E/CDK2 kinase activity. Indeed, roscovitine
(Seliciclib) is a purine derivative that preferentially inhibits the kinase activity of
CDK1 and 2 over other CDKs (191, 192). Recent study showed that roscovitine can
reverse LMW-E-induced resistance to letrozole treatment in breast cancer cells
(178). Moreover, when combined with doxorubicin or trastuzumab, roscovitine
exerts synergistic effects in the combination treatment on sarcoma and breast
cancer cells, respectively (173, 198). Roscovitine has entered phase I clinical trial
where it demonstrated response in metastatic ovarian cancer and nasopharyngeal
carcinoma while phase II trial which involves the combination of roscovitine with
either gemcitabine/cisplatin or docetaxel showed partial response in patients (199,
200). Perhaps the efficacy of roscovitine in these clinical studies can be improved if
these patients were selected based on their LMW-E expression status given that
CDK2-associated kinase activity is critical in inducing LMW-E-mediated tumor
development.
1.6d. Inhibition of LMW-E generation
Research in the last decade has moved towards a more mechanistic
approach utilizing information from molecular profiling to achieve personalized
treatment. Given the strong prognostic and predictive role of LMW-E in breast
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cancer, the regulation of cyclin E expression and post-translational processing is a
unique target for anti-cancer therapy. The generation of LMW-E isoforms is
proposed to be a result of high elastase proteolytic activity, which is expected to
result in enhanced cleavage of cyclin E into LMW isoforms and ultimately lead to
tumor development (165). Indeed, treatment of a breast cancer cell line (MDA-MB157) with a neutrophil elastase inhibitor CE-2072 reduced the production of some
LMW-E isoforms and also arrested the cells in G1 phase (201). In contrast, this
inhibitor showed no effect in an immortalized hMEC line MCF-10A. Another potent
and promising elastase inhibitor is ONO-5046, which has been demonstrated to
inhibit the proliferation and metastatic development of non-small cell lung cancer
cell line and tumor xenografts, respectively (202, 203). In addition, a recent study
discovered the phytochemical indole-3-carbinol (I3C) found in most leafy vegetables
as a neutrophil elastase inhibitor (204). Analysis of the proteolytic activity of
elastase by zymography revealed that I3C effectively disrupts the cleavage of cyclin
E into LMW isoforms and arrests MDA-MB-231 cells in G1 phase. These effects are
similarly observed with knockdown of elastase protein expression by siRNA.
Elastase expression is high in breast cancer and this is associated with poor patient
outcome and high frequency of metastatic progression (205-209). Combined with
the established oncogenic role of LMW-E in cancer, targeting elastase represents a
unique therapy for cancers with high LMW-E expression and elastase activity.
Another mechanism of targeting the proteolytic processing of cyclin E is
through the use of elafin, which is an endogenous elastase inhibitor that prevents
the cleavage of cyclin E into LMW isoforms by elastase. C/EBPβ is a transcription
factor that regulates elafin gene expression (210). In breast cancer cell lines and
patient tissues, C/EBPβ is downregulated resulting in reduced elafin transcription.
More specifically, elafin exerts its tumor suppressive role by inducing pRbdependent cell cycle arrest in breast cancer cells while triggering caspase-3dependent apoptosis in pRb-deficient cells (211). In immortalized hMECs with an
intact G1-S checkpoint, elafin does not exert cytotoxic effect suggesting a valuable
therapeutic utility of elafin in targeting tumor cells.
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1.7. GAP IN KNOWLEDGE
Cyclin E and more specifically, LMW-E, play critical role in the initiation,
progression, and metastasis in human cancer. Clinical and molecular studies clearly
identify the LMW-E isoforms as novel oncogenes and powerful predictors of patient
survival. Consequently, mechanistic examination of the oncogenic functions elicited
by LMW-E is necessary to better understand and target tumors with high LMW-E
levels. Biological and molecular studies accumulated from the last decade lead us
to the following questions:
•

Is LMW-E capable of initiating and maintaining tumor development?

•

What effect does LMW-E have on the proliferation and architecture of the
mammary acini, and if so, can inhibition of LMW-E by pharmacological
agents rectify these defects?

•

What signaling pathway(s) is/are deregulated in breast tumors with high
LMW-E expression?

•

Does LMW-E induce tumor initiation, progression, and metastasis by
altering gene expression to enhance invasiveness and self-renewal
capability?

•

Are these phenotypes driven by previously unidentified substrate(s) of the
LMW-E/CDK2 complex?

These are the main objectives of this dissertation, and the research data to
address them are described in the following chapters. The overall hypothesis of this
dissertation is that LMW-E initiate and maintain mammary tumor via
deregulation of mammary acinar morphogenesis, induction of the EMT, and
generation of cells with CSC properties. By examining these aspects of LMW-E
in respect to the mammary gland and human pathophysiology, the results obtained
will indeed move us closer to achieving personalized and molecularly targeted
therapy for cancer treatment.
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CHAPTER 2: LMW-E REQUIRES CDK2-ASSOCIATED KINASE ACTIVITY TO
INDUCE ABERRANT ACINAR MORPHOGENESIS AND MAMMARY
TUMORIGENESIS
2.1. INTRODUCTION
2.1a. LMW-E in breast cancer
Prior to the G1-S phase boundary, cyclin E associates with CDK2 to further
phosphorylate and inactivate the pRb-E2F complex to promote S phase entry (212214). Cyclin E overexpression by genomic and transcriptional amplification has
been reported in multiple cancers, particularly in breast cancer (157, 161, 215-219).
Additionally, posttranslational proteolytic cleavage of cyclin E mediated by serine
protease generates two LMW-E isoforms in cancer cells (165, 220). Compared to
full-length cyclin E, the LMW-E isoforms are hyperactive by forming tighter
interaction with CDK2 and are more resistant to CKI inhibition resulting in higher
rate of proliferation (175, 221). When subjected to antiestrogen treatment with
fulvestrant and aromatase inhibitor with letrozole, LMW-E mediates resistance to
the growth inhibitory effect of these agents (178, 201). Finally, retrospective
examination of 395 breast cancer patient tissues identifies LMW-E as an
independent and powerful prognostic and predictive marker of patient outcome
(160).
2.1b. The functional relationship between LMW-E and CDK2
There are a total of 16 cyclins and 9 CDKs identified to date, and most of them
participate in regulating the cell cycle (Figure 2) (21-24). Although the primary
structures of cyclins are different from each other, the tertiary structures are similar
consisting of 2 compact domains of 5 alpha helices. Additionally, all cyclins share a
homologous sequence of approximately 100 amino acids known as the cyclin box,
which mediates their interaction with CDKs (25). Interestingly, results from knockout
animal studies unveiled considerable functional redundancy and compensatory
mechanisms between the different cyclin/CDK complexes in normal tissues. Since
there are two cyclin E proteins (E1 and E2), mice with single cyclin E gene knockout
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carry out normal development (44, 45). However, double cyclin E knockout mice die
during gestation due to defects in endoreduplication of the giant trophoblast cells
and megakaryocytes. Surprisingly, CDK2-null mice are viable and show no
proliferation defects (94, 95).
In contrast to findings regarding cyclin E and CDK2 in normal development,
the inter-dependency between LMW-E and CDK2 is different in malignant
transformation. Transgenic mice expressing the LMW-E isoforms develop
mammary adenocarcinomas at higher frequency (27%) compared to mice
expressing full-length cyclin E (10%) (180). Furthermore, LMW-E overexpression
does not induce mammary tumor development in CDK2-/- transgenic mice, and
treatment of the mice with LMW-E-induced tumor using two different CDK inhibitors,
meriolin and roscovitine, significantly delayed mammary tumor formation by
approximately 6 weeks suggesting that the oncogenic potential of LMW-E requires
CDK2-associated kinase activity (197). Interestingly, these mice succumb to
salivary gland tumors indicating that perhaps LMW-E interacts with novel partner(s)
specifically expressed in this tissue to cause neoplastic transformation. These
findings suggest the tissue-specific requirement of CDK2 by LMW-E to induce
tumor development.
2.1c. Mammary acinar morphogenesis
The role of LMW-E in breast cancer is well established due to extensive
molecular examination of this oncogene in the last decade. Biological processes are
governed by the intimate relationship between form and function, which also helps
explain how alteration of gene expression drives the development of malignant
tumors. Perhaps by understanding the role of LMW-E in the context of the
mammary acinus and how its expression affects form, then we will gain insights into
its oncogenic function. Therefore, one of the objectives of this study is to examine
the role of the LMW-E isoforms during acinar morphogenesis, which is an in vitro
assay that closely recapitulates the mammary tissue.
Numerous studies have demonstrated that extracellular matrix interaction is
very important for proper structure and function of normal tissues (222-224). When
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cultured on 2-dimensional (2D) plates, both non-tumorigenic and tumorigenic
epithelial cells form spindle-shaped structures. However, in 3-dimensional (3D)
culture provided by a layer of laminin-rich basement membrane, non-tumorigenic
hMECs arrest proliferation and undergo structural differentiation to form highly
polarized acinar structures (Figure 1 & 3) (224). Meanwhile, tumorigenic cell lines
grown in 3D culture do not arrest growth or polarize but instead form disorganized
masses of cells. The acinus, or more commonly referred to as the alveolus, is the
basic structure of the mammary gland. The basement membrane containing
myoepithelial cells surrounds the single layer of luminal epithelial cells, which are
highly differentiated and polarized, to provide structural and molecular support for
the acinus (1, 225, 226). Towards the late stage of acinar morphogenesis, the cells
in the center of the structure undergo apoptosis that results in luminal clearance and
formation of a hollow lumen that serves to contain milk secretion during lactation
(227, 228). Acinar morphogenesis involves 4 distinct stages of development:
proliferation, polarization, luminal cell death, and continued proliferation along with
luminal cell death (Figure 3). In essence, the mammary acinus can serve as an
experimental “organism” to investigate mechanisms involved in tissue development
and derailment in malignancy (1). In fact, recent studies have shown that the
morphology of the acini is an accurate predictor for patient outcome. That is, human
breast tumors that share a gene expression signature to the nontumorigenic
HMECs in 3D culture are predicted to show significantly better prognosis (229). The
morphological and functional relevance of this 3D culture system provides proof that
this is a method of choice for studying form and function of the mammary gland in
vitro.
2.1d. Hypothesis and Specific Aims
Normal acinar morphogenesis is critical for maintaining homeostasis of the
mammary gland, and cell cycle regulation plays a pivotal role in this process.
Aberration from this control will undoubtedly result in uncontrollable proliferation and
genomic instability. Therefore, we hypothesize that LMW-E disrupts normal
mammary acinar development and serves as the initial route into breast tumor
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B

Day 0

Day 3

Day 5

Day 6-8
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Adapted from Methods 2003;30(3):256-68
Figure 3: In vitro acinar morphogenesis assay. (A) On day 0, cells in single
suspension are seeded on top of a 1 mm layer of solidified Matrigel. The cells are
covered with a layer of culture media containing 2% Matrigel and fresh media is
replaced every 4 days to provide continuous nourishment. After 15 days of culture,
these cells undergo proliferation and organization to form spherical acinar
structures. (B) Schematic of the progression of one cell seeded at day 0 into a fullyformed acinus on day 15.
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development. The oncogenicity of LMW-E depends on CDK2-associated kinase
activity and thus represents an ideal target for developing therapy to treat breast
cancer patients with high LMW-E expression. To address the hypothesis, we will
closely examine the following specific aims:
•

Investigate the role of LMW-E in regulating acinar development

•

Examine the tumorigenicity of overexpression of LMW-E in vivo

•

Determine whether the deregulation by LMW-E is dependent on the CDK2associated kinase activity.

•

Elucidate a common signaling pathway present in 3D cultures and patient
tissues that is deregulated by LMW-E
Briefly, the results presented in this chapter demonstrate that overexpression

of LMW-E disrupts normal acinar morphogenesis in 3D in vitro culture and promotes
tumorigenesis when expressed in non-transformed hMECs in vivo. CDK2associated kinase activity is necessary to induce these phenotypes, and roscovitine
(a CDK inhibitor) treatment can rescue the aberrant morphologies induced by LMWE expression. Reverse-phase protein array assay of 276 breast tumor patient
samples and cells cultured on monolayer and in 3D Matrigel demonstrated that in
terms of protein expression profile, mammary epithelial cells cultured in Matrigel
more closely resembled patient tissues than did cells cultured on monolayer.
Additionally, the b-Raf-ERK1/2-mTOR pathway was activated in LMW-E expressing
patient samples and activation of this pathway was associated with poor diseasespecific survival. Combination treatment with roscovitine plus either rapamycin
(mTOR inhibitor) or sorafenib (b-Raf inhibitor) effectively prevented aberrant acinar
formation in LMW-E-expressing cells by inducing G1/S cell cycle arrest.

2.2. MATERIALS and METHODS
2.2a. Constructs and cell culture
All immortalized cell lines were cultured in DFCI-1 medium as described
previously (230). FLAG-tagged cyclin E gene constructs EL and LMW-E were
cloned into the pcDNA 4.0 vector (Clontech, Mountain View, CA) and transfected
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into 76NE6 hMECs. Transfected cells were selected with 80 µg/mL zeocin
(Invitrogen, Carlsbad, CA), and stable transfectants were maintained in culture with
10 µg/mL zeocin.
To generate 76NE6 cells with tetracycline-inducible cyclin E expression the
cyclin E gene constructs were cloned into the pRetro-CMV/TO vector and
transfected into 293T cells to produce retroviruses carrying the cyclin E constructs,
and the pBMN-BSR-TetR vector to produce retroviruses carrying the Tet repressor.
The 76NE6 cells were infected first with the retroviruses carrying the Tet repressor
(TetR) gene fused with blasticidin-S resistance gene and then with the retroviruses
carrying the cyclin E constructs. 76NE6 cells inducibly expressing TetR-vector, EL,
LMW-E, ELR130A, and LMW-ER130A, were maintained in DFCI-1 medium with 20
µg/ml blasticidin-S and 1 µg/ml puromycin (InvivoGen, San Diego, CA). Other cell
lines used in this study (i.e. Hs578T and MDA-MB-231) were obtained from
American Type Tissue Collection and cultured as described previously (231).
2.2b. Tumorigenic assay and in vivo passaging
Nude mice were purchased from Charles River Laboratories (Wilmington,
MA) and maintained in the Department of Veterinary Medicine at The University of
Texas MD Anderson Cancer Center. The mice were injected subcutaneously in the
mammary fat pad with 1x106 cells suspended in 100 µL of a 1:1 Matrigel:media mix
(Matrigel from BD Biosciences, San Diego, CA). Doxycycline was added to drinking
water containing 1% sucrose, and water was replaced twice weekly. Mice were
sacrificed under an Animal Care and Use Committee (ACUF)-approved protocol
when tumors reached approximately 12 mm in diameter or 10 weeks after injection,
whichever came first. The tumors were harvested for histopathological analysis or
for expansion of tumor cells in tissue culture for reinjection into mice for in vivo
passaging. Tumors submitted for histopathology were fixed in 10% neutral buffered
formalin, paraffin embedded, and serially sectioned at 5 µm thickness.
2.2c. Staining of tumor sections
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Paraffin-embedded tumor sections were stained with hematoxylin and eosin
and for cyclin E using a polyclonal anti-cyclin E antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). The immunostaining was done as previously
described (180) using a Vectastain ABC kit (per manufacturer’s web site) and a
BCIP/NBT chromogen detection system (Vector Laboratories, Burlingame, CA).
Briefly, the sections were incubated in 1% H2O2 to block endogenous peroxidase
activity and then incubated for 20 min in 10 mmol/L sodium citrate buffer (pH 6.0) at
90°C to retrieve nuclear antigens. Both primary and secondary antibody incubations
were performed for 1 hr in blocking buffer (5% bovine serum albumin and 0.5%
Tween-20 in 1x phosphate-buffered saline [PBS]) at room temperature. Nuclei were
counterstained with hematoxylin.
2.2d. Morphogenesis assay and drug treatment
3D culture on basement membrane was performed as described previously
(232). Assay medium (DFCI-1 medium with 2% growth factor-reduced Matrigel) with
or without drugs was replaced every 4 days, and cells were cultured for 15 days.
2.2e. Indirect immunofluorescence analysis
Indirect immunofluorescence analysis of 3D cultures was performed as
previously described with minor modifications (233). Cells cultured in 8-well
chamber slides were fixed with 2% paraformaldehyde at room temperature for 20
min, permeabilized with 1% Triton X-100 in PBS for 20 min, washed thrice with
PBS/glycine buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, and 100 mM
glycine), and blocked with IF buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM
NaH2PO4, 7.7 mM NaN3, 0.1% bovine serum albumin, 0.2% Triton X-100, and
0.05% Tween-20) plus 10% goat serum for 1 hr at room temperature. Primary
antibodies (laminin V and α6-integrin [Chemicon, Billerica, MA], GM-130 & Ecadherin [BD Pharmingen, San Diego, CA], and Ki67 [Abcam, Cambridge, MA])
were incubated in IF buffer at 1:200 dilution overnight at 4°C. The cells were
incubated with Alexa fluor-conjugated rabbit (488), mouse (594), or rat (680)
secondary antibodies (Molecular Probes, Carlsbad, CA), counterstained with 4,6-
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diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO) for 15 min at room
temperature, and mounted with antifade solution (Molecular Probes, Carlsbad, CA).
Confocal microscopy was performed at room temperature using an Olympus FV300
laser scanning confocal microscope (Olympus America, Inc., Center Valley, PA) at
40x magnification, and images were processed using Adobe Photoshop (Version
11.0.2). For quantification, the diameter of each acinus was measured, and
unpaired Student t test was used for statistical analysis.
2.2f. Protein isolation for Western blot and kinase assay
Cell lysates were prepared and subjected to Western blot analysis as
described previously (220). To obtain lysates from acini, acini were washed once
with cold PBS, scraped, collected, and washed twice with cold PBS. Cell recovery
solution (BD Biosciences) was added to the Matrigel/acini mixture at 1:1 volume,
and cells were incubated on ice for 1 hr, washed with PBS, and lysed as described
previously (165) The protein blots were incubated with primary antibodies (cyclin E,
vinculin [Santa Cruz Biotechnology, Santa Cruz, CA], β-actin [Chemicon, Billerica,
MA], BIM [Epitomics, Burlingame, CA], FAK, b-Raf, ERK1/2, pERK1/2 (T202/Y204),
pMEK1/2 (S217/221), pS6 (S235/236), mTOR, eIF4E, Akt, pAkt(T308), and
pRb(S807/811) [Cell Signaling Technology, Danvers, MA]) at 4°C with gentle
shaking overnight. Kinase assay with histone H1 and GST-Rb as cyclin E
substrates was performed as described previously (165).
2.2g. Reverse-phase protein array (RPPA) analysis
The RPPA approach was performed as previously described (234). Cellular
proteins were prepared as described for western blotting were denatured by boiling
in 1% SDS (with beta-mercaptoethanol) and diluted in five 2-fold serial dilutions in
dilution buffer (lysis buffer containing 1% SDS). Serial diluted lysates were arrayed
on nitrocellulose-coated slides (Grace Biolab) using Aushon 2470 Arrayer (Aushon
BioSystems). Each sample was robotically printed in 5 fold serial dilutions on
multiple slide including positive and negative controls prepared from mixed cell
lysates or dilution buffer, respectively as well as multiple cell lines incubated with
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and without growth factors to provide dynamic range.
Each slide was probed with a validated primary antibody plus a biotinconjugated secondary antibody. Antibody targets were selected as being relevant to
breast cancer through a literature review. Antibodies where then obtained and
validated against each potential target. Only antibodies with a Pearson correlation
coefficient between RPPA and western blotting of greater than 0.7 were used in
reverse phase protein array study. Antibodies with a single or dominant band on
western blotting were further assessed by direct comparison to RPPA using cell
lines with differential protein expression or modulated with ligands/inhibitors or
siRNA for phospho- or structural proteins, respectively.
The signal obtained was amplified using a Dako Cytomation–catalyzed
system (Dako) and visualized by DAB colorimetric reaction. The slides were
scanned, analyzed, and quantified using a customerized-software Microvigene
(VigeneTech Inc.) to generate spot intensity.
Each dilution curve was fitted with a logistic model (“Supercurve Fitting”
developed by the Department of Bioinformatics and Computational Biology in MD
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits
a single curve using all the samples (i.e., dilution series) on a slide with the signal
intensity as the response variable and the dilution steps are independent variable.
The fitted curve is plotted with the signal intensities – both observed and fitted - on
the y-axis and the log2-concentration of proteins on the x-axis for diagnostic
purposes. The protein concentrations of each set of slides were then normalized by
median polish, which was corrected across samples by the linear expression values
using the median expression levels of all antibody experiments to calculate a
loading correction factor for each sample.
2.2h. Breast cancer patient samples and clinical data
The clinical data from 267 breast cancer patients used in this study were
reported previously (160). Each patient had received a diagnosis of breast cancer
between 1990 and 1995 at 1 of 12 hospitals in the Chicago area. The study was
approved by the institutional review board of the Wadsworth Center (Albany, NY). In
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the study reported herein, we used tissue samples from a portion of these for RPPA
analysis to investigate large-scale protein expression pattern.
2.2i. Statistical analysis
Each cell culture experiment was performed at least three times. Continuous
outcomes were summarized with means and standard deviations. Comparisons
among groups were analyzed by two-sided t test and Wilcoxon rank-sum test.
Analyses were performed using SPSS software, version 12.0. For analysis of the
RPPA results, the data for each protein were median-centered, and then the
medians of each sample were subtracted from the raw data for the sample. For the
71 proteins common between the 2D culture, 3D culture and patient data sets, the
data for each protein in each data set were standardized (subtraction of mean then
divided by standard deviation), and then the standardized data were combined. The
combined data set contains 93 cell line samples from 2D and 3D each, with three
technical replicates for each of the 31 unique samples, and 276 breast tumor patient
samples.
Disease-specific survival (DSS) was calculated from the date of surgical
resection of the primary tumor to the date of death or last follow-up. Data for
patients who died from causes other than breast cancer were censored at the time
of death. DSS curves were computed by the Kaplan-Meier method (235). Bivariate
analyses of DSS in patients with high LMW-E expression according to levels of
FAK, BIM, total Akt, and pAkt(T308) were performed with the use of a two-sided
log-rank test (236).
2.3. RESULTS
2.3a. Breast cancer cells fail to undergo acinar morphogenesis in 3D culture
Cellular context provided by the extracellular matrix plays a critical role in
defining the morphological development of the cell. Therefore, the acinar
morphogenesis assay was performed to determine if the 3D culture system can
distinguish acinar morphology between normal and breast cancer cells. This assay
involves culturing cells on top of a layer of Matrigel, a laminin-rich basement
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membrane, and a single cell seeded on day 0 is capable of forming a highly
polarized acinus that is fully differentiated by day 15 in culture (224, 233) (Figure
4A). The 76N cell line is a mortal hMEC line isolated from a reduction mammoplasty
specimen, and these cells senesce at passages 18-20 in tissue culture (230). The
76NE6 cell line was generated by infection of the 76N cells with the HPV E6 virus,
which binds and degrades p53 (237). As a result, the 76NE6 cells lack functional
p53, are immortalized, but remain nontumorigenic. MCF-10A is also a
nontumorigenic hMEC line that was immortalized spontaneously by extended
culture (238). The 2 breast cancer cell lines used were Hs 578T and MDA-MB-231,
which are p53+/mut and express endogenous LMW-E. These cells were cultured on
Matrigel surface for 15 days and then subjected to immunofluorescence (IF)
staining. The staining markers were GM-130 and α6-integrin, which stain the apical
and basal surfaces of the acinus, respectively (239). Figure 4A clearly shows that
the immortalized hMECs arrested proliferation and formed differentiated, polarized
acinar structures. More specifically, these acini were spherical in structure and
showed distinct α6-integrin staining on the outer surface (basal) and GM-130
staining on the inner surface (apical) of the acini. In contrast, the 2 breast cancer
cell lines maintained single-cell morphology in 3D culture. That is, these cells failed
to form coherent, round structures with unorganized α6-integrin and GM-130
staining.
To examine the effect of Matrigel culture on proliferation, a growth curve
assay was performed on these cells cultured on 2D and 3D culture conditions for a
total of 20 days. Both hMECs exhibited faster proliferation in 2D culture than in 3D
culture with the 76NE6 cells growing much faster than the MCF-10A cells in both
culture contexts (Figure 4B and C). Additionally, both hMECs demonstrated growth
arrest on day 20 with a total of approximately 300,000 cells. On the contrary, both
breast cancer cell lines displayed faster proliferation in 3D cultures as compared to
normal cells. (Figure 4D & E). Particularly, the breast cancer cells cultured on 2D
culture appeared to plateau at day 10 whereas those cultured in 3D culture seemed
to continue to proliferate until day 20. Perhaps in addition to having aberrant cell
cycle arrest machinery, the 3D culture environment provides more nutrients for the
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Figure 4: Breast cancer cells fail to undergo acinar morphogenesis in 3D
culture. (A) MCF-10A, 76NE6, Hs 578T and MDA-MB-231 cells were seeded at 70
cells/mm2 density on 1 mm Matrigel thickness. After 15 days in 3D culture, the cells
were fixed and immuno-stained with anti-GM-130 and anti-a6-integrin antibodies.
Nuclei were counter-stained with DAPI. Scale bar = 50 um. (B-E) On day 0, 5000
cells were seeded on 8 chamber slides for monolayer or coated with Matrigel as in
A and harvested every 2 days until day 20 for cell count using the automatic cell
culture counter.
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Hs 578T and MDA-MB-231 cells to continue to proliferate. Taken together, these
observations suggest that breast cancer cells lose the ability to respond to
environmental cues provided by the basement membrane to undergo
morphogenetic differentiation and growth arrest. Additionally, these results further
confirm the unique ability of this 3D culture system to morphologically distinguish
normal from cancer cells.
2.3b. hMECs but not breast cancer cells demonstrate cell cycle arrest in 3D
culture
Since the initial stage of acinar morphogenesis involves extensive cell
division, is cell cycle regulation responsible for the aberrant phenotypes observed?
To address this question, cell lysates of MCF-10A, 76NE6, Hs 578T, and MDA-MB231 cells from day 0 (2D) and day 15 of morphogenesis (3D) were subjected to
Western blot analysis for proteins that regulate cell cycle progression. Overall, the
protein expression profiles of the 4 cell lines examined were largely different from
2D to 3D culture condition. Both hMEC lines demonstrate cell cycle arrest by
reducing the expression levels of cyclin B, D, E, CDK1, 2 and upregulating p27Kip1.
In contrast, the breast cancer cells express high levels of cyclin D and CDK4
suggesting that perhaps G1 phase progression is active (Figure 5A). Matrigel is
composed of a protein mixture secreted from the Engelbreth-Holm-Swarm (EHS)
mouse sarcoma cells that also contains high growth factor level thus explaining the
elevated cyclin D and CDK4 proteins. In addition, all 4 cell lines express high levels
of pAkt (S473) in 3D culture, and phosphorylation of Akt activates both p21Cip1 and
p27Kip1, which in turn inhibit cyclin E/CDK2 activity. Cyclin E protein level is lower in
3D culture suggesting reduced G1-S phase transition. Moreover, a previous study
has shown that Akt is selectively activated in the matrix-attached cells and not in the
centrally located cells in the luminal space (239). Perhaps the presence of
extracellular matrix signaling enables these matrix-attached cells to survive by
activating the Akt pathway. This finding also explains the high levels of pAkt (S473)
in both the Hs 578T and MDA-MB-231 cell lines in 3D culture since these breast
cancer cells maintain single cell morphology and thus every cell is in contact with
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Figure 5: hMECs but not breast cancer cells
demonstrate cell cycle arrest in 3D culture. (A)
Lysates from 76NE6, MCF-10A, Hs 578T and
MDA-MB-231 cells were isolated at day 0 (2D)
and day 15 (3D) of acinar morphogenesis and
subjected to Western blot analysis with the
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and harvested at the indicated day during acinar
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the basement membrane. In addition, elafin is an endogenous inhibitor of elastase,
which is responsible for LMW-E cleavage. Elafin has been reported to be
downregulated in many breast cancer cell lines, and both the Hs 578T and MDAMB-231 cell lines completely lack elafin protein expression. Meanwhile, the hMECs
dramatically upregulate elafin expression in 3D culture suggesting that these cells
are entering cellular quiescence since elafin upregulation has been demonstrated to
induce cell cycle exit.
Fluorescence activated cell sorting (FACS) analysis with propidium iodide
(PI) staining was used to directly assess the cell cycle distribution of normal and
cancer cells grown on 3D culture from day 0 to day 15. As expected, the control
MCF-10A cells were mostly in G1 phase during the entire morphogenetic process
(Figure 5C). The 76NE6 cells also became G1 arrested and showed very low S
phase population (<5%) after 6 days in 3D culture (Figure 5B). Interestingly, the 2
breast cancer cell lines also showed decreasing S phase (but not until day 15 in the
MDA-MB-231 cells) and a slight increase in G1 phase from day 0 to day 15 in 3D
culture (Figure 5D & E). Collectively, the 76NE6 and MCF-10A cell lines showed
growth arrest and polarity organization in 3D culture, whereas the Hs 578T and
MDA-MB-231 cells, to some extent, failed to show these behaviors. These findings
suggest that cell cycle regulation is important for proper acinar morphogenesis, but
does not entirely account for the aberrant morphologies observed in the breast
cancer cells.
2.3c. LMW-E expression leads to aberrant acinar morphogenesis
We speculate that LMW-E is a critical initiator of oncogenesis and one of its
early roles during this process is to deregulate mammary acinar morphogenesis.
Similar to the parental 76NE6 cells, the 76NE6-vector cells formed perfectly
spherical acinar structures (Figure 6A). Interestingly, the acini developed from the
76NE6-EL cells are larger compared to those of vector control cells, but the
structures remained spherical in shape. In contrast, the 76NE6-LMW-E cells formed
very large, irregularly shaped structures with a few multi-acinar complexes. We
quantified the size of the acini by measuring the longest diameter of the structures
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Figure 6: LMW-E expression leads to aberrant acinar morphogenesis. (A)
76NF2V, and 76NE6 cells with stable expression of V, EL, and LMW-E(T1) were
seeded at 70 cells/mm2 density on 1 mm Matrigel thickness. After 15 days in 3D
culture, the cells were fixed and immuno-stained with anti-GM-130 and anti-a6integrin. Nuclei were counter-stained with DAPI. Scale bar = 50 um. (B) The diameter
of the acini were measured and averaged from 3 independent experiments. Error
bars = SEM (Student’s t test, *p<0.05). (C-F) On day 0, 5000 cells were seeded on 8
chamber slides for monolayer or coated with Matrigel as in A and harvested every 2
days until day 20 for cell count.
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and found that ectopic LMW-E expression in the 76NE6 cells does lead to
approximately 28% larger acini compared to vector control cells (p < 0.0001)
(Figure 6B). These results signify that, in the mammary gland, LMW-E is an
important regulator of the early onset of oncogenesis by perhaps causing
enlargement of mammary lobules.
As established previously, the morphology and growth patterns of human
mammary epithelial cells are dramatically different from 2D to 3D culture. Normal
hMECs grown in 3D culture provided by laminin rich basement membrane arrest
proliferation and form fully differentiated acinar structures. The 76NE6-vector,
76NE6-EL, LMW-E, and 76NF2V cells had almost identical doubling times in 2D
culture at approximately 45 hours (Figure 6C-F). In contrast, when cultured in 3D
medium, these cells exhibited fast rate of proliferation up to day 5 and begin to
plateau at day 10, which is consistent with previous observations (239). The
difference in growth behavior between the EL and LMW-E clone was not apparent
in 3D culture except that the total cell number of the EL clone was larger than the
LMW-E clone after 20 days of culture. Furthermore, the 76NF2V cell line showed
growth arrest at the latest time point, but the cell number declined noticeably after
reaching the peak. This is due to the control of the cell cycle by an intact p53. In
addition, these results also suggest that the 3D culture system is more sensitive at
distinguishing the differences between EL and LMW-E in the cells than the 2D
counterpart.
2.3d. Deregulation of the cell cycle progression by LMW-E during acinar
morphogenesis
Protein expression relies on different cellular context, depending what
environment the cell is in contact with. Since expression of key cell cycle regulators
could be modulated by signals received from the 3D environment, we questioned if
the addition of Matrigel was sufficient to mediate changes in expression levels of
these proteins. To address this question we subjected cells cultured in 2D and 3D
conditions to western blot analysis). The results from this experiment demonstrated
that in all cell lines examined (76NF2V, 76NE6-V, EL, and LMW-E), the activity of
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the cell cycle is greatly repressed in 3D context as evidenced by reduced
expression of many of the cyclins and CDK expression (Figure 7A). This suggests
that cells cultured on monolayer plates do not experience growth-inhibiting effects
from the extracellular matrix and exhibit high cell cycle activity continuously.
However, the cells in 3D culture showed dramatic proliferation arrest behavior after
15 days in culture with the protein levels of cyclin A, B, D, CDK1, 2, 4, and pAkt
(S473) significantly downregulated. In contrast, both the 76NE6-EL and 76NE6LMW-E cells upregulate cyclin E expression in 3D culture. Contrary to our
expectation, overexpression of LMW-E did not affect the expression of these cell
cycle proteins in 3D culture as the expression profile of the LMW-E cells is similar to
that of the vector control cells. Interestingly, the 76NE6-LMW-E cells express much
higher elafin proteins in 3D culture compared to the 76NE6-EL cells. Elafin is an
endogenous inhibitor of elastase and therefore can prevent the cleavage of cyclin E
into LMW isoforms (240). Maybe this induction of elafin expression can compensate
for the oncogenic effects of LMW-E in these cells by preventing further LMW-E
generation.
To determine the effect of overexpression of EL and LMW-E on the cell cycle
profile of hMECs during acinar morphogenesis, the cells were cultured on Matrigel
and subjected to FACS analysis with PI staining every 3 days post seeding on
matrigel. As observed previously with the 76NE6 cell cycle profile (Figure 5B), the
76NE6-V, EL and 76NF2V cells arrest in G1 phase by reducing the S and G2/M
population from day 6 to day 15 of acinar development (Figure 7B-D). In contrast,
the 76NE6- LMW-E cells demonstrate a dramatically different cell cycle distribution
during acinar morphogenesis (Figure 7E). On day 0, the cell cycle distribution of the
76NE6- LMW-E cells is similar to the parental cells with approximately 60% in G1,
15% in S, and 25% G2/M phase. After 6 days in 3D culture, these cells appear to
lack S and G2/M population as the DNA content represents mainly G1 phase. This
population then shifts gradually to S and then G2/M population from days 9 to 15 of
acinar morphogenesis. On day 15, approximately 90% of the population is in G2/M
phase while about 10% are in G1 phase. This unusual pattern of cell cycle
distribution suggests that the LMW-E overexpressing cells are able to traverse the
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Figure 7: Deregulation of the cell cycle
E
progression by LMW-E during acinar
morphogenesis. (A) Lysates from 76NF2V and
76NE6 cells with stable expression for V, EL,
LMW-E were isolated at day 0 (2D) and day 15
(3D) of acinar morphogenesis and subjected to
Western blot analysis with the indicated antibodies.
β-actin was used as a loading control.(B-E) Cells
were cultured as in A and harvested at the
indicated day during acinar morphogenesis for
FACS analysis. Cells were fixed in ethanol
overnight and stained with propidium iodide for cell
cycle analysis.
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G1-S phase transition but arrest in S and G2/M phase due to increasing DNA
damage that LMW-E overexpression can induce in these cells (176). Taken
together, these results suggest that LMW-E expression induces formation of large
and irregular acini, which could be explained by the aberrant cell cycle machinery
during the progression through the different developmental stages of acinar
morphogenesis.
2.3e. Elafin overexpression fails to completely revert breast cancer cells
during acinar morphogenesis
LMW-E expression is unique in cancer cells due to the action of elastase,
and their expression leads to more aggressive proliferative phenotype (165). Elafin
is a potent endogenous inhibitor specific for elastase and proteinase-3 (241). We
recently reported that elafin is transcriptionally down regulated in most tumor cell
lines and thus explaining the generation of LMW-E in tumor but not in normal cells
(210). Previous studies have shown that exogenous elafin expression can inhibit the
proliferation of MDA-MB-468, which express high levels of LMW-E, in vitro and in
xenograft mouse model suggesting that perhaps elafin is an effective candidate to
negate the growth advantage given by LMW-E expression. Therefore, we aim to
determine whether inhibition of elastase by overexpression of elafin in breast cancer
cells would cause reversion of these cells into highly organized acinar structures.
Adenovirus containing elafin DNA were infected into the 76NE6, MCF-10A, Hs
578T, and MDA-MB-231 cell lines and then cultured on Matrigel (Figure 8A). On
day 15 of morphogenesis, the cells were fixed and stained with GM-130 and a6integrin antibodies. The results obtained indicated that overexpression of elafin was
not toxic to immortalized cells (Figure 8B). That is, the 76NE6 and MCF-10A cells
still formed correct acinar structures in the presence of high levels of elafin.
However, the Ad-luciferase and Ad-elafin conditions generated larger acini perhaps
due to the presence of adenovirus in general. As for the breast cancer cells, the Hs
578T cells remained single-cell phenotype in contrast to the MDA-MB-231 cells,
which formed adherent round structures in the presence of both Ad-luciferase and
Ad-elafin. Western blot analysis confirmed that overexpression of elafin reduced
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Figure 8: Elafin overexpression fails to completely revert breast cancer cells
during acinar morphogenesis. Cells were treated with PBS and adenovirus
carrying luciferase and elafin DNA on 2D plates. Three days later, the cells were
extracted for (A) Western blot analysis with the indicated antibodies and (B) acinar
morphogenesis assay. On day 15 of morphogenesis, all cells were fixed and
immunostained with GM-130 and a6-integrin antibodies, and nuclei were
counterstained with DAPI.
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LMW-E expression and this is correlated with increased pAkt (S473) expression.
The pAkt pathway leads to many different downstream effects, one of which is
activation of p27Kip1, which then can act to inhibit the cyclinE/CDK2 complex.
Perhaps this pathway is activated to keep the cell cycle in check when elafin is
expressed.
2.3f. Loss of p53 control cooperates with LMW-E to drive aberrant acinar
formation
Cyclin E and p53 are both critical regulators of the cell cycle. Numerous
studies have shown that overexpression of cyclin E and its LMW isoforms lead to
high proliferation, aberrant expression of other cell cycle regulators, and
chromosomal instability. Furthermore, p53 is a tumor suppressor and was found to
have high frequency of mutation in breast tumors with high cyclin E protein content
(242). The association between cyclin E expression and p53 gene status plays
important role in maintaining the integrity of the cell cycle machinery in normal
mammary cells. Since previous experiments demonstrated that stable LMW-E
expression leads to formation of larger and irregularly shaped acini compared to the
76NE6 parental cells, we next aim to investigate whether p53 collaborates with
LMW-E to induce these phenotypes. Adenovirus containing the LMW-E DNA was
infected into the 76NE6 (degraded p53) and 76NF2V (wt p53) cells, and these cells
were cultured on Matrigel for 15 days to analyze acinar formation (Figure 9A). The
76NF2V cells infected with the LMW-E construct still maintain the spherical acinar
structure with the size of the acini slightly larger than those of the PBS and Adluciferase control cells (Figure 9B). However, the size of these acini is in similar
range to those of the 76NE6 parental cells. Meanwhile, the 76NE6 cells induced
with LMW-E expression via adenoviral infection lead to formation of acini with
misshapen structures that are about 2 times larger than the parental control cells.
The results obtained suggest that loss of p53 control cooperates with LMW-E
expression to drive aberrant acinar formation. This deregulation by p53 and LMW-E
appears to affect the size and shape of the acini only but not on the polarity and
lumen formation as even parental 76NF2V acini contain filled lumen.
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Figure 9: Loss of p53 control cooperates with LMW-E to drive aberrant
acinar formation. Cells were treated with PBS and adenovirus carrying
luciferase and LMW-E DNA on 2D plates. Three days later, the cells were
extracted for (A) Western blot analysis and (B) acinar morphogenesis assay.
On day 15 of morphogenesis, all cells were fixed and immunostained with
GM-130 and a6-integrin antibodies, and nuclei were counterstained with
DAPI.
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2.3g. Coculture with breast cancer cells cause formation of larger hMEC acini
The microenvironment provides physical support as well as molecular
crosstalk to nearby cells and thus creating a niche for these cells to grow and
differentiate into specific tissue. This experiment was designed to address the
question of whether signals released from normal cells can overcome those of
tumor cells or can tumor cells recruit normal cells to become more abnormal? The
cell lines examined were: 76NE6, MCF-10A, 76NF2V, Hs 578T, and MDA-MB-231.
These cells were cultured on Matrigel and brightfield images were taken at days 6,
10 and 15 of acinar morphogenesis. Figure 10A shows that the breast cancer cells
do not form coherent acinar structures but instead their morphologies are similar to
those observed on monolayer culture, which are single-celled and spindle-shaped
phenotypes. The MCF-10A, 76NF2V and 76NE6 cells were grown in 3 different 3D
culture conditions: 1) alone, 2) mixed with Hs 578T or MDA-MB-231 cells at 1:1
ratio, and 3) on the top layer (insert) of a transwell plate with the Hs 578T or MDAMB-231 cells on the bottom well (Figure 10B-D). Contrary to our expectation that
coculture could rescue the morphology of breast cancer cells, the results revealed
that it actually causes increase in acinar size of all 3 immortalized hMEC lines. The
results demonstrated that the morphology of breast cancer cells did not change
when cultured together with normal breast cells in 3D culture. However, the acinar
structures of the normal cells are slightly larger when cultured with breast cancer
cells. It is possible that breast cancer cells release certain growth factors or
cytokines to stimulate enhanced proliferation of the normal cells thus implicating
that tumor cells can recruit normal cells to become abnormal.
2.3h. LMW-E is tumorigenic
Previous experiments using cultured cells have demonstrated that the LMWE isoforms are both biochemically and biologically hyperactive and exhibit strong
oncogenic potentials (175). In addition, LMW-E is found in breast cancer cell lines
and patient samples but not in normal tissues suggesting that perhaps LMW-E
partakes unique oncogenic role in malignancy. To investigate whether ectopic
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Figure 10: Coculture with breast cancer cells cause formation of larger hMEC acini. (A) MDA-MB-231 and Hs578T cells
were seeded at 70 cells/mm2 density on 1 mm Matrigel thickness. Brightfield images were taken on days 6, 10, and 15 of acinar
morphogenesis. (B-D) MCF-10A, 76NF2V, and 76NE6 cells were cultured on Matrigel in 3 different 3D culture conditions: 1)
alone, 2) mixed with Hs 578T or MDA-MB-231 cells at 1:1 ratio, and 3) on the top layer (insert) of a transwell plate with the Hs
578T or MDA-MB-231 cells on the bottom well. Brightfield images were taken on days 6, 10, and 15 of acinar morphogenesis.

LMW-E expression in a non-tumorigenic hMEC line, 76NE6, induces cellular
transformation in vivo, we injected these cells stably expressing vector, EL, and
LMW-E subcutaneously into nude mice and observe for xenograft development
(Table 6). The MDA-MB-468 breast cancer cell line was injected as a positive
control. While injection of the vector control cell did not yield tumor development,
7% of the injection of the 76NE6-EL cells formed tumors. More importantly, the
76NE6-LMW-E is significantly more tumorigenic as their injection led to 74% tumor
incidence (p<0.0001). The significant difference in the tumorigenic potential
between EL and LMW-E led us to believe that the proteolytic cleavage of cyclin E
into LMW-E renders novel physical and molecular interactions with other proteins to
support tumor growth in mice.
Now that we have established that LMW-E is tumorigenic, the next question
to address is: does LMW-E function to sustain tumor maintenance and reinitiate
tumor development? Consequently, we subjected the LMW-E-expressing tumor
cells to serial in vivo passaging in the mouse mammary fat pad. The 76NE6-LMW-E
tumors were removed and prepared for culture in vitro (T1G2 clones) (see Figure
11A for schematic of in vivo passaging). Two clones from this generation were
injected back into the mice (T1G2.2 and T1G2.7) and all 10 of the injections
rendered tumor growth (Table 6). We repeated the passaging for two additional
rounds generating the T1G3 and T1G4 clones, and the injections also resulted in
100% tumor formation. We selected 3 clones from each generation for further
studies in vitro (T1G2.2, 5, 7; T1G3.1, 5, 8; and T1G4.2, 7, 8), and they are
collectively named tumor-derived cells (TDCs). Taken together, these results
strongly indicate that LMW-E expression by itself is capable of promoting tumor
development and enhancing tumorigenicity with in vivo passaging.
2.3i. In vivo passaging selects for increasing LMW-E and decreasing elafin
expression
To further investigate the mechanism of LMW-E-mediated tumorigenesis, the
TDCs were subjected to western blot analysis for cyclin E and elafin expression.
Most of the TDC clones show dramatic increase in LMW-E protein levels compared
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Figure 11: In vivo passaging
selects for increasing LMW-E and
decreasing elafin expression. (A)
Schematic of the generation of in vivo
passaged clones with 3 successive
injections (T1G2-G4). (B) Tumors
were removed from the fat pad of
76NE6-LMW-E mice, minced, and
cultured on monolayer plates.
Lysates were extracted and subjected
to Western blot analysis with
antibodies against cyclin E, elafin and
β-actin. EL (C), LMW-E(D), and elafin
(F) protein levels were quantified by
densitometry and compared between
different generations of in vivo
passaged cells (Student t test,
*p<0.05). (E) Paraffinmerge
embedded slides of
the 4 representative
tumors were stained
with hematoxylin and
eosin (top panel) and
cyclin E antibody
(bottom panel). (G)
Parafin-embedded
tumor sections from
normal human breast
tissue, T1G2, and
T1G4 tumors were
subjected to
immunofluorescent
staining with elafin
antibody and nuclei
were counterstained
with DAPI. Scale bar
= 100um.

to the 76NE6-LMW-E cells (Figure 11B). Furthermore, quantification of the cyclin E
protein levels by densitometric analysis suggested that in vivo passaging resulted in
the reduction of the full-length (EL) cyclin E level (Figure 11C) while the LMW-E
isoform level was increasing with each generation of passaging (Figure 11D).
Analysis of the tumor tissues by immunohistochemistry staining revealed strong
cyclin E expression (Figure 11E). Pathological analysis was performed by Dr.
Caroline Van Pelt and the results suggested that the tumors formed by the 76NE6LMW-E were characterized as adenosquamous carcinoma, adenocarcinoma with
pillar differentiation, and squamous cell carcinoma. The morphology of the tumors
also appear less organized, diffuse and lack obvious glandular structures.
In contrast to cyclin E, elafin is thought to play anti-tumor promoting role
since elafin prevents the cleavage of cyclin E by inhibiting elastase and its
expression is downregulated in most breast cancer cell lines (210). We speculate
that since the levels of LMW-E is augmented with in vivo passaging, this
phenomenon could be due to loss of elafin expression during growth selection in the
mouse fat pad. Most of the in vivo passaged clones demonstrated near complete
loss of elafin expression while the 76NE6-LMW-E parental cells express very high
elafin (Figure 11B). Densitometric analysis also showed that the expression level of
elafin (an endogenous inhibitor of serine protease (210) diminished with increasing
passaging in vivo indicated that cyclin E was subjected to elevated proteolytic
processing in the mouse microenvironment (Figure 11F). In addition,
immunofluorescence staining was performed using paraffin section of normal
human mammary tissue and the xenograft tumors from the T1G2 and T1G4
generations to examine elafin expression pattern in these tissues. The normal
human breast tissues contain numerous acini with a clear hollow lumen and contain
1 to 2 layers of luminal cells (Figure 11G, top panel white arrow). These luminal
cells and the cells in the interstitial region express relatively high elafin. In contrast,
the T1G2 tumor contains acini with filled lumen with noticeably reduced elafin
expression, especially in the cells that make up the acinar structures. More
convincingly, the T1G4 tumor shows even more disorganized acinar structures that
are less defined and elafin expression is almost completely lost. These observations
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suggest that with in vivo passaging, the LMW-E-expressing cells lose control of the
regulation of acinar morphogenesis, and elafin downregulation could be either the
cause or effect of this deregulation. These findings suggest that not only LMW-E is
tumorigenic, but also the fact that LMW-E expression was enhanced in most of the
TDCs implies that perhaps LMW-E expression is advantageous and selects for
growth and survival of these cells in the mice.
2.3j. The tumorigenicity of LMW-E requires CDK2-associated kinase activity
To eliminate potential false positive and effects from clonal variation, we
generated a more stringent model system in the 76NE6 cell line in which the
expression of FLAG-tagged vector, EL, and LMW-E can be induced with varying
doxycycline concentrations (Figure 12A). At the G1-S phase boundary, cyclin E
binds to CDK2 to form an active complex that phosphorylates multiple proteins to
induce S-phase entry. Immunoprecipitation using FLAG antibody followed by
incubation with 32P-γ-ATP and histone H1 confirms that inducible EL and LMW-E
have functional cyclin E-associated kinase activity (Figure 12A). The inducible
76NE6 cells expressing V, EL, and LMW-E and were injected subcutaneously into
the mammary fat pad of nude mice and cyclin E expression was induced by
doxycycline administration in drinking water 24 hours after the injection. Induction of
LMW-E expression with 500 µg/ml doxycycline led to significantly more tumor
formation at 95% for LMW-E and 90% for compared to uninduced cells at 11% as
assessed by the Fisher’s Exact test (p<0.0001) (Table 7). Similar to our previous
observation, induction of EL expression with doxycycline led to tumor formation at
17% compared to 11% uninduced cells.
Given that cyclin E requires interaction with CDK2 to exert its kinase activity,
we next aimed to investigate whether the oncogenicity of LMW-E requires CDK2associated kinase activity. Previous study reported that the R130 site on the cyclin
E protein is important for mediating the interaction between cyclin E and CDK2
(135). As a result, the point mutation R130A was introduced into the different
isoforms of cyclin E. Results shown in Figure 12A confirm that the cyclin E/CDK2
kinase activity of these cyclin E mutants is abolished by immunoprecipitating cyclin
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Figure 12: LMW-E deregulation of acinar morphogenesis is dependent on
CDK2-associated kinase activity. (A) 76NE6-TetR cells were cultured with or
without doxycycline induction, and the lysates were extracted and subjected to
Western blot analysis with antibodies against cyclin E and β-actin. In vitro kinase
assay was performed by immunoprecipitation with FLAG antibody and histone H1
and GST-Rb were added as substrates. Doxycycline was administered to achieve
approximately 1x and 2x cyclin E protein levels. (The doxycycline concentrations
for the 76NE6-TetR-V and wild-type EL and LMW-E cells were 0, 0.2, and 0.4
ng/ml, and the doxycycline concentrations for the ELR130Aand LMW-E R130Acells
were 0, 1, and 2 ng/ml.) (B) 76NE6-TetR cells were cultured on Matrigel for 15
days with or without doxycycline induction. Bright-field images were taken at day
15. Values underneath each figure represent mean diameter (µm) ± SEM. (C)
The diameters of at least 100 acini from 3 different experiments were measured.
Error bars = SEM (Wilcoxon rank-sum test, *p<0.05). (D) Multi-acinar complexes
were counted. Error bars = SEM (Wilcoxon rank-sum test, *p<0.05). Multi-acinar
complexes were defined as complexes with more than 2 acini growing on top of
each other. Logistic regression models were used to compare the rate of
formation of multi-acinar complexes between/among groups (*p<0.05).
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E FLAG-tagged proteins and measure the extent of histone H1 phosphorylation
(Figure 12A). Injection of the 76NE6 cells with inducible expression for ELR130A and
LMW-ER130A and into the mammary fat pad of nude mice revealed that LMW-E does
require CDK2-associated kinase activity to induce tumor formation (Table 7). In
other words, the tumor incidence caused by ELR130A and LMW-ER130A and compared
with vector control is not statistically significant. These data suggest that LMW-E
demonstrates stronger tumorigenic potential than EL, and this ability to induce
tumor formation requires the kinase activity exerted from interaction with CDK2.
2.3k. LMW-E deregulation of acinar morphogenesis is dependent on CDK2associated kinase activity
As CDK2-associated kinase activity is required for mammary tumor
development, we speculate that this same requirement is critical for LMW-Emediated acinar deregulation. Bright field images of 76NE6 cells with inducible
expression for different cyclin E constructs during acinar morphogenesis confirm
previous data that induction of EL led to generation of larger acini with the
structures remaining spherical (Figure 12B). In contrast, induction of the LMW-E
isoforms generated acini with very irregular shapes and multi-acinar aggregations.
The diameter of at least 100 acini were measured and the quantification revealed
that cyclin E expression lead to large acini formation in a dose dependent manner
(Figure 12C). On the contrary, we observed that induction of ELR130A and LMWER130A did not result in enlargement of acinar size (Figure 12C). In addition, LMW-E
expression tend to form multiacinar complexes in which at least 2 acini are
overlapping or fused into one aggregate (Figure 12B). Quantification revealed that
this phenotype was only observed in wild type LMW-E-expressing cells but not in
the cells expressing EL or the R130A mutant cyclin E variants (Figure 12D). These
results suggest that the LMW-E/CDK2-associated kinase activity is responsible for
driving mammary tumorigenesis by generating deregulated acinar structures in the
mammary gland. Previous clinical examination of breast cancer patient samples
revealed that high LMW-E protein levels significantly correlate with poor patient
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survival, and the data presented here further confirms that the level of LMW-E
expression positively correlates with aberrant acinar development.
2.3l. LMW-E generates enlarged acini by reducing apoptosis and enhancing
proliferation
To determine the mechanism of LMW-E-mediated tumorigenesis, the 9 TDC
clones were also subjected to acinar morphogenesis. Similar to our observation with
the stable and inducible model systems, all TDCs form large and non-spherical acini
that are approximately 28% larger than the 76NE6 parental acini (p < 0.05) (Figure
13A and B). The acinar morphogenesis process includes several distinctive stages.
During the first 8 days of culture on Matrigel, the cells undergo high rates of
proliferation, which continues to occur while the cells in the interior of the structure
undergo apoptosis due to anoikis or detachment from the basement membrane to
generate a hollow lumen (239). The luminal cell layer is highly polarized which is
important for milk secretion into the luminal space. Cell proliferation subsides
towards the late stage of morphogenesis from day 10 to day 15 to form a mature
acinus that is approximately 120 um in diameter. As expected, the levels of cyclin E
protein in the parental 76NE6 cells is lower in 3D culture compared to 2D culture
since these cells have arrested proliferation by downregulating the G1-S phase
cyclin (Figure 5A). However, the 76NE6-LMW-E and TDCs express dramatically
high cyclin E protein levels during acinar morphogenesis compared to the parental,
vector and 76NE6-EL cells (Figure 13C). In vitro kinase assay demonstrates that
the TDCs exhibit high cyclin E/CDK2 kinase activity indicating that these cells are
not arresting cell cycle progression but instead are actively traversing through the
G1-S phase transition (Figure 13C). Perhaps LMW-E expression generates an
aberrant positive feedback loop during acinar morphogenesis that leads to further
upregulation of cyclin E expression in the acini.
BIM is a Bcl2 pro-apoptotic protein that is upregulated during acinar
morphogenesis to induce cell death in the matrix-detached cells to create a hollow
lumen (243). Interestingly, the acini expressing cyclin E downregulate BIM
expression suggesting that there is reduced apoptosis in these acini (Figure 13C).
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Figure 13: LMW-E generates enlarged acini by reducing apoptosis and
enhancing proliferation. (A&B) 76NE6 cells stably transfected with vector, EL, and
LMW-E and tumor-derived cells (TDCs) were seeded at a density of 70 cells/mm2
on 1-mm-thick Matrigel. After 15 days in 3D culture, cells were fixed and
immunostained with GM-130 and α6-integrin antibodies. Nuclei were counterstained
with DAPI. Scale bar = 50 µm. The diameters of the acini were measured and
averaged from 3 independent experiments. Values underneath each figure
represents mean (µm) ± SEM. Error bars = SEM (Student t test, *p<0.05). (C)
Lysates from these cells were isolated at day 15 and subjected to Western blot
analysis with the indicated antibodies. In vitro kinase assay was performed by
immunoprecipitation of lysates from 3D culture using polyclonal cyclin E antibody
and incubation with (γP32)ATP and GST-Rb. (D&E) Cells cultured on Matrigel for 15
days were fixed and immunostained with E-cadherin and Ki67 antibodies. Nuclei
were counterstained with DAPI. Scale bar = 50 µm. The number of Ki67-positive
cells per acinus was counted and averaged from 3 independent experiments. Error
bars = SEM (Student t test, *p<0.05). (F) Linear regression of the correlation
between acinar diameter and percentage of Ki67-positive cells.
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To determine whether LMW-E expression was sufficient to prevent growth arrest of
cells in mature acini, we fixed acini at 15 days and stained them for Ki67. While
Ki67 expression was not detectable in the 76NE6-vector acini, LMW-E-expressing
acini displayed high Ki67 staining, particularly in cells that were in contact with the
basement membrane (Figure 13D & E). Furthermore, we determined a strong
positive correlation between the acinar diameter and the percentage of Ki67positive acini, indicating that the formation of large acini may be due to increased
proliferation (Figure 13F). Taken together, we demonstrate here that LMW-E
causes generation of large and misshapen acini by enhancing cell proliferation and
inhibiting apoptosis. These phenotypes share similarity with early-staged tumors
and those with HER2 overexpression (232). Therefore, we believe that this
deregulation of the mammary acinar morphogenesis by LMW-E occurs in vivo thus
explaining the tumorigenicity of LMW-E and its advantageous selection with
increasing in vivo passaging.
2.3m. Roscovitine rescues LMW-E-induced aberrant acinar development
Given that LMW-E-mediated tumorigenesis and aberrant acinar
morphologies depend on intact CDK2-associated kinase activity, we next aim to
determine whether inhibition of this kinase activity can reverse these phenotypes.
Roscovitine was the pharmacological agent of choice since it has demonstrated
high CDK1 and 2 specificity and potent anti-tumor effectiveness. The 76NE6 and
T1G2.2 cells were seeded on Matrigel culture and treated with roscovitine 24 hours
after seeding every 4 days until day 15 in culture. The results showed that the
treatment of the T1G2.2 cells during acinar morphogenesis with roscovitine led to
formation of smaller and spherical acini while showing no effects on the 76NE6
parental cells (Figure 14A & B). These data suggest that roscovitine is effective in
reversing the aberrant acinar phenotypes caused by LMW-E expression and is nontoxic to normal cells.
Further treatment of the TDCs with 3 different roscovitine concentrations
demonstrated significant reduction of acinar diameter (Figure 14C). Similar to the
76NE6 parental cells, the 76NE6-vector and EL acini show no significant effects in
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Figure 14: Roscovitine rescues LMW-E-induced aberrant acinar development. A) 76NE6 and T1G2.2 cells were
cultured on Matrigel for 15 days and treated with roscovitine from 0 to 16 uM on days 1, 5, 9, and 13. Cells were fixed and
immunostained with laminin V antibody and nuclei were counter-stained with DAPI. Scale bar = 50um. (B) The diameter of
at least 100 acini from 3 different experiments was measured. Error bars = SEM. (C) 76NE6 parental (P), vector (V), EL,
LMW-E and TDC cells were cultured on Matrigel for 15 days and treated with roscovitine at 0, 8 and 16 uM on days 1, 5, 9,
and 13. The diameter of at least 100 acini from 3 different experiments was measured. TDCs represent average of all 9
tumor clones. Error bars = SEM (Student’s t test, *p<0.05). (D) The number of multi-complexes were counted and
averaged from 3 experiments. Error bars = SEM (Student’s t test, *p<0.05). (E) Lysates from 3D culture were extracted
and subjected to Western blot analysis with antibodies against cyclin E, pRb (S807/811) and β-actin.
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response to roscovitine treatment. We also observed that roscovitine treatment
significantly reduces the multi-acinar complex formation by the LMW-E-expressing
cells (p < 0.05) (Figure 14D). Perhaps roscovitine induces a G1 arrest since cyclin E
and pRb protein levels are downregulated in the roscovitine-treated acini (Figure
14E). We speculate that inhibition of LMW-E/CDK2 complex by roscovitine allows
the acini to arrest proliferation and thereby suppressing the aberrant positive loop
that drives cyclin E protein overexpression. Growth arrest towards the end of
morphogenesis (days 12-15) also allows cells to properly organize into correct and
spherical acinar structures. Thus, our data suggest that roscovitine is an effective
pharmacological agent that can reverse the phenotypes mediated by LMW-E/CDK2
complex and sheds light into our effort to develop therapeutic strategy for breast
cancer patients with high LMW-E expression levels.
2.3n. High LMW-E expression is associated with activated b-Raf-ERK1/2mTOR pathway in vitro and in human tumor tissues
While it is widely accepted that the 3D culture system serves as a more
physiologically relevant model for the investigation of cell behavior compared to 2D
plastic surface (223, 228), no direct comparison between cells cultured on this 3D
model and human samples has been performed. To provide such a comparison, we
analyzed the protein expression of the TDCs grown on monolayer and Matrigel
cultures as well as 276 breast cancer patient tissues by performing Reverse Phase
Protein Array (RPPA) analysis (234). The RPPA method is a proteomic protein
expression analysis that has been shown to be highly reproducible in analyzing the
expression patterns of proteins involved in cell signaling (16, 234, 244). Hierarchical
clustering was performed using Euclidean distance and Ward’s minimum variance
for agglomeration (Figure 15A). The resulting heat map demonstrated that the cells
from 2D and 3D cultures had strikingly different protein expression patterns and that
the protein expression pattern of the cells from 3D cultures (mammary epithelial
cells cultured in Matrigel) more closely resembled that of patient tissues than did the
protein expression pattern of cells grown on monolayer. These results were
expected since it is has been established that the 3D culture system is a more
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Figure 15: High LMWE expression is
associated with
activated b-RafERK1/2-mTOR
pathway in vitro and
in patient tissues. (A)
Hierarchal cluster
analysis of protein
expression in 76NE6,
76NE6-LMW-E and all
of the TDC clones
grown on 2D (red) and
3D (green) cultures
and 276 breast cancer
patient samples (blue).
Unsupervised
clustering of the top 50
proteins separated by
low versus high EL (B)
and LMW-E (C)
expression. (Red:
patients with low cyclin
E expression; blue:
patients with
high cyclin E
expression.) (D)
Proteins whose
expression was
associated with high
LMW-E levels. Red
indicates that high LMWE along with high protein
expression was
associated with poor
prognosis; grey indicates
that high LMW-E along
with low protein
expression was
associated with poor
prognosis. (E) The lysates from 3D
culture were subjected to Western blot
analysis to validate the RPPA data. The
cell lines are 76NE6-parental (P) and
with stable expression of vector (V), EL,
and LMW-E and the tumor-derived cells
(TDCs). (F) Linear regression analysis
between the RPPA data and the
densitometry values from Western blot
analysis of the proteins from (E).

physiologically relevant model than cell culture on a 2D plastic surface for the
investigation of cell behavior (223, 228). Furthermore, in an unsupervised analysis
of the patient RPPA data, we observed separate clustering between the low and
high LMW-E-expressing breast tumors but not between low and high full-length
cyclin E (Figure 15B & C).
We next identified the proteins whose expression was significantly
associated with LMW-E levels as well as patient survival in the tumor database. Our
analysis revealed that in the breast cancer patient samples with high LMW-E
expression, the b-Raf-ERK1/2-mTOR pathway was also activated (Figure 15D).
Furthermore, Western blot analysis of the lysates from the TDCs grown on Matrigel
showed high concordance with the RPPA data and also validated the activation of
this signaling axis in vitro: (Figure 15E & F). Additionally, breast cancer patient
tumors with high LMW-E expression also expressed high levels of b-Raf, pMEK1/2
(S217), ERK2, mTOR, and eIF4E and a low level of pAkt (T308) while those with
high EL expression only showed significant difference in the expression of b-Raf,
mTOR, and eIF4E (Table 8). Collectively, these data suggested that in terms of
proteomic expression patterns, breast cancer cells grown in 3D culture more closely
resemble human tumors than do breast cancer cells grown in 2D culture and that
3D culture thereby facilitates the identification of signaling events that correlate with
LMW-E levels.
2.3o. Combination drug treatment prevents induction of aberrant acinar
development by LMW-E
Having established the importance of CDK2-associated kinase activity in
aberrant acinar morphogenesis in 3D culture and given that the b-Raf-ERK1/2mTOR signaling axis was deregulated in tumor cells and patient samples with high
LMW-E expression, we hypothesized that combination treatment with roscovitine (a
CDK inhibitor) plus either rapamycin (an mTOR inhibitor) or sorafenib (a pan kinase
inhibitor that has activity against b-Raf) normalizes acinar morphology. Combination
treatments of cells cultured in Matrigel using these agents resulted in a larger
reduction of the levels of pS6 (S235/236), pERK1/2 (T202/Y204), and pRb

82

Table 8. Pa$ent protein expression based on low and high LMW‐E and
EL levels by RPPA analysis

* Wilcoxon ranksum test
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(S807/811) than no treatment or treatment with single agents (Figure 16A).
Moreover, the combination treatments upregulated the expression of the CDK
inhibitors p21 and p27, consistent with a cell cycle arrest at the G1/S phase (data
not shown). Examination of the acinar formation as a result of the combination drug
treatments revealed that the TDCs displayed a significant reduction in acinar size
and Ki67 levels compared to the untreated cells and cells treated with single agents
(p < 0.05) (Figure 16B-D). More specifically, both combination drug treatment
conditions led to a 2-fold reduction in both acinar size and the number of Ki67positive acini compared to the single agent conditions (Figure 16C & D). In contrast,
the 76NE6-vector and 76NE6-EL cells displayed no change in these phenotypes in
response to the drug treatments, suggesting that the absence of LMW-E expression
may protect these cells from the toxic effects of the drugs. Thus, roscovitine in
combination with either rapamycin or sorafenib can prevent the development of the
aberrant acinar phenotypes caused by LMW-E expression, confirming a role for
LMW-E/CDK2 kinase activity in causing formation of large, multilobular acini and
demonstrating a potential therapeutic approach to treat cancer patients with high
LMW-E expression.
2.3p. Activated b-Raf-ERK1/2-mTOR signaling pathway and high LMW-E
expression predict poor survival
In a large retrospective clinical study, we previously found that breast cancer
patients whose tumors had high levels of LMW-E expression, as determined by
Western blot analysis, have significantly worse DSS than patients whose tumors
had low LMW-E expression (160). In the study reported herein, we used tissue
samples from a portion of this patient cohort for RPPA analysis to investigate largescale protein expression pattern. Similar to our previous observation, we found that
patients with high LMW-E protein levels had significantly worse DSS than patients
with low LMW-E expression (p<0.0001) (Figure 17A). More specifically, patients
with high LMW-E and low full-length cyclin E expression demonstrated significantly
worse DSS compared to patients with high LMW-E and also high full-length cyclin E
(p=0.004). Bivariate analysis of LMW-E along with key nodes in the b-Raf-ERK1/2-
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Figure 16: Combination drug treatment prevents induction of aberrant acinar
development by LMW-E. (A) Cells were seeded on Matrigel for 24 hours and then
treated with rapamycin, sorafenib, and roscovitine as indicated. Medium containing
drugs was replaced every 4 days, and lysates were collected on day 15 for
Western blot analysis with the indicated antibodies. (B) On day 15 of Matrigel
culture, cells grown as in (A) were fixed and stained with E-cadherin (red) and Ki67
(green), and nuclei were counterstained with DAPI (blue). Scale bar = 50 µm. (C)
The diameters of the acini were measured and averaged from three independent
experiments. Error bars = SEM (Student t test, *p<0.05). (D) The number of Ki67positive cells per acinus was counted and averaged from three independent
experiments. Error bars = SEM (Student t test, *p<0.05).
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Figure 17: Activated b-RafERK1/2-mTOR signaling
pathway and high LMW-E
expression predict poor
survival in breast cancer
patients. (A) Kaplan-Meier
estimates of disease-specific
survival based on the
expression of low and high EL
and LMW-E measured by
Western blot analysis of 276
p = 0.0109
breast cancer patient samples.
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mTOR pathway revealed that among breast cancer patients with high LMW-E
expression, those with high FAK levels had significantly worse DSS than those with
low FAK levels (p=0.0042) (Figure 17B). In contrast, among patients with high
LMW-E expression, low BIM or low total Akt levels was associated with worse
survival. Additionally, the overall DSS of patients with high LMW-E combined with
these proteins in the b-Raf-ERK1/2-mTOR pathway was dramatically worse than in
the patients with high full-length cyclin E expression (Figure 17B).
To determine whether these individual proteins collaborate to reduce patient
survival, we performed multivariate analysis by analyzing patients with high LMW-E
expression and combining 2 additional proteins. We found that patients with high
LMW-E, high FAK, and low BIM, Akt, or pAkt (T308) experienced significantly worse
DSS than the other groups (p<0.05) (Figure 17D). In addition, patients with high
LMW-E, low BIM, and low Akt or pAkt (T308) experienced significantly worse DSS
(p<0.05). Interestingly, we were not able to find statistical significance between fulllength cyclin E expression in the same multivariate analysis with these proteins
(Figure 17C). Essentially, our statistical analysis suggests that it is likely that LMWE, FAK, BIM, Akt, and pAkt (T308) function in the same pathway to adversely affect
patient survival in breast cancer.
2.4. CONCLUSIONS
The extracellular matrix provides environmental cues that induce differentiation
and senescence of normal epithelial cells, and this response is lost when a cell
transforms into a cancer cell. The acinar morphogenesis assay is an in vitro model
system that can clearly distinguish the difference in growth behavior between
normal epithelial cells and tumor cells (224, 232). The results from this study
demonstrate that immortalized hMECs growth arrest and form differentiated and
polarized acinar structures in laminin rich basement membrane while breast cancer
cell lines fail to exhibit these behaviors. The morphological difference between
normal and cancer cells displayed on Matrigel culture is because signaling from the
extracellular matrix greatly influences the progression of the cell cycle intracellularly.
Previous studies have demonstrated that malignant breast cancer cells express
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high levels of β1-integrin receptor and exhibit disorganized distribution of the
receptor in the acinar structures (245). Treatment of these structures with a blocking
b1-integrin antibody reverts the aberrant morphologies, downregulates cyclin D
expression while upregulating p21Cip1 levels (245). Therefore, cell cycle regulation is
critical for the maintenance of the integrity of the differentiation state of the cells and
tissue. Without this regulation, the cells ignore the signals provided from the
surrounding and become highly proliferative and cancerous. The difference in
cellular proliferation is observed in cells cultured on monolayer and 3D matrix.
Immortalized hMECs (76NE6, 76NF2V, and MCF-10A) exhibited growth arrest
when cultured on 3D Matrigel compared with those cultured on monolayer.
High rate of proliferation resulting from deregulated G1-S phase transition
mediated by overactive LMW-E/CDK2 complex is morphologically distinguishable
during acinar morphogenesis. This uncontrolled proliferation is apparent by high
Ki67 staining in the matrix-attached cells of the LMW-E-expressing acini but not in
EL and vector control acini. The highly proliferative luminal cells may also explain
the large and non-spherical acinar structures since coordination of cellular arrest
and differentiation is lost. In addition to hyperactive proliferation, the LMW-Eexpressing acini also downregulate bim indicating failure of the central cells to
undergo apoptosis thus leaving a filled lumen (243). Elevated proliferation and
reduced apoptosis observed in the acinar structures may explain the ability of LMWE to induce tumor growth in the mouse mammary fat pad.
While the cyclin E/CDK2 complex is the accelerator of the G1-S checkpoint,
p53 is the brake. Acting as a tumor suppressor, one of the major functions of p53 is
to activate p21Cip1 transcription in response to DNA damage, which in turn inhibits
the cyclin E/CDK2 complex (246). The molecular link between cyclin E
overexpression and loss of p53 control in breast cancer has been suggested in a
number of reports. In one study, 56% of breast cancer patients with high cyclin E
content were found to also possess p53 gene mutations (242). Furthermore, in our
transgenic mouse model, overexpression of LMW-E is sufficient to induce
mammary adenocarcinomas with 25% of the tumors advancing to metastasis (180).
Moreover, these mice were found to select for loss of heterozygosity (LOH) of p53
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and spontaneous inactivation of the ARF-p53 pathway. The aberrant acinar
phenotypes induced by LMW-E worsen with loss of p53 expression. Therefore, the
counterbalance between LMW-E and p53 has biochemical and functional
implications in normal mammary acinar development, and deregulation of this
process could act as the first step of derailment into malignancy.
Elafin is an elastase inhibitor and thus can prevent the generation of LMW-E.
We recently reported that elafin is transcriptionally down regulated in most tumor
cell lines, rendering the generation of LMW-E in tumor but not in normal cells (210).
Ectopic elafin expression is able to some extent induce MDA-MB-231 cells to form
spherical structure from single cell morphology. Furthermore, results from the
xenograft study suggest that perhaps LMW-E-mediated tumorigenesis is due to
elafin downregulation since the in vivo passaged tumors exhibit high LMW-E
expression and suppressed elafin protein level. Research from our lab indicate that
elafin is upregulated upon growth factor starvation or basement membrane
detachment to elicit cell cycle arrest and or apoptosis, depending on the cell’s pRb
status. While the mechanism of elafin transcriptional downregulation remains to be
elucidated, it is possible that loss of elastase inhibition mediated by elafin is
responsible for the high levels of LMW-E in the xenograft tumors.
LMW-E is necessary and sufficient for growth of cancer cells in vivo. Xenograft
transplantation experiment indicates that 74% of injection of hMECs expressing
LMW-E led to tumor development whereas the percentage of tumor formation with
injection of EL-expressing hMECs was 10 folds lower. This observation is consistent
with previous study using transgenic mouse model to illustrate that LMW-E is a
stronger oncogene than EL (180). Moreover, LMW-E expression is selected with
increasing passaging of the tumor cells through the mice suggesting that LMW-E
provides advantageous growth and survival for the tumor. With each generation of
passaging, the LMW-E-expressing tumors developed at higher efficiency compared
to the first generation. The microenvironment can exert selective pressure to induce
genetic and epigenetic changes to favor progression of the tumor (247).
Our previous studies showed that LMW-E isoforms form tighter complexes
with CDK2 compared to EL isoform and thereby exhibit higher kinase activity (175,
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221). Furthermore, the LMW-E/CDK2 complexes are significantly more resistant to
inhibition by p21 and p27 over EL/CDK2 complexes (175). Alteration in the
interaction with CDK2 and inhibitory response to CKIs explains the difference in the
oncogenicity between EL and LMW-E isoforms described in this report.
Interestingly, the oncogenicity of LMW-E and formation of multiacinar complexes
are strictly dependent on CDK2 kinase activity suggesting that perhaps unbound
LMW-E exhibits no oncogenic activity. Therefore, CDK2 kinase activity presents as
an ideal target to treat patients with high LMW-E expression. Roscovitine treatment
can rescue the formation of large and multi-acinar complexes induced by LMW-E
while showing no toxic effects on parental control acini. In the literature, roscovitine
has proven to be an effective therapeutic agent in targeting numerous types of
tumor cells including breast cancer, non-small cell lung cancer, sarcoma, multiple
myeloma and lymphoma (173, 178, 198, 248, 249). Since the tumorigenic activity of
LMW-E strongly depends on CDK-associated kinase activity, roscovitine becomes
an apparent choice for designing therapeutic strategies for cancer patients with high
LMW-E expression. The fact that LMW-E requires CDK2 kinase activity to drive
multiacinar complexes and promote tumor-initiating activity of hMECs in mice
suggests that LMW-E itself has no intrinsic oncogenic activity. Therefore, treatment
of tumors with high LMW-E protein levels can be achieved by inhibiting CDK2
kinase activity. Our data demonstrate that combination treatment using roscovitine
together with rapamycin or sorafenib of LMW-E-expressing acini efficiently prevents
the aberrant morphogenetic phenotypes without toxic effects on hMECs lacking
LMW-E expression.
The results from proteomic analysis demonstrated a marked contrast in the
protein expression profiles of cells grown on monolayer and cells grown in 3D
culture and illustrated a high similarity between cells in 3D culture and human tumor
tissues, thus establishing a bridge between the 3D culture system and human
tissues and further supporting the use of this culture system for biological study
(250). In fact, gene expression signatures of mammary cells extracted from this 3D
culture system can be reliably used to predict patient outcome in which the
signature of growth-arrested and well-organized hMECs predicts favorable clinical
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outcome (229, 251). Data from this analysis also allowed for the delineation of a
signaling pathway that is deregulated in breast cancer patients who express high
LMW-E levels. We demonstrated that tumors and cell lines with high LMW-E
expression have upregulated b-Raf-ERK1/2-mTOR signaling, which has been
reported to result in enhanced cell survival and reduced apoptosis (252-254).
In this chapter, multiple experimental systems were employed to explore the
role of LMW-E with CDK2 in tumorigenesis. The results obtained indicate that LMWE induces aberrant acinar morphologies and is clearly a much stronger oncogene
compared to EL. More importantly, these oncogenic phenotypes mediated by LMWE are dependent on its ability to interact with CDK2 to exert its kinase activity.
Furthermore, proteomic analysis also identifies a signaling pathway involving rafERK1/2-mTOR that is activated in tumor cells with high LMW-E expression and
associate with poor patient outcome. Clinically, there is a high percentage of breast
cancer patients whose expression of LMW-E significantly predicts poor prognosis
and adverse clinical outcomes (160). Our data suggest that the combination of
roscovitine with either rapamycin or sorafenib should be evaluated as a therapeutic
strategy to treat breast cancer patients with high LMW-E expression.
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CHAPTER 3: LMW-E INDUCES THE EMT AND ENRICHES FOR CELLS WITH
CSC PROPERTIES
3.1. INTRODUCTION
3.1a. The cancer stem cell (CSC) theory
Cancer is a multi-step heterogeneous disease caused by accumulation of
genetic and epigenetic alterations that lead to uncontrolled growth of normal cells.
This theory is supported by epidemiological data demonstrating that breast cancer
development occurs many years after the actual oncogenic event (255, 256).
Indeed, stem cells or progenitor cells are believed to be more susceptible to these
alterations since they endure longer lifespan and thus are able to gain sufficient
mutations to initiate and sustain tumor development (257). However, recent
research in this field suggests that CSCs can in fact arise from a differentiated cell
of origin.
The CSC theory states that there is a small population of cells within the
tumor mass that possess unique properties shared by stem cells such as selfrenewal capacity, multi-potency, and unlimited proliferation (257, 258). More
specifically, CSCs have the ability to proliferate extensively and give rise to diverse
cell types with reduced development or proliferation potential. Recent research
presents vast evidence supporting the existence of CSCs in both hematological
cancers as well as solid tumors (259-269). The Hierarchy stem cell model states
that there are different subpopulations of cells within the tumor mass that possess
different capabilities of self-renewal and differentiation (Figure 18A) (257, 260). This
model emphasizes that only a small definable subset of tumor cells has the
potential to initiate tumor growth and reproduce the hierarchy of cells that comprise
the tumor. Indeed, numerous studies reported that many tumors are heterogeneous
and contain many cell types thus suggesting that the few CSCs are multi-potent
(270-274). In contrast, the Stochastic model predicts that the process of each
individual cell within a tumor to self-renew and differentiate occurs randomly and
can be predicted by statistics (Figure 18B) (257, 258, 275). This model maintains
that the tumor is composed of a homogeneous population of cells and every cell
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Adapted from Nature 2001;414(6859):105-11.
Figure 18: CSC models. (A) In the Hierarchy model, only a small subset of cells
termed CSCs (red cells) are capable of self-renewal and form new tumors. The
more differentiated cells do not possess self-renewal capability (blue cells), cannot
form new tumors, and eventually reach terminal differentiation. (B) The Stochastic
model argues that the tumor is composed of a homogenous population and every
cell in the tumor has an equal but small chance to self-renew and form new tumors.
97

has a low but equal chance of acquiring tumorigenic potential. Clonal outgrowth of
an individual cell due to genetic/epigenetic insult leads to selection and
accumulation of this dominant population that then forms the bulk of the tumor
(276). Currently there is no clear evidence that is sufficient to distinguish between
these two models suggesting that they are not mutually exclusive. While the
discussion on the origin of tumor cells and how to appropriately define these cells is
ongoing, research in the last few years have further strengthen the fact that these
CSCs are important in tumor initiation, maintenance, metastasis, and resistance to
therapy.
3.1b. Molecular markers of mammary CSCs
CSCs are not only present in hematological cancers but are also identified in
numerous solid tumors, most notably in breast cancer (263). Accumulating evidence
from a number of publications indicate that mammary CSCs can be identified and
isolated based on their expression for the CD44hi/CD24lo surface markers, aldehyde
dehydrogenase (ALDH) enzymatic activity, and the ability to form tumors at low cell
numbers and mammospheres in low attachment and non-differentiating culture
conditions (263, 277, 278). Early work by Al-Hajj and colleagues demonstrated that
as few as 100 primary breast cancer cells that are defined by the CD44hi/CD24lo cell
surface expression pattern can form tumors when injected into the mammary fat
pad of nude mice and also can be serially passaged while tens of thousands of cells
with the CD44hi/CD24hi phenotype cannot (263). Particularly, the in vivo passaged
tumors from the second and third generations display similar population distribution
as the original tumor suggesting that the CD44hi/CD24lo population possess selfrenewal capability as well as the ability to differentiate into non-CSCs.
Although, as of yet, there are no functions associated with this cell surface
marker, CD44hi/CD24lo cells are able to form mammosphere structures under nonadherent and non-differentiating culture condition, which is a functional test that has
been reliably employed to investigate the self-renewal and differentiation capability
of neuronal stem cells (279). While epithelial cells require basement attachment for
survival and proliferation, Dontu and colleagues demonstrated that a single
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mammary progenitor cell is able to proliferate and differentiate to form a floating
mammosphere when cultured on non-adhesive substratum (277). Furthermore,
mammospheres contain undifferentiated cells that are able to give rise to the 3
types of cells in the mammary gland, which are myoepithelial, ductal, and alveolar
(luminal) epithelial cells (Figure1). Breast cancer cells grown in mammosphere
culture condition exhibit increased tumorigenicity and downregulate CD24
expression, and these phenotypes can be reversed with passage in monolayer
culture (280, 281).
Another functional marker identified to be associated with CSC is ALDH,
which is a detoxifying enzyme that has been shown to be involved in early
differentiation of stem cells by oxidizing retinol to retinoic acid (282) and is believed
to mediate self-protection against some alkylating chemotherapeutic agents (283).
Similar to the CD44hi/CD24lo cells, sorted ALDHhi cells injected into xenograft
mouse model are capable of recapitulating the phenotypic distribution of the original
tumor (278). Although there is a small percentage of CD44hi/CD24lo cells that are
also ALDHhi (approximately 1% of the tumor population), as few as 20 cells with the
CD44hi/CD24lo/ALDHhi phenotype are able to generate tumors in mice, which are 5
folds more tumorigenic compared to the CD44hi/CD24lo population alone (278).
Clinically, breast cancer patients whose tumors contain high ALDH expression are
predicted to have poor clinical outcome (278, 284). Overall, the identification of
these CSC markers have greatly facilitated our understanding of mammary tumor
biology and allowed for examination into the mechanism of drug resistance and
tumor relapse.
3.1c. The EMT connection to CSCs
The cells defined by the CD44hi/CD24lo antigenic phenotype are enriched in
tumor-initiating cells, exhibit enhanced tumor invasiveness, and can be generated
through induction of the EMT (263, 285, 286). Mani and colleagues first reported
that induction of the EMT by ectopic expression of twist, TGFβ1 or snail results in
an enrichment of the CD44hi/CD24lo population, mammosphere formation, and
tumorigenicity in hMECs (285). EMT is a developmental process in which epithelial
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cells gain mesenchymal phenotypes and behaviors such as increased motility and
invasion to allow formation of new tissues and organs (287). However, aberrant
induction of the EMT in tumor cells is known to enhance proliferation and invasion
(288). Indeed, acquisition of the EMT traits is thought to aid tumor cells to invade
and migrate to form metastasis at distant organ and the reverse process termed
mesenchymal-epithelial transition (MET) is necessary for successful colonization at
the new tumor location.
3.1d. LMW-E associates with basal-like breast cancer
Analysis of the breast cancer subtypes indicated that the CD44hi/CD24lo cell
population is enriched in the basal-like breast tumors, which are clinically
associated with poor prognosis (289, 290). The basal-like subtype of breast cancer
was first defined by gene expression microarrays to be negative for ER, PR, and
HER2, and positive for cytokeratin 5/6 and EGFR (10). Interestingly, the mammary
tumors formed from overexpression of LMW-E also assume the basal-like
phenotypes and resemble the morphological characteristics of the tumors caused
by deregulation of the Wnt pathway, which are acinar, glandular, papillary, solid,
and adenosquamous (180, 291). Rosner and colleagues demonstrated that the
phenotypes of the tumors often predict the genotypes signifying that tumors that
share the same morphological characteristics are predicted to exhibit deregulation
to the same pathway (292). Recent analysis of our breast cancer patient samples
further indicated that of the LMW-E-expressing tumors, triple negative (TN) tumors
(negative receptor status for ER, PR, and HER2) expressed dramatically higher
levels of LMW-E than other tumors with at least one positive receptor, and these TN
patients are significantly more likely to experience tumor recurrence (p = 0.045).
Given that the mammary tumors formed from ectopic expression of LMW-E assume
the basal-like phenotypes and LMW-E expression is high in TN breast cancer
patients, we speculate that the mechanism that specifically allows LMW-E to initiate
and maintain breast cancer is through activation of the EMT as well as acquisition of
mammary CSC characteristics.
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3.1e. Anti-CSC therapy
Most chemotherapeutic agents are designed to target highly proliferative
cells, which typically form the bulk of the tumor. CSCs however exhibit low
proliferation index, and consequently they are resistant to many current cancer
treatments including chemo- and radiation therapy (293, 294). More specifically, the
CD44hi/CD24lo population was reported to be enriched in the tumor mass after
chemotherapy and these cells demonstrate enhanced mammosphere formation
efficiency (295). The CSCs that remain after therapy are capable of regenerating a
new tumor thereby leading to tumor relapse. In addition, CSCs express high levels
of the multi-drug resistance proteins and the ATP-binding cassette (ABC)
transporter family, which function by pumping chemotherapeutic agents out of the
cell (296).
The overwhelming evidence supporting the existence of CSCs suggests that
our conventional therapeutic approaches would only target the non-CSCs that make
up the bulk of the tumor but spare the CSCs that are capable of regenerating the
tumor post-treatment. As a result, we need to improve our therapeutic strategy by
specifically targeting these CSCs in addition to eradicating the non-CSCs. A rational
strategy to overcome this challenge is to combine agents that can target both the
CSC and non-CSC populations. Recently, a large screen for small compounds that
can specifically target the CSC population revealed that salinomycin, an
antibacterial drug, exerts highly specific toxicity against CD44hi/CD24lo cells
compared to paclitaxel (297). Therefore, combination of this agent with a general
chemotherapeutic agent such as doxorubicin, which can kill proliferating non-CSCs,
will likely to result in complete remission.
3.1f. Hypothesis and Specific Aims
Initiation and maintenance of cancer depends on a strong oncogene that can
elicit multiple downstream effects to convert a normal cell to a tumor cell. We
believe that the tumorigenicity of LMW-E is mediated through induction of the EMT
that leads to enrichment of the CSC population, and these tumor cells can be
effectively targeted with combination treatment using doxorubicin and salinomycin.
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Additionally, the ProtoArray microarray analysis, which will be discussed in greater
details in the Results section, will be used to identify novel substrate(s) of the LMWE/CDK2 complex that will allow for elucidation into the mechanism of LMW-Emediated mammary tumorigenesis. The following specific aims are designed to
address this hypothesis:
1. Understand the role of LMW-E in the induction of the EMT
2. Analyze the CSC properties of cells induced with LMW-E expression
3. Identify a therapeutic regimen to target the LMW-E-induced CSCs
4. Identify novel LMW-E/CDK2-associated substrates and/or interacting
proteins
Briefly, the tumor-derived cells (TDCs) isolated from in vivo passaging
exhibited phenotypes characteristic of the EMT, which are reduced cell-cell contact
by downregulation of E-cadherin, upregulated gene expression profile associated
with the EMT, and enhanced basement membrane invasion. Moreover, the LMW-Eexpressing tumor cells demonstrated an increase in the CD44hi/CD24lo population,
and examination of patient tumor samples indicated that cytoplasmic cyclin E IHC
staining significantly associate with high CD44hi/CD24lo score compared to nuclear
cyclin E staining (p = 0.0435). Further analysis for the CSC characteristics revealed
that the TDCs possess self-renewal capability by forming mammosphere structures
and also upregulated ALDH expression and enzymatic activity. Combination drug
treatment with doxorubicin and salinomycin reduced the CSC population and
synergistically killed the CSCs while sparing normal cells that do not express LMWE. Finally, ProtoArray analysis revealed that LMW-E/CDK2 phosphorylates Hbo1 in
the N-terminal domain, which demonstrated no effects on the in vitro histone
acetyltransferase activity of Hbo1. Co-expression of LMW-E/CDK2 with Hbo1 in
HEK293T resulted in an enrichment of cells with CSC properties and knockdown of
Hbo1 in the TDCs reduced these properties. Taken together, these data suggest
that Hbo1 is downstream of LMW-E/CDK2 overactive kinase activity, and increased
Hbo1’s HAT activity may be critical for the CSC phenotypes observed.
3.2. MATERIALS and METHODS
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3.2a. General reagents
Antibodies used for western blot analysis are: E-cadherin and ALDH (BD
Bioscienes, Sparks, MD), CDK2 and CD24 (Santa Cruz Biotechnology Santa Cruz,
CA), CD44 (Cambridge, MA), Hbo1 (Proteintech Group, Chicago, IL), FLAG-tag
(Sigma, St. Louis, MO), Myc-tag (Cell Signaling Technology, Boston, MA).
3.2b. Brightfield and indirect immunofluorescence analysis
Cells grown on tissue culture dish were photographed using the Leica DM
4000M microscope (Buffalo Grove, IL) at 5X objective with an attached digital
camera, and images were processed with the Photoshop software (Version 11.0.2).
Indirect immunofluorescence analysis was performed as described in chapter II with
minor modifications. Cells were grown directly on the 8-chamber slides for
monolayer culture and the E-cadherin primary antibody (BD) was incubated in IF
buffer at 1:200 dilution overnight at 4°C. The cells were incubated with Alexa fluorconjugated mouse secondary antibodies (Molecular Probes, Carlsbad, California),
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO) for
15 min at RT, and mounted with antifade solution (Molecular Probes). Confocal
analyses were performed using the Olympus FV300 laser scanning confocal
microscope (Olympus America, Inc., Center Valley, PA) using the exact same
setting for all samples.
3.2c. Transwell invasion assay
For each sample, 100 µl of 1 mg/ml Matrigel in serum free-cold MEM media
was aliquoted into the upper chamber of 24-well transwell plate (Corning, Corning,
NY) and incubated at 37oC for at least 4-5 hours for adequate gelling. The cells
were washed and suspended in serum free medium at a 1x106 cells/ml
concentration. One hundred µl of cell suspension was transferred onto the upper
chamber containing the Matrigel layer. The lower chamber of the transwell was filled
with 600 µl of complete media containing 10 µg/ml fibronectin as an adhesive
substrate. After 24 hours, the cells were fixed with 4% formaldehyde for 15 minutes,
rinsed with PBS, and stained with 0.2% crystal violet for 10 minutes. The crystal
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violet was rinsed with excess ddH2O and the top chamber containing the Matrigel
was thoroughly cleansed with Q-tips and the invaded cells were photographed with
a light microscope. For quantification, the cells on the top and bottom of the
chamber are collected using trypsin and counted using the culture counter. Each
sample was counted 3 times and each experiment was repeated independently 3
times.
3.2d. Quantitative RT-PCR analysis
Total RNA was isolated from cell culture with TRIzol reagent according to the
manufacture's protocol (Invitrogen). After treatment with DNase I (NEB, Ipswich,
MA), 1 µg of the RNA samples was reverse-transcribed using Transcriptor First
Strand cDNA Synthesis Kit (Roche, Branford, CT) with the control reactions
excluding reverse transcriptase. Realtime PCR was done with aliquots of the cDNA
samples mixed with SYBR Green Master Mix (Sigma). The primer sequences were:
cyclin E forward 5'-TGTGTCCTGGATGTTGACTG-3', reverse 5'CAAGCTGTCTCTGTGGGTCT-3’; E-cadherin forward 5’TGCCCAGAAAATGAAAAAGG, reverse 3’-GTGTATGTGGCAATGCGTTC; Ncadherin forward 5’-ACAGTGGCCACCTACAAAGG, reverse 3’CCGAGATGGGGTTGATAATG; Twist forward 5’-GGAGTCCGCAGTCTTACGAG,
reverse 3’-TCTGGAGGACCTGGTAGAGG; Slug forward 5’GGGGAGAAGCCTTTTTCTTG, reverse 3’-TCCTCATGTTTGTGCAGGAG;
Vimentin forward 5’-GAGAACTTTGCCGTTGAAGC, reverse 3’GCTTCCTGTAGGTGGCAATC; and GAPDH forward 5’ACCCAGAAGACTGTGGATGG-3’, reverse 5’-CTGGACTGGACGGCAGATCT-3’;
3.2e. CD24/CD44 FACS analysis
To perform doublestaining of the cell surface markers, 500,000 cells were
washed 3 times with PBS containing 1% horse serum and resuspended with 10 µl
PE anti-mouse CD24, 10 µl APC anti-mouse CD44 (BD Pharmingen, San Jose, CA,
USA) and 30 µl of the 1% serum PBS buffer. The samples were incubated for 20
minutes on ice, washed with 1% serum PBS buffer, analyzed with the FACS
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Calibur, and the data was analyzed by the Flowjo software (version 8.8.6) (Tree
Star, Inc., Ashland, OR). Cells only and single antibody label were used to set up
the gates for analysis. For cell sorting experiments, antibody staining was
performed similarly but under sterile condition and sorted using the FACSAria cell
sorter (BD, Franklin Lakes, NJ).
3.2f. Study patients, Western blot analysis, and immunohistochemical
staining
The target population for the study is women with a diagnosis of invasive
breast cancer stages I, II and III who are scheduled for surgery to remove the breast
cancer with axillary lymph node dissection or sentinel lymph node dissection. IHC
analyses of Cyclin E and CDK2 will be performed using available paraffinembedded tumor specimens from residual tissue prepared and archived by the
MDACC Institutional Tissue Bank per the standard procedure for surgical cases.
Results of the IHC analyses compared with results previously obtained by Western
Blot analysis of freshly resected surgical tissue.
Lysates were prepared from freshly resected surgical tissues as described
previously (165,228) and subjected to Western blot analysis using cyclin E
monoclonal antibody HE12 from Santa Cruz Biotechnology (Santa Cruz, CA).
Densitometry of the Western blots were measured using the IP-Lab Gel software
(Scanalytics) and normalized to β-actin protein levels. Full-length, LMW-E, and total
cyclin E densitometric values were separated into low (less than or equal to normal
tissues) and high groups (higher than the levels found in normal tissues).
Tumor tissues from 118 breast cancer patients were subjected to double IHC
staining with antibodies to CD24 (Clone SN3b, 1:400) and CD44 (Clone 156-3C11,
1:800) from Neomarkers (Thermo Fisher, Fremont, CA). Briefly, sections were
deparaffinized in xylene, rehydrated in ethanol, antigen retrieval in Trisethylenediamine tetraacetic acid buffer (pH 9.0) at 125oC for 5 minutes. The DAKO
EnVision G2 Doublestain System Rabbit/Mouse (diaminobenzidene
(DAB+)/Permanent Red) kit was used for detection of CD44 and CD24. CD44 was
detected with Permanent Red and CD24 was detected using DAB. In general,
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CD24 staining was detected mainly in the cytoplasm and CD44 staining was mainly
in the membrane as noted previously (289). Scoring was done blindly by 2
investigators blinded to patient annotation and the percentage of CD44hi/CD24lo
tumor cells were scored as follows: 0 (0%), 1 (1-10%), 2 (11-25%), 3 (26-50%), 4
(51-75%), 5 (76-100%).
Cyclin E IHC was accomplished using C-terminal cyclin E (C-19) antibody
detecting both EL and LMW-E forms (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), diluted at 1:2000 in normal goat serum. Cyclin E staining intensity and percent
positivity were evaluated both in the nucleus and cytoplasm of cancer cells. We
identify four different phenotypes of cyclin E distinguished with respect to
predominant nuclear or cytoplasmic localization of staining. Breast tumors were
considered negative when no staining was detected either in the nucleus or in the
cytoplasm (score = 1). Among the cases evaluated as cyclin E positive, if the score
assigned to the nucleus exceeded the score assigned to the cytoplasm, cyclin E
expression was considered predominantly nuclear (score = 2). When the nucleus
and the cytoplasm received equal scores, cyclin E expression was considered both
nuclear and cytoplasmic (score = 3). If cytoplasmic staining was graded higher than
nuclear staining, cyclin E expression was considered predominantly cytoplasmic
(score = 4).
3.2g. Soft agar transformation and mammosphere formation assays
For soft agar transformation assay, the base agar was made by mixing 90 ml
10% FBS MEM with 22.5 ml 2.4% Noble agar (DIFCO, Lawrence, KS). The solution
was heated to melt the agar and then aliquot to 6-well plates with 1 ml per well and
allowed to solidify at RT. For the top agar, 2000 cells were mixed with 850 µl 10%
FBS MEM and 125 µl 2.4% agar and transferred to the base agar for each well of 6well plate. The cells were cultured for 15 days, stained with 0.005% crystal violet in
25% methanol for 1.5 hours, washed with ddH20 and counted using the GelCount
(Oxford Optronix Ltd., Oxford, UK). For mammosphere culture, cells were plated at
40,000 cells/ml in ultra-low attachment plates (Corning, Corning, NY) in MEM media
(Media Tech, Manassas, VA) containing 1% methylcellulose (Sigma, St. Louis, MO)
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and supplemented with 20 ng/mL EGF and B27 (Invitrogen, Carlsbad, CA). For
quantification, 10% v/v 5 mg/ml MTT solution was added to each well after 7 days in
culture, incubated for 1 hour at 37oC and counted using the GelCount software.
3.2i. ALDEFLUOR assay
All contents of the ALDEFLUOR assay are included in the kit from Stem Cell
Technologies (Durham, NC). To measure the ALDH enzymatic activity, 1 million
cells were washed in assay buffer. For each sample, ALDH substrate (1 µmol/l
BAAA) and ALDH inhibitor (50 mmol/l DEAB) were added to 500,000 cells in
separate tubes and incubated at 37oC for 1 hour. The cells were washed in assay
buffer and analyzed with FACS Calibur. The DEAB sample was used to gate each
individual sample to achieve less than 2% positive.
3.2h. Drug treatment & high-throughput survival assay (HTSA)
For CD24/CD44 FACS analysis, cells were seed at 20,000 cells/cm2 density
on 6-well plates 24 hours before drug treatment (day 0) (Figure 19A). On day 1,
medium containing varying doxorubicin or salinomycin concentrations was added to
the cells and replaced every 2 days for a total of 4 days. On day 5, the cells were
allowed to recover for 3 days in drug-free medium before FACS analysis. For
HTSA, cells were seeded at 3,000 cells/cm2 density for 24 hours in 96-well plates
and medium containing doxorubicin or salinomycin were added on days 1 and 3
(Figure 19B). The cells were allowed to recover for 5 days in drug-free media before
analysis. On day 10, 50 µl of 2.5 mg/ml MTT solution (Sigma) was added to each
well and incubated at 37°C for 4 hours in the dark. The media were removed and
100 µl of solubilization solution (0.04 N HCl, 1% SDS, in isopropyl alcohol) was
added per well and gently rocked for 1 hour. After solubilization, cell viability was
measured at 590 nm absorbance using the Wallac-Victor3 multilabel plate reader
(PerkinElmer, Waltham, MA). At least 3 independent experiments were performed
for each analysis.
3.2i. ProtoArray Human Protein Microarray analysis
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Figure 19: Schematic of the doxorubicin and salinomycin combination
treatment. (A) For CD24/CD44 FACS analysis, the cells were seeded at
20,000 cells/cm2 density on 6-well plates on day 0. On days 1 and 3,
medium containing doxorubicin or salinomycin was added to the cells. On
days 5 and 7, the cells were fed with drug-free medium and harvested for
FACS analysis on day 8. (B) For the HTSA, the cells were seeded at 3,000
cells/cm2 density on 96-well plates on day 0. On days 5, 7, and 9, the cells
were fed with drug-free medium and subjected to the MTT assay on day 10.
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The ProtoArray human protein microarrays (Invitrogen, Carlsbad, CA)
contain more than 6,100 kinase substrates expressed as N-terminus GST fusion
(www.invitrogen.com⁄protoarray). Purified FLAG-EL/CDK2 and FLAG-LMW-E/CDK2
complexes were produced in sf9 insect cells, purified by IP with FLAG-tagged
antibody and eluted with 3X FLAG peptide (Sigma, St. Louis, MO). Arrays were
incubated either with recombinant active EL/CDK2 or LMW-E/CDK2 at a
concentration of 50 nM in the presence of 33P-γ-ATP for 1 hour at 30°C. After
washing and drying, arrays were exposed to X-ray film overnight. Imaging and data
analysis were performed as recommended by the manufacturer. Briefly, the films
were scanned to obtain 50 µm resolution and the arrays were aligned using the
ProtoArray(R) Prospector Imager. The radioactive spots were quantified and
analyzed using the ProtoArray(R) Prospector Analyzer, and the EL/CDK2 and
LMW-E/CDK2 arrays were compared directly.
3.2i. Cyclin E/CDK2 substrate screening using ATP analog
pVL1392-hCDK2 F80G mutant was generated using the QuikChange XL
site-directed mutagenesis (Qiagen) per instruction provided by the manufacturer.
CDK2 (wild type and F80G), EL and LMW-E were expressed, purified from sf9
insect cells, and incubated with GST-Rb, ATP or PE- ATP-γ-S (BioSite, Täby,
Sweden) at 30°C for 30 minutes. The samples were boiled with 2x sample buffer
and separated by SDS-PAGE. The gel was fixed in 50% (v/v) ethanol in water with
10% (v/v) acetic acid and stained with 0.1% (w/v) Coomassie blue R350.
The ATP analog (PE-ATP-γS) can fit into the ATP pocket of the F80G CDK2
but not the wild-type CDK2 kinase. The replacement of the γ-phosphoryl oxygen
with sulfur allows for specific tagging of the substrates with the thiophosphate
group. Thio-containing groups can react with iodoacetyl-agarose to form covalent
bond while unbound peptides are washed away. Thiophosphopeptides are
specifically liberated by oxidation-promoted hydrolysis of the sulfur-phosphorus
bond and recovered peptides can be analyzed by nanoscale liquid chromatography
coupled to a Q TRAP tandem mass spectrometer.
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3.2j. HAT activity colorimetric assay
To obtain purified proteins, pEXP-N-Myc-Hbo1 (wt, T88A, T88D), pEXP-NSFB-(EL, LMW-E, CDK2) were transfected into HEK293T cells using LipoD293
transfection reagents (SignaGen, Rockville, MD) and lysates were harvested 24
hours later. The proteins were purified by IP using Myc-tag or FLAG-tag antibodies
and purified Myc-tagged proteins were left on beads in 1x wash buffer, while
purified FLAG-tagged proteins were eluted using 3X FLAG peptides (Sigma, St.
Louis, MO). The HAT activity colorimetric assay kit was purchased from MBL
International (Woburn, MA) and performed according to manufacturer’s instructions.
Briefly, purified proteins or 25 µg of HeLa nuclear extract (positive control supplied
with the kit) were diluted in 40 µl water per well of 96-well plates. The samples were
mixed with the assay mix, which contains 50 µl of 2X HAT assay buffer, 5 µl HAT
substrate I, 5 µl HAT substrate II, and 5 µl NADH generating enzyme. The plates
were incubated at 37°C for 2 hours and the samples were read at 440 nm using the
Wallac-Victor3 multilabel plate reader (PerkinElmer, Waltham, MA).
3.2k. Lentiviral packaging and infection of shRNAs
All shRNA constructs were purchased from Thermo Scientific (Open
Biosystem, Huntsville, AL). To generate lentivirus expressing shRNAs, HEK293T
cells were co-transfected with pCMVdeltaR8.2, pMD2.G, and pGIPZ-(empty,
shGAPDH, or shHbo1) using LipoD293 transfection reagents (SignaGen,
Gaithersburg, MD). The supernatants containing the virus were filtered through 0.45
µm filter and directly added to cells for infection. GFP expression was confirmed
prior to selection with 0.5 µg/ml puromycin.
3.3. RESULTS
3.3a. LMW-E-expressing tumor cells exhibit reduced cell-cell contact and
enhanced invasion
One unique feature of mammary epithelial cells is that they tend to form
isolated islands when cultured as a monolayer by forming tight junctions with nearby
cells. In the previous chapter, we have extensively described the tumorigenic
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phenotypes of hMECs with exogenous LMW-E expression through 3 serial in vivo
passaging generations. In addition to deregulating mammary acinar
morphogenesis, we observed that the TDCs display reduced cell-cell contact by
growing further away from neighbor cells. To examine cell-cell adhesion, the TDCs
were immunostained with E-cadherin, a transmembrane protein that maintains cell
adhesion by ensuring that the cells within a tissue are bound together. Figure 20A
clearly shows that the LMW-E-expressing cells demonstrate dramatically reduced
E-cadherin expression, particularly at the membrane junction, while the parental
76NE6 cells display strong membranous E-cadherin staining (white arrows).
Downregulation of E-cadherin protein levels are confirmed by Western blot analysis
demonstrating that cells with LMW-E expression have reduced E-cadherin protein
levels (Figure 20B & C).
Cellular invasion is one of the critical events leading to successful metastasis
and requires migration of the tumor cells through the basement membrane to
invade the surrounding tissues (298). Given that E-cadherin regulates cellular
adhesion, downregulation of E-cadherin is known to be associated with tumor
progression and metastasis. Cells with E-cadherin knockdown are more motile
resulting in their enhanced ability to penetrate the basement membrane and thus
invade into surrounding tissues to form metastasis (299, 300). The Boyden chamber
invasion assay was performed to investigate whether LMW-E expression enhances
cellular invasiveness. The cells were seeded on a microporous transwell insert on
top of a thin layer of Matrigel with fibronectin on the other side of the membrane to
act as a chemo-attractant. After 24 hours, the cells that have invaded to the bottom
side of the membrane were stained with crystal violet for visualization. Figure 20D
shows that while the vector control cells were unable to invade through the Matrigel
basement membrane, cells with cyclin E expression were highly invasive. More
specifically, quantification of the invaded cells demonstrate that while all cells with
cyclin E expression invade significantly more than vector control cells, the 76NE6LMW-E and TDCs combined invade significantly more than the 76NE6-EL cells (p <
0.05) (Figure 20E). Collectively, we provide evidence suggesting that
overexpression of LMW-E downregulates E-cadherin expression and thereby
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Figure 20: LMW-E-expressing tumor cells exhibit reduced cell-cell contact
and enhanced invasion. (A) Cells were fixed and immunostained with E-cadherin
antibody and nuclei were counterstained with DAPI (scale bar = 100 µm). (B)
Lysates were extracted and subjected to Western blot analysis with antibodies
against cyclin E, E-cadherin, and β-actin. (C) Densitometric values of the Western
blot analysis. (D) Cells were seeded on Matrigel-coated transwell chamber and
incubated on top of fibronectin-containing media for 24 hours. The cells on top of
the membrane were removed and the cells remaining on the bottom were stained
with crystal violet and images were taken with a light microscope. (E) After 24
hours incubation, the cells on the bottom of the transwell were collected and
counted. Statistical analysis used was unpaired student’s t-test.
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enhance the invasiveness of hMECs.
3.3b. LMW-E activates gene expression associated with the EMT
Loss of cell-cell contact and reduced E-cadherin expression typically signify
that the cells have undergone the morphogenetic reprogramming from epithelial to
mesenchymal phenotype, which is commonly known as the epithelial-mesenchymal
transition or EMT. The EMT is an epigenetic process that involves modulation of
numerous transcription factors to transform the cells from epithelial to mesenchymal
characteristic to allow them to migrate and invade through the basement
membrane. The transcriptional levels of genes known to be involved in the EMT
were analyzed by realtime qRT-PCR. Firstly, analysis of cyclin E mRNA level
confirmed high expression in the 76NE6-LMW-E and the TDCs and these cells
exhibited downregulation of E-cadherin (Figure 21A & B). Furthermore, in the cells
that show high cyclin E expression, they also upregulate N-cadherin, twist, slug, and
vimentin mRNA levels, which are the genes associated with the EMT (Figure 21CF). Interestingly, we observed that the levels of cyclin E protein as well as mRNA
transcript were much higher in the 76NE6-LMW-E cells compared to the 76NE6-EL
cells (Figure 20B, 20C & 21A), which is a phenomenon that was also observed in
the transgenic mouse model with overexpression of LMW-E. We speculate that high
LMW-E protein levels may lead to hyperactive G1-S transition causing a positive
feedback loop through activation of E2F, and increased E2F activity has been
shown to stabilize cyclin E by reducing conjugation with ubiquitin (301). Additionally,
cyclin E transcription has been reported to be positively regulated by the E2F
transcription factor, and in fact, the cyclin E promoter does contains several E2F
binding sites (302). Taken together, exogenous LMW-E expression in the 76NE6
cells resulted in reduced cell-cell adhesion and induced transcriptional changes that
are featured as the EMT.
3.3c. LMW-E expression enriches for the CD44hi/CD24lo population
As the connection between induction of the EMT and generation of cells with
CSC properties was recently demonstrated, we suspect that the tumorigenicity of
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Figure 21: LMW-E activates gene expression associated with the EMT. (A –
F) Cells were grown in monolayer culture to 70% confluency and RNA were
extracted and subjected to qRT-PCR analysis for the mRNA levels of cyclin E (A),
E-cadherin (B), twist (C), vimentin (D), N-cadherin (E), and slug (F). These values
were normalized against GAPDH mRNA levels and statistical analysis used was
unpaired student’s t-test.
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LMW-E could be due to its ability to induce the EMT and enrich for CSCs. To date,
many surface markers have been demonstrated to be unique CSC markers, and
CD44hi/CD24lo is the best well-established markers for mammary CSCs. We aim to
investigate whether ectopic expression of EL or LMW-E in the 76NE6 cells and
whether in vivo passaging of these cells would enrich for this population. The cells
were stained using antibodies to the surface markers CD24 and CD44 that are
conjugated to different fluorophores, and their relative expression levels were
measured by FACS analysis (Figure 22).
The majority of the 76NE6-vector cells were CD44hi/CD24hi with only 1.5% of
the population was CD44hi/CD24lo (Figure 22A & B). While stable expression of EL
increased the CD44hi/CD24lo population to approximately 10%, the 76NE6-LMW-E
cells have significantly more CD44hi/CD24lo population compared to the 76NE6-EL
cells (p = 0.001) (Figure 22A & B). The difference was more remarkable in the
TDCs, in which most of the clones contained approximately 10 folds higher of this
CSC population. Furthermore, Western blot analysis using CD24 and CD44
antibodies confirmed that indeed LMW-E-expressing cells downregulated CD24 and
upregulated CD44 protein levels (Figure 22C). Since in vivo passaging led to
enhancement of LMW-E expression as well as enrichment for the CD44hi/CD24lo
population, we believe that cyclin E may be involved in selecting for this CSC
population. In fact, correlation analysis revealed that cyclin E expression level
positively correlate with the CD44hi/CD24lo population with R2 = 0.853 (p < 0.0001)
indicating that cells with high cyclin E expression are also statistically likely to be
CD44hi/CD24lo (Figure 22D).
3.3d. Cytoplasmic cyclin E expression correlates with high CD44hi/CD24lo
population in breast cancer patient tissue
Given that cyclin E expression positively associates with the CD44hi/CD24lo
population in hMECs, we now aim to determine whether this correlation also exists
in breast cancer patient samples. A total of 118 breast cancer patient tissues were
analyzed for the CD24 and CD44 expression by double IHC staining on the tissue
sections and visualized with 3,3'-Diaminobenzidine (DAB) and permanent red,
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Figure 22: LMW-E expression
enriches for the CD44hi/CD24lo
population. (A & B) Cells were
incubated with PE-CD24 and
APC-CD44 antibodies and
analyzed with a FACS Calibur.
Statistical analysis used was
unpaired student’s t-test. (C)
Lysates were extracted and
subjected to Western blot
analysis with antibodies against
cyclin E, CD24, CD44, β-actin.
(D) Percent of CD44hi/CD24lo
population were subjected to
correlation analysis versus cyclin
E mRNA levels.

respectively (Figure 23A). The slides were given a score of 0 to 5 that correspond to
a range of the percentage of the CD44hi/CD24lo population as follows: 0 (0%), 1 (110%), 2 (11-25%), 3 (26-50%), 4 (51-75%), 5 (76-100%). In addition, these same
tissue slides were also subjected to IHC staining using antibody to cyclin E (Figure
23B). We scored the cyclin E staining based on its intensity as well as localization.
Breast tumors were considered negative when no staining was detected either in
the nucleus or in the cytoplasm (score = 1). Among the cases evaluated as cyclin E
positive, if the score assigned to the nucleus exceeded the score assigned to the
cytoplasm, cyclin E expression was considered predominantly nuclear (score = 2).
When the nucleus and the cytoplasm received equal scores, cyclin E expression
was considered both nuclear and cytoplasmic (score = 3). If cytoplasmic staining
was graded higher than nuclear staining, cyclin E expression was considered
predominantly cytoplasmic (score = 4). Lastly, lysates prepared from these patient
samples were also analyzed for the protein levels of EL and LMW-E by Western
blot followed by densitometric analysis (Figure 23C). Statistical analysis was applied
to data obtained from 1) CD24/CD44 double IHC staining, 2) cyclin E IHC staining,
and 3) EL versus LMW-E protein levels from Western blot analysis.
Statistical analysis revealed that more than 60% of the patient tissues
contain less than 10% of the CD44hi/CD24lo population, and this patient distribution
was similar to that previously reported (Table 9) (289). More specifically, we found
that cytoplasmic staining of cyclin E significantly correlated with high percentage of
the CD44hi/CD24lo population (p = 0.0435), and the fact that the patient sample was
relatively small further demonstrates the strength of the relationship between these
two factors (Figure 24A). In fact, when cytoplasmic versus nuclear cyclin E IHC
scores were compared with the densitometry values from Western blot analysis of
the patient tissues, we found that high LMW-E expression levels significantly
associated with cytoplasmic cyclin E staining (p = 0.0194) while full-length and total
cyclin E expression levels did not (Figure 24B-D). Since LMW-E lacks an N-terminal
nuclear signal sequence, previous report has shown that LMW-E preferentially
accumulates in the cytoplasm, and these results further support this observation
(169). In conclusion, similar to our cell line data, breast cancer patients who have
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Figure 23: IHC analysis for CD24, CD44 and cyclin E expression in breast
cancer patient samples. (A) A total of 118 breast cancer patient tissue slides
were subjected to IHC double staining with CD24 and CD44 antibodies and
scored for %CD44hi/CD24lo. (B) IHC single staining using cyclin E antibody and
scored with respect to intensity as well as cytoplasmic versus nuclear
localization (1: no staining, 2: nuclear > cytoplasmic, 3: nuclear = cytoplasmic, 4:
nuclear < cytoplasmic). The slides were scored blindly by 2 independent
investigators. (C) Cyclin E EL and LMW-E protein levels were measured by
Western blot analysis from breast cancer patient tissues and quantified by
densitometry. Shown here are representative samples to illustrate the IHC
staining that reflect the scoring assigned and the LMW-E protein levels by
densitometry.
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Figure 24: Cytoplasmic cyclin E expression correlates with high
CD44hi/CD24lo score in breast cancer patient tissue. (A Patient tissues were
subjected to IHC analysis using CD24, CD44, and cyclin E antibodies. The
CD44hi/CD24lo scores were correlated to the nuclear versus cytoplasmic cyclin E
staining scores. Statistical analysis used was unpaired student’s t-test. The
cyclin E nuclear and cytoplasmic staining scores were correlated with total cyclin
E (B), EL (C), and LMW-E (D) protein levels from densitometry of Western blot
analysis. Statistical analysis used was Pearson’s chi-square test.
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high CD44hi/CD24lo population significantly correlate with cytoplasmic cyclin E, and
we have demonstrated that cytoplasmic cyclin E protein represents the LMW
isoforms.
3.3e. LMW-E-expressing cells exhibit enhanced anchorage-independent
growth, self-renewal capability, and ALDH activity
LMW-E expression increased with in vivo passaging suggesting that perhaps
LMW-E provided oncogenic advantage to tumor-initiating cells that will continue to
select for those cells possessing tumorigenic phenotypes such as transformation.
Anchorage independent growth is one of the characteristics of neoplastic cellular
transformation and is traditionally tested by culturing cells on soft agar medium. The
cells were embedded in between 2 layers of soft agar at 200 cells/cm2 density. After
15 days in culture, the plates were stained with crystal violet and automatically
counted using the GelCount software. As expected, the LMW-E-expressing cells
formed more transformed colonies compared to cells with vector and EL expression
(Figure 25A). To confirm that the CD44hi/CD24lo cells have higher tumorigenic
potential than the CD44hi/CD24hi cells, these cells were sorted into these 2
respective populations and subjected to soft agar transformation assay. The results
obtained clearly demonstrated that the sorted CD44hi/CD24lo population was able to
form much more colonies than unsorted cells, and the CD44hi/CD24hi population
was unable to sustain growth on soft agar (Figure 25A). These observations may
explain the ability of LMW-E-expressing cells to form tumor in vivo due to the high
CD44hi/CD24lo population that allow them to grow in the absence of a basement
membrane compared to EL-expressing cells.
In addition to the CD44hi/CD24lo population, mammary CSCs also possess
self-renewal capability and thus a single cell can give rise to multiple lineages of
more differentiated cell types to form a mammosphere (277). Although similar to the
soft agar transformation assay in some aspects, the mammosphere formation assay
specifically tests the ability of cells to grow in an ultra-low attachment dish in the
presence of high EGF and no serum, which is a non-differentiating culture condition.
CSCs are able to undergo proliferation and self-renewal to form a floating colony
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Figure 25: LMW-E-expressing cells exhibit enhanced anchorageindependent growth, self-renewal capability, and ALDH activity. (A)
Anchorage-independent growth was tested by culturing cells in soft agar
medium. Unsorted cells and cells stained with CD24 and CD44
conjugated antibodies and sorted for the CD44hi/CD24hi and
CD44hi/CD24lo populations were seeded in soft agar culture. After 15
days in culture, the colonies were stained with crystal violet and counted
using the GelCount program. (B) Representative brightfield images of
cells cultured on ultra-low attachment plates for 7 days (scale bar =100
µm). The vector control cells undergo apoptosis as apparent by extensive
membrane blebbing (white arrows). (C) MTT solution was added to the
mammosphere cultures at 500 µg/ml concentration and incubated at 37oC
for 1 hour. Number of mammospheres were quantified using the
automated GelCount program and statistical analysis used was unpaired
student’s t-test. (D) Lysates from mammosphere cultures were extracted
and subjected to Western blot analysis with antibodies to cyclin E, ALDH,
and β-actin. (E & F) ALDELUOR assay was performed on cells grown on
monolayer. For each sample, 500,000 cells were incubated with the
ALDH substrate alone or with the ALDH inhibitor (DEAB) and subjected to
FACS analysis. The ALDH activity is obtained by subtracting the DEAB
inhibitor value and the statistical analysis used was unpaired student’s ttest.

125

while differentiated epithelial cells undergo anoikis, which is apoptosis due to lack of
basement membrane attachment (277). As expected, the 76NE6-vector control
cells underwent apoptosis as apparent by extensive membrane blebbing (Figure
25B). In contrast, the 76NE6-LMW-E and the TDCs were able to form larger and
more mammospheres compared to those formed by the 76NE6-EL cells (Figure
25B). Sum159 is a breast cancer cell line that has been shown to contain very high
percentage of the CD44hi/CD24lo population and form very robust and reliable
mammospheres and therefore are used in this experiment as a positive control
(303). To quantify the number of mammospheres formed and confirm the viability of
the cells in these structures, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) was added to the cells after 7 days in culture and the
viable colonies were automatically counted using the GelCount software. Statistical
analysis revealed that cells with LMW-E expression formed significantly more
mammospheres than cells with full-length cyclin E expression (p < 0.05) (Figure
25C).
High ALDH protein and enzymatic levels are found to be associated with
CSC phenotypes such as high CD44hi/CD24lo population and mammosphere
formation (278). Western blot analysis of the mammosphere cultures showed that
the 76NE6-LMW-E cells and the TDCs indeed express high LMW-E and ALDH
protein levels compared to the 76NE6-EL and vector control cells (Figure 25D).
Therefore, we subjected the cells to the ALDEFLUOR assay to measure the ALDH
enzymatic activity by FACS analysis. Briefly, the cells were incubated with Bodipyaminoacetaldehyde (BAAA), an ALDH substrate that can freely diffuse across the
plasma membrane (304). The presence of ALDH inside the cell catalyzes the
substrate into Bodipy-aminoacetate (BAA), which is fluorescent and can be
detected with flow cytometry. Diethylamino-benzaldehyde (DEAB) is an inhibitor of
ALDH and is used to normalize the ALDH activity. The results obtained showed that
the 76NE6-LMW-E cells and the TDCs exhibit high ALDH activity compared to the
76NE6-EL and vector control cells (Figure 25E). Statistical analysis demonstrated
that the LMW-E-expressing cells have higher ALDH enzymatic activity compared to
cells expressing EL (p < 0.05) (Figure 25F). Collectively, the evidences presented

126

here suggest that LMW-E enriches for cells with CSC properties by upregulating the
ALDH activity level and enabling hMECs to survive and undergo self-renewal in the
absence of basement membrane attachment thus explaining the enhanced
tumorigenicity of LMW-E over full-length cyclin E.
3.3f. Doxorubicin synergizes with salinomycin to kill LMW-E-expressing tumor
cells
Salinomycin is a pharmacological agent recently identified from a large
screen of small molecule inhibitors to specifically kill CSCs (297). Particularly,
breast cancer cells treated with salinomycin demonstrated a decrease in the
CD44hi/CD24lo population, reduction in their ability to form mammospheres, and the
4T1 xenograft tumors formed less metastasis compared to parallel paclitaxel
treatment (297). Therefore, we aim to determine whether salinomycin can
specifically target the CD44hi/CD24lo population in the tumor cells with LMW-E
expression. The cells were treated with salinomycin for 4 days and then allowed to
recover in drug-free medium for 3 days (Figure 19A). The cells were then harvested
and stained with PE-CD24 and APC-CD44 conjugated antibodies, and the
CD44hi/CD24lo population was measured by FACS analysis. The results showed
that salinomycin treatment reduced the CD44hi/CD24lo population in a dose
dependent manner (Figure 26A). More specifically, the TDCs contain approximately
80% of the CD44hi/CD24lo population in which only 10% of these cells remained
after treatment with 8 µM salinomycin. Additionally, salinomycin treatment also
effectively disrupted their ability to form mammospheres (Figure 26B). Similar to the
results previously published, we also showed that salinomycin demonstrated high
effectiveness in targeting the phenotypes associated with CSCs that are induced
with LMW-E expression (297).
Most highly proliferative cancer cells are sensitive to conventional
chemotherapies drugs while CSCs are believed to be more resistant to them thus
resulting in high frequency of tumor relapse (293). Doxorubicin, a common
chemotherapeutic agent, is an anthracycline antibiotic, which functions by
intercalating DNA and thereby inhibits DNA replication. As anticipated, doxorubicin
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Figure 26: Doxorubicin synergizes with salinomycin to kill LMW-Eexpressing tumor cells. (A) Cells were seeded on monolayer for 24 hours and
treated with salinomycin for 4 days with the drug-containing media replaced every
48 hours. After 3 days of recovery in drug-free medium, the cells were trypsinized
and stained for PE-CD24 and APC-CD44 antibodies and analyzed by FACS
analysis. (B) Cells were seeded on ultra-low attachment plates on day 0 and then
treated with salinomycin on days 1 and 3. On day 7, MTT solution was added to
the mammosphere cultures and incubated at 37oC for 1 hour. Number of
mammospheres were quantified using the automated GelCount program. (C)
Cells were seeded on monolayer for 24 hours and treated with doxorubicin and
analyzed by FACS as in (A). (D) HTSA was performed to examine the toxicity of
combining doxorubicin and salinomycin. Cells were seeded at 3000 cells/cm2
density in 96-well plates on day 0, treated with doxorubicin on day 1 and then with
salinomycin on day 3, and allowed to recover for 5 days in drug-free medium. On
day 11, MTT solution was added to the cells and cell viability was measured at
590nm absorbance using a spectrophotometer. (E) An isobologram illustrates the
effects of the combined drugs calculated from the Calcusyn software. The
combination indices calculated that lay above the line of additivity represent
antagonistic, on the line are additive and underneath the line are synergistic effect.
(F) The results obtained from A were subjected to calculation using the Calcusyn
software. The isobolograms shown are representative from 3 independent
experiments. (G) The combination indices were averaged from 3 independent
experiments and the statistical analysis used was unpaired student’s t-test.
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treatment with increasing drug concentration did not affect the distribution of the
CD44hi/CD24lo population of any of the cell line tested (Figure 26C). These
observations led us to develop a combination treatment regimen in which the LMWE tumor cells will be first treated with doxorubicin to eliminate the non-CSC
population and then followed by salinomycin to target the CSC population. One
advantage of combining drug treatment is that it allows for administration of the
drugs at low concentration and therefore lessens the toxic side effects. To achieve
this goal, the combined drugs must exert a synergistic effect in which the outcome
is greater than the sum of the single agent alone. To examine the toxicity of
combining doxorubicin and salinomycin, we utilized the high-throughput survival
assay (HTSA). After seeding at 3000 cells/cm2 density for 24 hours in 96-well
plates, the cells were first treated with doxorubicin for 48 hours, followed by
salinomycin for 48 hours, and then allowed to recover for 5 days in drug-free
medium (Figure 19B). On the 10th day, MTT solution was added to the cells and cell
viability was measured at 590 nm absorbance using a spectrophotometer. While the
IC50 of doxorubicin and salinomycin alone were approximately 7.5 nM and 3 µM,
respectively, the combination of these drugs resulted in higher fraction of cell death
(Figure 26D).
The Calcusyn software was used to calculate the combined drug effects on
the viability of the cells. This program analyzes the effects from the 2 drugs and
generates an isobologram, a graph that displays the effects of the combined drugs:
synergistic, additive, or antagonistic (Figure 26E). The Calcusyn program calculates
a combination index based on the fractions of cell death due to doxorubicin and
salinomycin treatments, and a line of additivity is placed at a value of 1 on each
axis. A combination index of 1 represents additive effect, greater than 1 represents
antagonistic effect, and less than 1 represents synergistic effect. The isobolograms
of the 76NE6-V and 76NE6-EL cells indicated that the combined drug treatment
resulted in additive to antagonistic effects (Figure 26F). In contrast, the drug
treatment demonstrated a clear synergistic effect in the LMW-E-expressing cells
(76NE6-LMW-E, T1G2.2, T1G3.1, and T1G4.2). An average of the combination
indices revealed that the doxorubicin and salinomycin combination resulted in
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additive/antagonistic effects in the 76NE6-V and 76NE6-EL cells but synergistic
effects in the 76NE6-LMW-E and the TDCs (Figure 26G). These results suggest a
promising and effective therapeutic strategy of combining doxorubicin and
salinomycin to treat breast cancer patients who have high levels of LMW-E
expression and high CSC population.
3.3g. Identification of human EL/CDK2 and LMW-E/CDK2 substrates
To elucidate the signaling pathway downstream of LMW-E, we utilized two
distinct methods to discover potential substrates/interacting partners for EL/CDK2
and LMW-E/CDK2 on a proteome-wide scale: (1) the ProtoArray® Human Protein
Microarray from Invitrogen and (2) the chemical/genetic manipulation of CDK2
approach.
In the first approach, we purified recombinant EL/CDK2 and LMW-E/CDK2
complexes from insect cell lysates and confirmed that the complexes were active
using GST-Rb as substrates in a kinase assay (Figure 27A & B). The microarrays,
which contain more than 9,000 unique human proteins, were incubated either with
recombinant active EL/CDK2 or LMW-E/CDK2 at a concentration of 50 nM in the
presence of 33P-γ-ATP for 1 hour at 30°C. The radioactive signals were directly
compared to generate a list of proteins that were most differentially phosphorylated
by EL/CDK2 and LMW-E/CDK2 complexes (Figure 27C). Our screen identified a
total of 146 potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes
(Table 10). Interestingly, we only identified 4 proteins (myotilin, tomosyn, PRP38
pre-mRNA processing factor 38 (PRPF38A), and p27Kip1) that were phosphorylated
by EL/CDK2 significantly more than by LMW-E/CDK2 as compared to the 14
(histone acetyltransferase binding to ORC (Hbo1), RAD51 associated protein 1
(RAD51AP1), non-metastatic cells 1/2 (NME1/E2), protein regulator of cytokinesis 1
(PRC1), cyclin-dependent kinase 2-interacting protein (CINP), ligase III (LIG3),
mitochondrial GTPase 1 (MTG1), polypeptide N-acetylgalactosaminyltransferase
10, mitochondrial ribosomal protein L40 (MRPL40), tektin 2 (testicular) (TEKT2),
Ribosomal protein S6 kinase alpha-5, interleukin-1 receptor-associated kinase 3
(IRAK3), FAD-dependent oxidoreductase domain containing 1 (FOXRED1), and cell
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Figure 25
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Figure 27: Identification of human EL/CDK2 and LMW-E/CDK2 substrates
using the ProtoArray microarray. (A) FLAG-EL/CDK2 and FLAG-LMW-E/CDK2
complexes were expressed in sf9 insect cells, purified by IP with FLAG-tagged
antibody, eluted with 3X FLAG peptide and visualized by silver stain and Western
blot analysis. (Only LMW-E/CDK2 results are shown here). (B) In vitro kinase
assay using purified EL/CDK2 and LMW-E/CDK2 kinase complexes with GST-Rb
as substrate to confirm the relative amount of the kinase complexes for use in the
microarray analysis. The kinase assay was performed with 32P-γ-ATP, separated
by SDS-PAGE and exposed to x-ray films. (C) The microarrays were incubated
either with recombinant EL/CDK2 or LMW-E/CDK2 in the presence of 33P-γ-ATP
and the radioactive signals were exposed to x-ray films. (D) Venn diagram showing
the number of proteins whose phosphorylation signal by EL/CDK2 is greater than
LMW-E/CDK2 by more than 1.5 (red), LMW-E/CDK2 signal is greater than
EL/CDK2 signal by 1.5 (blue) and EL/CDK2 and LMW-E/CDK2 signals are
between 0.5 and 1.5 (black).
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Table 10. Potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes
from the ProtoArray Microarray analysis. Proteins that are phosphorylated by
EL/CDK2 more than LMW-E/CDK2 are highlighted in yellow. Proteins that are
phosphorylated by LMW-E/CDK2 more than EL/CDK2 are highlighted in pink.
Protein
1 cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
2 myotilin (MYOT)
3 syntaxin binding protein 5 (tomosyn) (STXBP5)
4 PRP38 pre-mRNA processing factor 38 (PRPF38A)
5 E2F transcription factor (E2F)
6 Proto-oncogene tyrosine-protein kinase MER
7 hydrolethalus syndrome 1 (HYLS1)
8 Phosphatidylinositol 4-kinase beta
9 Ribosomal protein S6 kinase
10 sciellin (SCEL)
11 Rho GTPase-activating protein 15
12 Bruton agammaglobulinemia tyrosine kinase (BTK)
13 Fibroblast growth factor receptor 2
14 Peripheral plasma membrane protein CASK
15 BRCA1 associated protein-1 (BAP1)
16 ankyrin repeat and sterile alpha motif domain containing 3 (ANKS3)
17 schlafen-like 1 (SLFNL1)
18 BMP-2-inducible protein kinase
19 Receptor tyrosine-protein kinase erbB-2
20 Dual specificity protein kinase CLK1
21 platelet-derived growth factor receptor (PDGFR)
22 BTB (POZ) domain containing 12 (BTBD12)
23 anaplastic lymphoma kinase (Ki-1) (ALK)
24 met proto-oncogene (MET)
25 serum/glucocorticoid regulated kinase (SGK)
26 pim oncogene (PIM)
27 fms-related tyrosine kinase 1 (FLT1)
28 WEE1 homolog (WEE1)
29 Interleukin-1 receptor-associated kinase (IRAK)
30 PRKR interacting protein 1 (IL11 inducible) (PRKRIP1)
31 Ephrin type-B receptor 1
32 cyclin E2 (CCNE2)
33 Rho-associated protein kinase 2
34 PTK2B protein tyrosine kinase 2 beta (PTK2B)
35 REX2, RNA exonuclease 2 homolog (REXO2)
36 ret proto-oncogene (RET)
37 epidermal growth factor receptor (EGFR)
38 tau tubulin kinase 2 (TTBK2)
39 Dual specificity tyrosine-phosphorylation-regulated kinase 1B
40 Eukaryotic translation initiation factor 2-alpha kinase 3
41 F-box/WD repeat-containing protein 11
42 p21 (CDKN1A)-activated kinase (PAK)
43 Proto-oncogene tyrosine-protein kinase FER
44 inhibitor of kappa light polypeptide gene enhancer in B-cells (IKBKB)
45 death-associated protein kinase (DAPK)
46 tropomyosin 4 (TPM4)
47 Receptor tyrosine-protein kinase erbB-4
48 CHK1 checkpoint homolog (CHEK1)
49 mitogen-activated protein kinase kinase kinase kinase (MAP4K)
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Table 10. Potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes
from the ProtoArray Microarray analysis. Proteins that are phosphorylated by
EL/CDK2 more than LMW-E/CDK2 are highlighted in yellow. Proteins that are
phosphorylated by LMW-E/CDK2 more than EL/CDK2 are highlighted in pink.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97

Protein
TTK protein kinase (TTK)
TANK-binding kinase 1 (TBK1)
MAP kinase-interacting serine/threonine-protein kinase
doublecortin and CaM kinase-like 2 (DCAMKL2)
bone morphogenetic protein receptor, type IB (BMPR1B)
transforming growth factor, beta receptor II (TGFBR2)
B lymphoid tyrosine kinase (BLK)
cyclin-dependent kinase 5 (CDK5)
Basic fibroblast growth factor receptor 1
BMX non-receptor tyrosine kinase (BMX)
dystrophin
Activin receptor type-2A
Cartilage intermediate layer protein 2
Inhibitor of nuclear factor kappa-B kinase
Tyrosine-protein kinase ABL2
TYRO3 protein tyrosine kinase (TYRO3)
protein kinase D (PRKD)
SFRS protein kinase 3 (SRPK3)
alanine-glyoxylate aminotransferase 2-like 2 (AGXT2L2)
calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2)
3-phosphoinositide dependent protein kinase-1 (PDPK1)
RIO kinase (RIOK)
Cas scaffolding protein family member 4
protein kinase C (PRKC)
Insulin receptor
Wolf-Hirschhorn syndrome candidate 1 (WHSC1)
spleen tyrosine kinase (SYK)
leukocyte tyrosine kinase (LTK)
phosphorylase kinase
microcephaly (MCPH1)
NCK adaptor protein 2 (NCK2)
SNF1-like kinase 2 (SNF1LK2)
suppressor of cytokine signaling 2 (SOCS2)
MAP/microtubule affinity-regulating kinase (MARK)
Macrophage-stimulating protein receptor
polo-like kinase 1 (PLK1)
Protein tyrosine kinase 2
MAP kinase-activated protein kinase 2
Glycogen synthase kinase-3 beta
IL2-inducible T-cell kinase (ITK)
Tyrosine-protein kinase FRK
CDC-like kinase (CLK)
myomegalin (PDE4DIP)
casein kinase 1
hypothetical protein MGC42105 (MGC42105)
male-specific lethal 3-like 1 (MSL3L1)
PTK2 protein tyrosine kinase 2 (PTK2)
cGMP-dependent protein kinase 1
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Table 10. Potential substrates to both EL/CDK2 and LMW-E/CDK2 complexes
from the ProtoArray Microarray analysis. Proteins that are phosphorylated by
EL/CDK2 more than LMW-E/CDK2 are highlighted in yellow. Proteins that are
phosphorylated by LMW-E/CDK2 more than EL/CDK2 are highlighted in pink.
Protein
98 Band 4.1-like protein 4A
99 ephrin receptor B4 (EPHB4)
100 homeodomain interacting protein kinase (HIPK)
101 TBC1 domain family, member 22A (TBC1D22A)
102 splicing factor, arginine/serine-rich 2B (SFRS2B)
103 fyn-related kinase (FRK)
104 Small conductance calcium-activated potassium channel protein 2
105 Cyclin-dependent kinase-like 2
106 family with sequence similarity 122A (FAM122A)
107 inositol(myo)-1(or 4)-monophosphatase 1 (IMPA1)
108 G patch domain containing 2 (GPATCH2)
109 testis-specific serine kinase 2 (TSSK2)
110 chromodomain helicase DNA binding protein 2 (CHD2)
111 mitogen-activated protein kinase kinase kinase (MAP3K)
112 casein kinase 2
113 ets variant gene 3 (ETV3)
114 TAO kinase 3 (TAOK3)
115 HIRA interacting protein 3 (HIRIP3)
116 PRP40 pre-mRNA processing factor 40 (PRPF40A)
117 feline sarcoma oncogene (FES)
118 Focal adhesion kinase 1
119 SH3 and cysteine rich domain (STAC)
120 cyclin G associated kinase (GAK)
121 phytanoyl-CoA 2-hydroxylase interacting protein-like (PHYHIPL)
122 mitogen-activated protein kinase (MAPK)
123 SMAD family member 3 (SMAD3)
124 G protein-coupled receptor kinase (GRK)
125 ribosomal protein S10 (RPS10)
126 ribosomal protein L41 (RPL41)
127 NUAK family (NUAK2)
128 SLAIN motif family, member 2 (SLAIN2)
129 Cytoplasmic tyrosine-protein kinase BMX
130 cell division cycle associated 7 (CDCA7)
131 Ephrin receptor A1 (EPHA1)
132 tripartite motif-containing 63 (TRIM63)
133 mitochondrial GTPase 1 (MTG1)
134 non-metastatic cells 1 (NME1)
135 Polypeptide N-acetylgalactosaminyltransferase 10
136 MYST histone acetyltransferase 2 (MYST2)
137 mitochondrial ribosomal protein L40 (MRPL40)
138 tektin 2 (testicular) (TEKT2)
139 Ribosomal protein S6 kinase alpha-5
140 interleukin-1 receptor-associated kinase 3 (IRAK3)
141 FAD-dependent oxidoreductase domain containing 1 (FOXRED1)
142 cell division cycle 2 (CDC2)
143 RAD51 associated protein 1 (RAD51AP1)
144 protein regulator of cytokinesis 1 (PRC1)
145 cyclin-dependent kinase 2-interacting protein (CINP)
146 ligase III (LIG3)
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division cycle 2 (CDC2)) potential substrates that were preferentially phosphorylated
by LMW-E/CDK2 suggesting that by losing the N-terminal portion, the LMWE/CDK2 kinase complex is able to specifically interact and phosphorylate additional
proteins (Figure 27D). We chose 6 top candidates from the list of 14 potential
substrates that were phosphorylated by LMW-E/CDK2 at higher intensity than by
EL/CDK2 (Hbo1, CINP, LIG3, PRC1, RAD51AP1, and NME1/E2) to further validate
using in vitro kinase assay (Table 11). These 6 genes were tagged with a Myc-tag,
expressed in HEK293T cells, and purified by IP using Myc-tagged antibody. The
purified proteins were then subjected to the in vitro kinase assay as substrates to
the EL/CDK2 and LMW-E/CDK2 kinase complexes (Figure 28). The results from the
kinase assay revealed that Hbo1, CINP, LIG3, and PRC1 were indeed
phosphorylated by both the EL/CDK2 and LMW-E/CDK2 kinase complexes, and the
phosphorylation was efficiently inhibited with addition of roscovitine (Figure 28A-D).
However, we could not detect any phosphorylation signal with RAD51AP1 and
NME1/E2 as substrates (Figure 28E & F).
The second screening approach involves generating a modified CDK2 kinase
that can accept an ATP analog to facilitate covalent modification and subsequent
purification of substrate peptides (Figure 29A & B) (305). CDK2 F80G mutant was
generated by amino acid exchange at a conserved bulky phenylalanine residue in
the ATP binding pocket to a smaller glycine amino acid to allow this mutant CDK2 to
use PE-ATP-γS as a substrate. The γ sulfur group in the PE-ATP-γS analog allows
for specific tagging of the substrates with the thiophosphate group, which can be
used to identify any peptide that has been phosphorylated by CDK2 F80G. Then
incubated with GST-Rb, both EL/CDK2 F80G and LMW-E/CDK2 F80G kinase
complexes can use both ATP and PE-ATP-γS to phosphorylate GST-Rb as
indicated by its electromobility shift while the wild type CDK2 kinase complexes can
only use ATP, but not PE-ATP-γS (Figure 29C). The next steps will be to
phosphorylate cell lysates in vitro using EL/CDK2 F80G and LMW-E/CDK2 F80G
with PE-ATP-γ-S as substrate, digest the protein mixture, capture the
thiophosphopeptides with thiopropyl sepharose, and the thiophosphopeptides will
be specifically released by treatment of the resin with a strong base. The recovered
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Figure 26
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Figure 28: Hbo1, CINP, LIG3 and PRC1 are phosphorylated by both
EL/CDK2 and LMW-E/CDK2 kinase complexes. (A) Purified EL/CDK2 and
LMW-E/CDK2 kinase complexes were subjected to in vitro kinase assay using
purified Myc-tagged Hbo1 (A), CINP (B), LIG3 (C), PRC1 (D), NME1/E2 (E) and
RAD51AP1 (F) as substrates. The kinase assays were performed with 32P-γATP, separated by SDS-PAGE and exposed to x-ray films.
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Figure 29: EL/CDK2 and LMW-E/CDK2 substrate screening using ATP analog
and F80G CDK2. (Adapated from PNAS 2008, 105(5):1442-7.) (A) Schematic of
the screening approach demonstrating that the ATP analog (PE-ATP-γS) can fit
into the ATP pocket of the F80G CDK2 but not the wild-type CDK2 kinase. The
replacement of the γ-phosphoryl oxygen with sulfur allows for specific tagging of
the substrates with the thiophosphate group. (B) Thio-containing groups can react
with iodoacetyl-agarose to form covalent bond while unbound peptides are washed
away. Thiophosphopeptides are specifically liberated by oxidation-promoted
hydrolysis of the sulfur-phosphorus bond and recovered peptides can be analyzed
by nanoscale liquid chromatography coupled to a Q TRAP tandem mass
spectrometer. (C) In vitro kinase assay with wild-type and F80G CDK2 mutant in
complex with EL or LMW-E in the presence of either ATP or PE-ATP-γS and GSTRb. The samples were separated by SDS-PAGE and stained with Coomassie blue.
The top band represents pGST-Rb and the bottom band represents the
unphosphorylated form.
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peptides will be subjected to liquid chromatography-MS/MS analysis to identify and
to compare the substrate peptides phosphorylated by EL/CDK2 and LMW-E/CDK2
kinase complexes. Since the first screening method produced a number of
interesting hits and given the time constraint, we decided to postpone this
experiment and focus our studies on the discovered potential hits.
3.3h. Hbo1 is a novel substrate of the cyclin E/CDK2 complex
From the 2 independent ProtoArray microarray experiments, Hbo1 (histone
acetyltransferase (HAT) binding to ORC1 (origin recognition complex 1)) was
among the top potential hits with phosphorylation signal by LMW-E/CDK2 being 3
folds higher than that by EL/CDK2 (Figure 30A). Hbo1 is a member of the MYST
family (named after its original 4 founding members: MOZ, Ybf2/Sas3, Sas2,
TIP60), which is highly conserved from yeast to humans, and has been implicated
in regulating gene expression, DNA replication, and DNA repair (306-311). The
Hbo1 protein structure contains a defining MYST domain consisting of an acetylCoA binding motif, a zinc finger, and a serine-rich region. During S phase, ORC is a
key protein for initiating DNA replication by recruiting components for the formation
of the pre-replication complex (pre-RC). Hbo1 was first identified to bind to ORC1
and subsequently shown to interact with MCM-2 to positively regulate the assembly
of the pre-RC and DNA replication initiation (306, 311-313).
The coding region of Hbo1 has been shown to be a common site for
retroviral integration and has been linked to B/T-cell lymphoma and myeloid
leukemia in mice (314). Additionally, in a screen for genetic alterations and
oncogenic pathways in breast cancer, Hu and colleagues identified the coding
region of Hbo1 with recurrent chromosomal gain in ER+/PR+/HER2+ tumors (315).
Furthermore, ectopic overexpression of Hbo1 in MCF7 and SKBR3 cells enhanced
soft agar colony formation while knockdown of Hbo1 with siRNA blocked S phase
progression and reduced cell proliferation (315, 316). These data suggest that Hbo1
plays a role in supporting the oncogenic transformed state, and genetic
amplification at this chromosomal region implicates Hbo1 as an important oncogene
in breast cancer. Aside from interacting with the pre-RC, Hbo1 has been
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Figure 30: Hbo1 is a novel substrate of the cyclin E/CDK2 complex. (A) The
ProtoArray microarray experiment was performed in two independent experiments.
The phosphorylation signals indicate relative radioactive signal detected in the
microarray spots. (B) FLAG-EL or LMW-E, HA-CDK2, and Myc-Hbo1 constructs
were transfected into HEK293T cells and IP with either Myc-tagged or FLAGtagged antibodies and probed with the indicated antibodies. (C) SFB-EL or SFBLMW-E was co-transfected with SFB-CDK2 into HEK293T cells, purified using
FLAG-tagged antibody, eluted with 3X FLAG peptide and visualized by Western
blot analysis. Myc-Hbo1 was transfected into HEK293T cells, purified using Myctagged antibody and the bead-Myc protein complex was resuspended in 1X wash
buffer. (D) The EL/CDK2 or LMW-E/CDK2 kinase complex was incubated with
purified Hbo1 in the presence of 32P-γ-ATP and with or without roscovitine. The
samples were separated by SDS-PAGE and exposed to x-ray films. (E) Schematic
of the Hbo1 gene construct with the potential phosphorylation sites predicted
based on the CDK2 consensus phosphorylation motif (S/T-P-X-R/K/H). (F & G)
The six potential phosphorylation sites were mutated to alanine, expressed,
purified and subjected to similar kinase assay as in (D).
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demonstrated to bind to AR (androgen receptor) and NF-κB to mediate
transcriptional repression (308, 309). Furthermore, Hbo1 is highly expressed in
breast cancer tissues and correlates positively with histology grade in ERα positive
tumors (317). Given the important role of Hbo1 in breast cancer, we decided to
further investigate its relationship with cyclin E/CDK2 in mediating mammary
tumorigenesis.
Since the ProtoArray results showed that Hbo1 was phosphorylated by the
cyclin E/CDK2 complex, the first question to address is does Hbo1 interact directly
with this kinase complex? DNA plasmids containing FLAG-EL or LMW-E, HACDK2, and Myc-Hbo1 were transiently transfected into HEK293T cells followed by
IP/Western analysis. Immunoprecipitation using Myc-tagged antibody showed that
EL and LMW-E as well as CDK2 were pulled-down along with Hbo1 (Figure 30B).
Moreover, IP using FLAG-tagged antibody also pulled-down Hbo1 along with EL or
LMW-E, and CDK2. These results indicated that Hbo1 exists in the same protein
complex with EL/CDK2 and LMW-E/CDK2, at least in this in vitro experimental
condition.
To confirm whether Hbo1 is a substrate of the cyclin E/CDK2 kinase
complex, the EL/CDK2 and LMW-E/CDK2 kinase complexes and Myc-Hbo1
proteins were purified by IP with FLAG-tagged and Myc-tagged antibodies (Figure
30C). Results from the in vitro kinase assay showed that both EL/CDK2 and LMWE/CDK2 kinase complexes phosphorylate Hbo1 at relatively similar levels, and
addition of roscovitine efficiently inhibited the phosphorylation signal (Figure 30D).
Perhaps the reason that we cannot detect a difference in the extent of Hbo1
phosphorylation between the EL/CDK2 and LMW-E/CDK2 complexes is due to the
saturated concentrations of the kinase as well as the substrate in this in vitro kinase
assay condition compared to the condition performed for the ProtoArray. (The
kinase concentration was 50 nM in the microarray experiment and was
approximately 500 nM in this in vitro kinase assay.) Additionally, since the LMW-E
isoforms are overexpressed in breast cancer, we speculate that it is these truncated
forms of cyclin E in complex with CDK2 that phosphorylate Hbo1 and not the fulllength cyclin E form.
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Based on the consensus CDK2 phosphorylation motifs (S/T-P-X-R/K/H and
R-X-L), there are six potential phosphorylation sites on the Hbo1 gene sequence
(Figure 30E), and these sites were mutated to alanine to identify which site is being
phosphorylated by the LMW-E/CDK2 complex. The mutant proteins were
transfected into HEK293T cells, purified by IP, and then followed by kinase assay
(Figure 30F). Of the six potential sites, LMW-E/CDK2 phosphorylate Hbo1 at T88
since the T88A mutant showed abolished radioactive signal (Figure 30G).
Collectively, the Protoarray analysis led us to discover Hbo1 as a novel substrate of
the LMW-E/CDK2 complex that may mediate critical downstream signaling to
contribute to the oncogenic potential of LMW-E in breast cancer.
3.3i. Cyclin E/CDK2 phosphorylation of Hbo1 does not affect the HAT activity
of Hbo1
A recent study reported that CDK11p58 interacts with Hbo1 in the nucleus and
enhances Hbo1’s HAT activity leading us to speculate that the interaction and
phosphorylation of Hbo1 by the cyclin E/CDK2 complex may also affect the HAT
activity of Hbo1 (318). The Myc-Hbo1 (wt, T88A, and T88D), SFB-EL, SFB-LMW-E,
and SFB-CDK2 constructs were purified by IP with Myc or FLAG-tagged antibody
and then subjected to an in vitro HAT activity colorimetric assay (Figure 31A & B).
As shown in Figure 31C, phosphorylation of Hbo1 at T88 did not alter Hbo1’s HAT
activity since the T88A and T88D mutants exhibited similar HAT activity levels to
wild type Hbo1. Furthermore, inhibition of the kinase activity of EL/CDK2 and LMWE/CDK2 by addition of roscovitine did not affect the HAT activity level. Perhaps the
phosphorylation of Hbo1 at T88 may affect its binding to other proteins or to DNA
but not necessarily alter its function as a HAT. In fact, it has been demonstrated that
CDK1 phosphorylates Hbo1 at T85/T88 to create a docking site for polo-like kinase
1 (Plk1) (319). The recruited Plk1 subsequently phosphorylates Hbo1 at S57 and
activates the HAT enzymatic activity of Hbo1. We speculate that in the cellular
context, phosphorylation of Hbo1 by the LMW-E/CDK2 complex at T88 may also
create docking site for Plk1 or perhaps other kinases/proteins to be recruited to
regulate Hbo1’s HAT activity. Alternatively, the HAT activity of Hbo1 is not required
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Figure 31: Cyclin E/CDK2
phosphorylation of Hbo1 does
not affect the HAT activity of
Hbo1. (A) Schematic of the
colorimetric HAT activity assay. As
a HAT, Hbo1 transfers the acetyl
group to the peptide substrate
leaving coenzyme A to react with
NAD+ to generate NADH in the
presence of NADH generating
enzyme. NADH then reacts with a
tetrazolium dye giving rise to a
yellow color product that can be
detected at 440nm optical density.
(B) SFB-EL or SFB-LMW-E was cotransfected with SFB-CDK2 into
HEK293T cells, purified using
FLAG-tagged antibody, and eluted
with 3X FLAG peptide. Myc-Hbo1
was transfected into HEK293T
cells, purified using Myc-tagged
antibody and the bead-Myc protein
complex was resuspended in 1X
wash buffer. The purified proteins
were visualized by immunoblotting.
(C) Results from the HAT activity
assay with the values first
subtracted from a water control and
then normalized to the positive
control, which used HeLa nuclear
extract as a source of HAT.

for its transcriptional repression function. In fact, two independent reports indicated
that the N-terminal region of Hbo1 (in which the T88 site is located) is necessary to
repress AR and NF-κB transcriptional activation while the C-terminal domain (which
contains the HAT domain) displays no effect (317,318).
3.3j. Hbo1 is overexpressed in breast cancer cell lines and co-expression with
LMW-E/CDK2 enhances self-renewal capability of hMECs.
If Hbo1 is a novel downstream substrate of the cyclin E/CDK2 complex, we
next hypothesize that Hbo1 may play a role in inducing the CSC properties of the
LMW-E-expressing cells. We first determined that Hbo1 is highly expressed in 13 of
the 18 breast cancer cell lines tested compared to the relatively low levels in the 3
hMEC cell lines (Figure 32A). Interestingly, we observed no significant correlation
between Hbo1 expression and the different breast cancer subtypes (Figure 32A).
Furthermore, in our cell line model system, the 76NE6-LMW-E, T1G2.2, T1G3.1,
and T1G4.2 cells also express high level of Hbo1 protein compared to the 76NE6vector and 76NE6-EL cells (Figure 32B). To determine if transient co-expression of
Hbo1 with EL/CDK2 or LMW-E/CDK2 enriches for the CSC population, these
constructs were transfected into HEK293T cells and examined the change in the
CD44hi/CD24lo population four days later. Results from FACS analysis clearly
showed that while expression of EL/CDK2 and LMW-E/CDK2 led to an increase in
the CD44hi/CD24lo population compared to control cells, co-expression with Hbo1
further doubled this population (Figure 32C). More importantly, the increase in the
CD44hi/CD24lo population by LMW-E expression was significantly more than with
EL expression (p = 0.042). Additionally, Western blot analysis confirmed that coexpression of Hbo1 with EL/CDK2 and LMW-E/CDK2 resulted in reduced CD24 and
elevated ALDH protein levels (Figure 32D). While the HEK293T cells facilitate
efficient overexpression of proteins, they are however not an ideal model system to
examine physiologically relevant biological processes. Therefore, we co-expressed
cyclin E (EL or LMW-E), CDK2, and Hbo1 in the 76NE6 cells via lentiviral infection
and generated stable cell lines through antibiotic selection (Figure 32E).
Examination of the CD44hi/CD24lo population by FACS analysis revealed no
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Figure 32: Hbo1 is overexpressed in breast cancer cell lines and coexpression with LMW-E/CDK2 enhances self-renewal capability of hMECs.
(A) Cell lysates from 3 hMECs lines and 18 breast cancer cell lines were
subjected to Western blot analysis with antibodies to Hbo1 and β-actin. (B) The
76NE6 stable cell panel and the TDCs were subjected to similar analysis as in
(A). (C) SFB-EL or SFB-LMW-E, HA-CDK2, and Myc-Hbo1 constructs were cotransfected into HEK293T cells. Four days later, the cells were subjected to
CD24/CD44 FACS and (D) Western blot analysis. The FACS results were
averaged from 3 independent experiments and the statistical analysis used was
unpaired student’s t-test. (E & F) Lentivirus were generated in HEK293T cells
carrying the EL, LMW-E, CDK2, or Hbo1 (wt, T88A, or T88D) constructs were
used to infect the 76NE6 cells and stable expression was achieved by selection
with 20 µg/ml blasticidin for 2 weeks. The cells were then subjected to
CD44/CD24 FACS analysis (E) and mammosphere culture (F). The FACS and
mammosphere formation results were averaged from at least 2 independent
experiments and the statistical analysis used was unpaired student’s t-test.
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statistical difference between the different stable cell lines (Figure 32E). In contrast,
when we tested the ability of these cells to form mammospheres, we found that the
76NE6 cells co-expressing wild-type Hbo1 with the LMW-E/CDK2 complex (76NE68) formed significantly more mammospheres than those co-expressing the
EL/CDK2 complex (76NE6-7) (p = 0.0027) (Figure 32F). Additionally, co-expression
of the T88A Hbo1 mutant in the 76NE6 cells (76NE6-9,10) reduced the number of
mammospheres to similar levels as in the cells without Hbo1 overexpression
(76NE6-5,6) suggesting that the phosphorylation of Hbo1 by the cyclin E/CDK2
complex is critical for the enhanced self-renewal capability of these cells.
Interestingly, the cells with the T88D Hbo1 phosphorylation mimetic expression
(76NE6-11,12) also demonstrated reduced mammosphere formation compared to
wild-type Hbo1 (76NE6-7,8). We speculate that the aspartic acid substitution is not
an ideal phosphorylation mimetic for phospho-threonine as it has one less chemical
bond. Perhaps glutamate will be a better substitution for phospho-threonine mimetic
and may explain the importance of the phosphorylation of Hbo1 at T88 by the cyclin
E/CDK2 complex to generate a docking site for protein recruitment. Collectively,
these results indicate that Hbo1 along with LMW-E/CDK2 function to alter the
physiology of the cell as manifested in the properties associated with CSCs.
3.3k. Knockdown of Hbo1 reduced the properties associated with CSCs.
To investigate whether Hbo1 plays a role in enriching for the CSC population,
shRNAs targeting the Hbo1 mRNA transcript with an internal ribosome entry site for
GFP were packaged into lentivirus with HEK293T cells and used to infect the
76NE6-V, EL, LMW-E, T1G2.2, T1G4.2 and Sum159 cells. After two week of 0.5
µg/ml puromycin selection, approximately 98% of the cells express high levels of
GFP suggesting that the shRNAs were integrated successfully (Figure 33A).
Western blot analysis indicated that the two shHbo1 constructs were efficient at
knocking down Hbo1 protein levels (Figure 33B). Additionally, FACS analysis for
CD44/CD24 expression revealed that knockdown of Hbo1 significantly reduced the
CD44hi/CD24lo population as well as the ability of the cells to form mammosphere
structures compared to the shControl cells (Figure 33C & D). Furthermore, we
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Figure 33: Knockdown of Hbo1 reduced the properties associated with
CSCs. shControl, shHbo1-4, and shHbo1-5 lentivirus were produced in
HEK293T cells and used to infect the 76NE6 stable cell panel, two of the TDCs
and Sum159 cells. After selection with 0.5 µg/ml puromycin for 2 weeks, the
cells were subjected to (A) GFP FACS analysis, (B) Western blot analysis, (C)
CD44/CD24 FACS analysis, and (D) mammosphere formation assay. These
cells were then infected with lentivirus carrying the shHbo1-5R construct and
selected with 20 µg/ml blasticidin for 2 weeks followed by similar in vitro
analysis. The FACS and mammosphere formation results were averaged from
at least 2 independent experiments and the statistical analysis used was
unpaired student’s t-test (*p<0.05).
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rescued Hbo1 expression by infecting the cells with an shHbo1-5 resistant construct
(shHbo1-5R) by taking advantage of the wobble effect of the amino acid code and
select for stable expression with 20 µg/ml blasticidin for two weeks (Figure 33B).
Analysis of the CSC properties of these cells showed that re-expression of the
shHbo1-5R construct rescued the reduced CD44hi/CD24lo population as well as the
number of mammosphere formation (Figure 33C & D). Collectively, our findings
implicate that the presence of Hbo1 in LMW-E-expressing cells enhanced the
properties associated with CSCs, which can be reduced by knockdown of Hbo1
expression.
3.4. CONCLUSIONS
The role of LMW-E in breast cancer was first strongly established by its
association with patient samples and poor clinical outcome and was subsequently
reinforced by the demonstration that transgenic mice with ectopic LMW-E
expression develop mammary carcinoma and metastasis at significantly higher
frequency compared to transgenic mice with EL expression (160, 180). In chapter 2,
we described similar findings in xenograft mouse model in which hMECs expressing
LMW-E/CDK2 yielded higher tumor incidence compared to cells with EL/CDK2
expression.
By expressing LMW-E, the 76NE6 mammary epithelial cells underwent a
morphological switch by adopting mesenchymal characteristics as well as CSC
properties. That is, these cells altered gene expression that is consistent with the
EMT and demonstrated increased invasiveness through the basement membrane.
In addition, LMW-E-expressing cells contain a high percentage of the
CD44hi/CD24lo population, were able to form mammospheres in non-adherent
culture, and upregulated the expression and enzymatic activity of ALDH. More
importantly, the fact that the phenotypes observed were more robust with
exogenous LMW-E overexpression than with EL overexpression provides evidence
for the difference in their tumorigenic potential.
Furthermore, we observed a strong positive association between LMW-E
expression and the CD44hi/CD24lo population in the tumor cell line model,
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particularly in the cells obtained from in vivo passaging in which both the levels of
LMW-E expression and the CD44hi/CD24lo population showed dramatic elevation
compared to the stable cell lines. This connection was further strengthened by the
clinical examination of breast cancer patient tissues in which LMW-E expression
associated with tumors that contain high CD44hi/CD24lo population suggesting that
perhaps breast cancer cells with LMW-E expression are CSCs. More importantly,
statistical analysis also revealed a significant association between LMW-E
expression and their cytoplasmic localization from IHC staining of the tumor tissues
thus implicating a more efficient way to identify LMW-E expression in tumor tissues
by IHC rather than by Western blot analysis.
Given that the understanding of breast CSCs has only recently evolved,
clinical therapy aimed at targeting these cells is currently under active investigation.
In a large screen for small molecule inhibitors that can specifically kill CSCs, Gupta
and colleagues identified salinomycin as a potent agent that can abrogate the
phenotypes associated with CSCs and thereby reduce tumor aggressiveness and
regrowth (297). Although the mechanism of salinomycin-induced CSC death is
currently unclear, it is speculated that it may be due to its function as a potassium
ionophore since nigericin, another potassium ionophore, was also identified as a
CSC inhibitor in the same screening study (297). Recently, salinomycin was
reported to sensitize cancer cells to doxorubicin and etoposide leading to increased
DNA damage and apoptosis (320). In our study, we also demonstrated that the
combination of doxorubicin and salinomycin effectively targeted both the tumor bulk
(non-CSCs) as well as the CSCs. Doxorubicin is a strong anti-tumor agent;
however, due to its life-threatening cardiac toxicity, doxorubicin’s use in the clinic is
limited (321, 322). Similarly, salinomycin also has a narrow therapeutic window due
to its high toxicity. However, the synergistic effects mediated by salinomycin and
doxorubicin in LMW-E tumor cells but not in control and EL-expressing cells may
allow for administration of these drugs at a lower and thus less toxic dose in
patients with high LMW-E protein levels.
Our screen for novel substrates of the cyclin E/CDK2 complex identified
Hbo1, which is a HAT that can alter the expression pattern of multiple genes. The
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consensus phosphorylation motif for CDK2 is S/T-P-X-R/K/H, and we found that
cyclin E/CDK2 phosphorylated Hbo1 at T88PKK confirming that the phosphorylation
is specific. T88 is located within the N-terminal serine-rich region of the Hbo1 gene,
which is the regulatory domain, while the C-terminal region contains the Zn-finger
and a HAT domain that carries out the enzymatic function (306, 311). Plk1 was
previously shown to phosphorylate Hbo1 at S57A, which is in the regulatory Nterminal region, and this phosphorylation exerts positive control over the HAT
activity indicating that this domain is critical in regulating the enzymatic activity of
Hbo1 (319). The fact that co-expression of Hbo1 with LMW-E/CDK2 further
increased the CSC properties of both HEK293T and 76NE6 cells while knockdown
of Hbo1 expression reduced the CD44hi/CD24lo population and mammosphere
formation ability suggests that Hbo1 plays a role downstream of LMW-E in enriching
for the CSC population. Even though results from the in vitro HAT activity assay
indicated that LMW-E/CDK2 phosphorylation of Hbo1 did not directly affect its HAT
activity, in the cellular physiological context, this phosphorylation may create a
docking site to recruit other kinases to further phosphorylate Hbo1 and thereby alter
its HAT activity. Indeed this phenomenon has been previously observed in which
CDK1 phosphorylates Hbo1 to recruit further phosphorylation by Plk1 to increase
the HAT activity of Hbo1 (319).
Although the role of cyclin E has been strictly confined to the control of the
cell cycle, our data suggest that when deregulated, such as cleavage into LMW
isoforms, this oncogene is capable of inducing phenotypes associated with the EMT
and CSCs, which are further enhanced with the co-expression of Hbo1. Moreover,
phosphorylation of Hbo1 in the regulatory N-terminal region by the LMW-E/CDK2
complex implicates potential alteration in the regulation of gene transcription
associated with the EMT and CSCs. More importantly, combination treatment using
doxorubicin and salinomycin produced synergistic effect on cancer cellular toxicity
and thus further encourages investigation onto other drug combinations that target
both the CSC and non-CSC populations to bring to the clinic.
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CHAPTER 4: CONCLUDING REMARKS AND FUTURE DIRECTIONS
4.1. HIGHLIGHT OF MAJOR FINDINGS
The role of LMW-E in breast cancer has been well documented for more than
a decade, and research from this dissertation has shed light into our understanding
of how LMW-E deregulate the cells in the mammary gland as well as provide
possible therapeutic implications to intervene this process. The central hypothesis
of this dissertation is that LMW-E initiates and maintains mammary tumor via
deregulation of mammary acinar morphogenesis, induction of the EMT, and
generation of cells with CSC properties. The data obtained from this dissertation
provided answers to the following five questions that were raised at the end of
chapter 1.
1. Is LMW-E capable of initiating and maintaining tumor development?
•

Both stable and inducible LMW-E expression systems are capable of
rendering a nontumorigenic hMEC tumorigenic. Moreover, the tumorigenic
potential mediated by LMW-E is approximately 10 folds stronger compared to
that of EL.

2. What effect does LMW-E have on the proliferation and architecture of the
mammary acini, and if so, can inhibition of LMW-E by pharmacological
agents rectify these defects?
•

LMW-E induced hyper-proliferation during mammary acinar morphogenesis
causing formation of large and misshapen acinar structures. Treatment of
these acini using combination of rapamycin and roscovitine or sorafenib and
roscovitine prevents development of these phenotypes.

3. What signaling pathway is deregulated in breast tumors with high LMWE expression?
•

Proteomic analysis identified the b-raf/ERK2/mTOR pathway is activated in
both breast cancer patient tissues and cells with high LMW-E levels. More
importantly, expression levels of the proteins from this pathway along with
LMW-E predicted poor clinical outcome.

4. Does LMW-E induce tumor initiation, progression, and metastasis by
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altering gene expression to enhance invasiveness and self-renewal
capability?
•

LMW-E altered the gene signature associated with the EMT thereby reducing
cell-cell contact and enhancing cellular invasion. Furthermore, LMW-E
enriched for cells with CSC properties and, in breast cancer patient samples,
cytoplasmic cyclin E significantly correlated with the CD44hi/CD24lo mammary
CSC population. Combination treatment using salinomycin and doxorubicin
demonstrated synergistic toxicity in LMW-E-expressing cells but not in control
and EL-expressing cells.

5. Are these phenotypes driven by previously unidentified substrate(s) of
the LMW-E/CDK2 complex?
•

ProtoArray microarray analysis identified Hbo1 as a novel substrate of cyclin
E/CDK2. Co-expression of Hbo1 with LMW-E/CDK2 resulted in an enrichment
of the CSC population while knockdown of Hbo1 expression significantly
reduced the CSC population.

4.2. FUTURE DIRECTIONS
While research from this dissertation has addressed some of the critical
aspects of LMW-E deregulation in mammary tumorigenesis, the data generated
inevitably raised new questions that are essential to further understand this process
in order to apply therapeutic intervention in the clinical setting.
Firstly, we identified several different therapeutic strategies involving
combining pharmacological agents to specifically target mammary tumor cells with
high LMW-E expression. The first strategy was to target the activated b-RafERK1/2-mTOR pathway by combining roscovitine with rapamycin or sorafenib,
which was effective at preventing the formation of hyperproliferative mammary
acinar structures in LMW-E-expressing cells. In the inducible transgenic mouse
model with LMW-E expression, we also observed similar hyperproliferation of the
terminal end buds and activated MAPK pathway. Therefore, this mouse model is
valuable to test the preclinical effectiveness of combining roscovitine with rapamycin
or sorafenib at both preventing LMW-E-induced mammary tumor development as
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well as inducing tumor toxicity post tumor formation. This therapeutic strategy is
anticipated to demonstrate strong anti-tumor effect in the mouse model since we
observed activation of the MAPK pathway in this mouse model and strong
correlation between high LMW-E expression and activation of the b-raf/ERK/mTOR
pathway with patient survival outcome.
The second therapeutic approach that we identified was by combining
salinomycin with doxorubicin to target the LMW-E-induced CSCs. Again, the
inducible transgenic mouse model with LMW-E expression is valuable to test the
effectiveness of this drug combination. However, it is necessary to first determine
whether the LMW-E-induced mammary tumors in the transgenic mice also
demonstrate features of the EMT and enrichment for mammary CSCs. We
speculate that the LMW-E-mediated mammary tumors likely undergo the EMT to
facilitate metastasis development since it was reported that approximately 25% of
LMW-E-tumor-bearing mice formed distant metastasis (180). If the salinomycin and
doxorubicin combination proves to be effective at targeting the LMW-E-induced
mammary tumors in the mouse model, this therapeutic strategy will undoubtedly
implicate possible clinical application for breast cancer patients with high LMW-E
expression given the fact that we have also provided evidence demonstrating a
positive correlation between cytoplasmic cyclin E and the CD44hi/CD24lo CSC
population.
We ended this project with the finding that Hbo1 is a novel substrate of the
cyclin E/CDK2 kinase complex. Given that the cyclin E/CDK2 complex has been
shown to be involved during the assembly of the prereplication complex (pre-RC), it
is not surprising that Hbo1 (a HAT binding to ORC1) was found to be a substrate of
this kinase complex. DNA replication requires the assembly of the pre-RC, which is
formed by the sequential loading of Cdc6/Cdcl8, Cdtl, and MCM2-7. More
specifically, the interaction between cyclin E/CDK2 and Cdc6 was found to be
critical for the initiation and maintenance of DNA replication at the G1-S phase
boundary (115, 116). Recently, Hbo1 was reported to be important for the chromatin
loading of the MCM2-7 since depletion of Hbo1 blocked MCM2-7 assembly into the
pre-RC and subsequently inhibited DNA replication (313). Therefore, it is intriguing
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to investigate the mechanistic function of cyclin E/CDK2 phosphorylation of Hbo1 on
DNA replication licensing in the normal cellular context as well as the consequence
of deregulated phosphorylation of Hbo1 due to hyperactive LMW-E/CDK2 activity in
tumor cells. Perhaps phosphorylation of Hbo1 by the cyclin E/CDK2 complex
provides a docking site on Hbo1 to recruit other proteins required for the assembly
of the pre-RC. However, aberrant cyclin E/CDK2 kinase activity manifested by
LMW-E/CDK2, whose activity has been shown to be deregulated throughout the cell
cycle, can cause untimely DNA replication leading to genomic instability (173,184).
Indeed, one mechanism of cyclin E-mediated oncogenesis is through inducing
genomic instability (162-164) and tumor cells with p53 loss and cyclin E
overexpression were observed to have elevated frequency of centrosomal
hyperamplification (120). In fact, in response to DNA replication fork arrest and
hyperosmotic shock, stablized p53 has been shown to interact with Hbo1 and
negatively regulates its HAT activity (307). Therefore, aberrant Hbo1 HAT activity
due to lack of repression by p53 and overexpression of cyclin E may lead to
deregulated DNA replication and predispose the cell to genomic instability.
Studies have shown that Hbo1 is the major HAT for histone H4 acetylation in
vivo, however recent work by Kueh and colleagues demonstrated that Hbo1 is also
necessary for H3K14 acetylation to transcriptionally activate genes associated with
embryonic development (313, 316, 323, 324). While H4 acetylation is linked with
DNA replication, H3 acetylation is thought to control transcriptional activity
suggesting that aside from playing an important role during replication licensing in
S-phase, Hbo1 also exerts control over gene expression (323). In fact, Hbo1 has
been shown to affect the transcriptional activity of a few transcription factors such
as ER, PR, AR and NF-κB (308-310). Interestingly, the N-terminal region of Hbo1
exerts repression of AR and NF-κB transcriptional activation while the C-terminal
domain displays no effect suggesting that the HAT activity of Hbo1, which is located
in the C-terminal region, is not necessarily required for Hbo1 to mediate
transcriptional regulation (308, 309). Particularly, Contzler and colleagues further
demonstrated that the mechanism of Hbo1-mediated suppression of NF-κB
transcriptional activity is not through binding directly to NF-κB nor to the κB
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consensus sequence but perhaps via interaction with NF-κB’s coactivator(s) and
thereby squelching them from NF-κB (309). One likely possible coactivator is SRC1 since it has been shown to co-IP with the N-terminal domain but not the Cterminal region of Hbo1, and the interaction between these two proteins cooperates
to enhance the transcriptional activities mediated by ER and PR (310). Finally,
studies have shown that the N-terminal domain of Hbo1 is able to mediate
transcriptional control both in trans and in cis thus implicating that this domain of
Hbo1 is critical for the recruitment and binding of other factors to Hbo1 to regulate
gene expression (325, 326). Therefore, phosphorylation of Hbo1 at T88 by the
cyclin E/CDK2 complex may affect the ability of Hbo1 to regulate the transcriptional
activities of PR, AR, NF-κB, and perhaps other transcription factors yet to be
identified. This speculation can be addressed by using the T88A and T88D (or
T88E) Hbo1 mutants to examine the extent of Hbo1’s regulation on the
transcriptional activities of ER, PR, AR and NF-κB through the use of a luciferase
gene reporter assay.
In addition, in vitro HAT activity assay also showed that phosphorylation of
Hbo1 at T88 by the cyclin E/CDK2 complex did not affect the HAT activity of Hbo1.
Similar to the context of CDK1 phosphorylation and subsequent recruitment of Plk1
to Hbo1, we speculate that phosphorylation of Hbo1 by cyclin E/CDK2 also provides
docking site for other proteins to bind to Hbo1. Again, T88A and T88D (or T88E)
Hbo1 mutants can be used to co-IP possible interacting proteins and then identified
via mass spectrometry. Alternatively, the retrovirus-based protein-fragment
complementation assay can also be used to screen for interacting proteins to Hbo1
when phosphorylated at T88. This approach involves fusing the N-terminal half of
the GFP gene to the Hbo1 mutants and the C-terminal half of the GFP gene is
fused to an endogenously expressed protein through an in-frame exon trap. The
difference in the hits obtained between the two mutants will uncover the proteins
that interact specifically to Hbo1 when the T88 site is phosphorylated. Given that the
N-terminal domain of Hbo1 is critical for its regulation of gene transcription, the
identified interacting proteins to pT88 Hbo1 will further reveal other transcription
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factors and co-activators that are critical in controlling the gene transcriptional
activity of Hbo1.
Although the in vitro kinase assay was understandably not adequate in
distinguishing the difference in the extent of phosphorylation between EL/CDK2 and
LMW-E/CDK2 complexes, it is likely that high LMW-E levels in the tumor tissues of
patients are responsible for phosphorylation of Hbo1. To address this hypothesis,
an antibody specific to phospho-T88 Hbo1 can be produced and used for
immunoblot analysis of our patient data set to correlate with LMW-E protein levels.
Furthermore, the level of Hbo1 phosphorylation can also be analyzed for
association with the percentage of the CD44hi/CD24lo population as well as survival
outcome in patients. These findings will better define the molecular deregulation
mediated by LMW-E and thus bring us closer to identifying a therapeutic approach
that is specific for patients with high LMW-E expression. For instance, a
combination between a CDK inhibitor (i.e. roscovitine) and salinomycin might be
effective at inhibiting the CSC population in patients with high LMW-E expression.
Although CDK inhibitors such as flavopiridol and roscovitine have demonstrated
unimpressive response in clinical trials as a single agent, it must be noted that the
patients in these trials were not selected based on LMW-E levels (327, 328). By
inhibiting the CSC population in the high LMW-E-expressing tumors, we may be
able to achieve favorable outcome and avoid tumor relapse due to the specific
targeting of the CSCs. In addition, another possible target is Hbo1 using HAT
inhibitor if the HAT activity of Hbo1 were found to be important in enriching for the
CSC populations. However, similar to HDACs, HATs also have both oncogenic and
tumor suppressive roles in cancer biology thus complicating its use in the clinic. To
date, there are a few HAT inhibitors available for mechanistic studies as possible
antitumor agents such as garcinol, anacardic acid, and curcumin, which are among
the natural inhibitors found in plants. Particularly, anacardic acid was shown to be a
radiation sensitizer while garcinol and curcumin demonstrated strong cytotoxic
effect in human leukemic cell lines (329, 330). As with all natural compounds, their
mechanism of action is typically complex and non-specific and thus warrants more
extensive investigation prior to use in the clinic. In contrast to the plant-derived
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inhibitors, lys-CoA, which is a synthetic HAT inhibitor (lysine amino acid conjugated
to coenzyme A), has been shown to exhibit highly specific and potent activity
against HAT activity although its use in vivo has been limited due to high metabolic
instability and cell impermeability (331). While HAT inhibitors are currently not ideal
for clinical therapy, they can serve as valuable tools for mechanistic studies as
proofs of principle.
4.3. SIGNIFICANCE
The incident rate of breast cancer worldwide is steadily increasing over the
past few decades, and the problem of tumor recurrence remains difficult to address.
Clinical studies demonstrated that a high percentage of breast cancer patients
express LMW-E, and this occurrence is linked to adverse clinical outcomes (160). In
this dissertation, we identified two therapeutic approaches of targeting breast tumor
cells with high LMW-E expression: 1) combination of roscovitine with sorafenib or
rapamycin and 2) combination of doxorubicin and salinomycin. We believe that the
results from this study provided important preclinical basis for the use of these
agents first in the animal model and hopefully into the clinic in the near future.
Furthermore, the identification of Hbo1 as a downstream substrate of the LMWE/CDK2 complex undoubtedly unveils additional mechanism of how LMW-E
mediates mammary tumorigenesis.
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